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Abstract
Serotonin (5-hydroxytryptamlne, 5-HT) is a neurotransmitter which exerts its 
cardiovascular effects predominantly by interaction with specific 5-HTi and 5- 
HT2 receptors. The effects of serotonergic agents differ between in vivo and in 
vitro preparations and display wide Inter-species variation. It is therefore 
impossible to extrapolate results from animal or in vitro studies to the clinical 
situation. The role of these two receptors has therefore been studied in patients 
with suspected coronary artery disease using 3 different 5-HTi agonists and 
ketanserin, a 5-HT2 antagonist.
Sumatriptan and naratriptan, 5-HT ib/d receptor agonists, vasoconstrict the 
systemic and pulmonary circulations. Sumatriptan-induced vasoconstriction 
appears more pronounced in the pulmonary circulation suggesting a greater 
density of 5-HTi receptors in the pulmonary compared to the systemic 
circulation. Although left ventricular end diastolic pressure and pulmonary artery 
wedge pressure rose after sumatriptan, there was no change in peak rate of left 
ventricular pressure rise, indicating the absence of a negative inotropic action. 
Naratriptan, an analogue of sumatriptan, displayed no significant effect on 
coronary artery diameter, a finding previously noted with sumatriptan.
Eletriptan, a selective 5-HTid agonist with less 5-HTib activity, had little 
vasoconstrictor effect on the systemic, pulmonary or coronary circulation 
perhaps suggesting that the 5-HTib receptor subtype mediates vasoconstriction.
 ^ ; y '
The effect of sumatriptan on systolic time intervals and forearm blood flow was 
also assessed. The results suggest that STI's are of potential use in the non-
I
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invasive assessment of 5~HTi agonists. No significant effect on forearm blood 
flow was observed but plasma noradrenaline levels fell after subcutaneous 
sumatriptan.
Ketanserin, a 5-HT2 antagonist, acted as a vasodilator in the systemic and 
pulmonary circulation but failed to vasodilate the coronary arteries, presumably 
because the patients in this study had stable angina without platelet activation 
and therefore had low circulating levels of serotonin.
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CHAPTER 1
INTRODUCTION: CARDIOVASCULAR SEROTONERGIC RECEPTORS
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introduction
Over a century ago it was recognised that coagulated blood contained a 
substance with vasoconstrictor properties. In 1948 Rapport isolated this
1substance from serum and named it serotonin (5-hydroxytryptamine, 5-HT). 
Serotonin was noted to be released from platelets as they were degraded in the 
clotting process. Subsequent work soon demonstrated that serotonin also 
existed in the enterochromaffin cells of the gastrointestinal tract where it 
enhanced gastrointestinal motility.^ Within a very short period of time serotonin 
was isolated in the brain and thereafter its role as a neurotransmitter was 
acknowledged. Despite a further four decades of extensive research, many 
aspects of the physiological and pathophysiological role of 5-HT remain unclear. 
This thesis will therefore examine aspects of the role of serotonergic agents on 
the cardiovascular system.
Synthesis of Serotonin
The structure and pathway of serotonin synthesis are outlined in figures 1.1 and 
1.2. Tryptophan, the aminoacid precursor of 5-HT is obtained in the diet. 
Approximately 1 % of dietary tryptophan is converted to 5-hydroxytryptophan via
:the enzyme tryptophan-hydroxylase which is present in the enterochromaffin 
cells of the small intestine, but not in platelets. Serotonin in the CNS is 
synthesised locally as it crosses the blood brain barrier poorly.
Tissue Stores of Serotonin
Serotonin is located in the following sites:
j...
■I-
1. Intestine .'a
The enterochromaffin cells of the intestinal tract account for approximately 90%. T
10% of the remaining 5-HT is found in the myenteric plexus of the intestine, 
where it is believed to act as an excitatory neurotransmitter increasing Gl 
motility.
13
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2. Blood
5-HT is present in high concentrations in platelets. On platelet aggregation, 5- 
HT is rapidly released and, together with thromboxane A2 , a potent
vasoconstrictor effect can be observed. Platelets also avidly re-uptake 
serotonin and therefore circulating serum 5-HT levels are normally low in the 
absence of platelet activation.
3. Central Nervous System
5-HT can also be identified in the brain, particularly in the midbrain and spinal 
cord. At these sites 5-HT serves a plethora of relatively poorly understood 
functions.
Metabolism of 5-hy d roxy try ptam I ne
Oxidative deamination is the main mechanism by which 5-HT is metabolised.
Within the brain, liver and in several other sites, the enzymes 
monoamineoxidase, methyl transferase and aldehyde dehydrogenase degrade 
serotonin to an aldehyde, and subsequently an acid (Figurel .3). The principle 
metabolite of 5-hydroxytryptamine is 5-hydroxyindole 3-acetlc acid (5-HIAA) 
which is excreted in the urine. Measurement of 5-HIAA in the urine acts as an 
indicator of endogenous 5-HT metabolism and is of clinical use in the carcinoid 
syndrome, allowing the response to treatment, for example, to be assessed.
Classification of 5-HT Receptors
Gaddam and Picarelli (1957) were the first to attempt clarification of 
serotonergic receptors, describing D and M receptors following work on the 
guinea pig ileum. M receptors were classified on the basis that Morphine
%
inhibited the 5-HT mediated release of acetyl choline from myenteric cells of the 
guineapig ileum. Phenoxybenzamine was however observed to antagonise 5- 
HT-induced contractions of the same preparation and the D nomenclature was
therefore established. This nomenclature persisted for nearly three decades
14
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until further studies recognised various binding sites for 5-HT. The 
observation that certain functions of serotonin, for example serotonin-induced 
vasoconstriction, were not mediated by D or M receptors altered thinking. In 
1979 Peroutka and Snyder identified high and low affinity binding sites for [^H]
55-HT in rat cortex. The low affinity binding sites were subsequently shown to
correspond with Gaddam and Picarelli's 'D' receptor and were re-classified as 5- 
HT2 r ecep to rs .The  high affinity binding sites were classified as 5-HT-i
receptors. Further characterisation of 5-HT2 receptors was advanced by the 
discovery of a potent, selective reversible antagonist at this receptor site,
8 9namely ketanserin. ’ In the last decade, the development of new specific 
receptor agonists and antagonists, together with genetic engineering techniques 
has led to the recognition of new receptors and subtypes. Current 
nomenclature recognises seven main types of serotonin receptor; 5-HT 1, 5- 
HT2 , 5-HT3^ 5-HT4^ 5-HT5 ,5-HTeand 5-HT7 receptors. Each of these receptor 
characteristics are discussed below, paying particular attention to those which 
exist at vascular sites. Variation in receptor density at differing vascular sites 
within the same species and inter-species variations will become evident.
S-HT^a  Receptors
The 5-HT-^/\ receptor is a 421 aminoacid structure. The observation that 
serotonin agonist activity at 5-HT-j/\ receptors inhibits synaptic activity in the rat
5-HT 1 Receptor Characteristics
Radioligand binding studies have confirmed the 5-HT  ^ receptor to be 
heterogeneous in nature comprising of 5-HT-{A, 5-HTiB, 5-HT'|q, 5-HT 1 o and 
5-HT 1E subtypes. The functional status of these binding sites has also been
established by the identification of second messenger coupling systems, but 
there still appears to be a lack of correlation between all receptor subtypes and 
functional a c t i v i t y . T h e  term b-HT^j-like receptor is therefore sometimes
used in this setting.
15
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locus coerulus provides evidence that the 5-HT-^a  receptor exhibits
12autoreceptor activity. This receptor therefore appears to be located primarily 
at pre-synaptic nerve terminals where it inhibits neuronal transmission. DNA 
analysis of the S-HT^a  receptor reveals areas of similarity to (i ad renoreceptors
and this may explain mutual receptor agonists and antagonists. Cyclic 
adenosine monophosphate (cAMP) acts as a second messenger system at this 
receptor. Stimulation of S-HT-ia  receptors leads to a reduction in cAMP,
13channel activation and hyperpolarisation. The primary locations of 5-HT'j a  
receptors are cerebral cortex, raphe nucleus and the hippocampus.
5-HT^ B Receptor I
This 386 amino acid receptor has been characterised best in the rat, but is now 
recognised to be the rodent homologue of the 5-HT -j q receptor. It was initially
14 "believed not to exist in human brain , but subsequently has been recognised. if-The b-HT'i g receptor is also negatively coupled to adenylate cyclase, reducing
■IcAMP accumulation. Its autoreceptor activity reduces acetylcholine and
phosphatidylinositol acts as a second messenger for both. The two receptors 
however do not show similar orders of potency for agonists and antagonists. 
For example, 5-HT is more potent in stimulating 5-HTic mediated responses 
and spiperone is approximately 1000 times weaker at 5-HTic receptors.
16
noradrenaline release.
5-HTic Receptor
The 5-HT'Iq receptor has not yet been convincingly demonstrated due to the 
lack of selective agents. Similarities however exist between the S-HT'i q and 5- 
HTg receptors. There is a high degree of amino acid sequence homology and
16
: ,  ■? a
5-HTi D Receptor
18This receptor was first identified in bovine brain in 1987 and in humans in 
1991 In pig and human cortex it inhibits 5-HT release from its location on
17
19pre-synaptic nerve terminals. receptors are found in the substantia
nigra, caudate, globus pallidus and intracranial blood vessels. This receptor is 
also negatively coupled to cAMP.
■I
5-H Ï1E Receptor
A fifth 5-HT1-like receptor subtype has been cloned from human and rat 
b r a i n . A l t h o u g h  sharing a degree of amino acid identity with other 5-HTi-like 
receptors and being negatively coupled to adenylate cyclase, this receptor 
displays different binding affinities, confirming its separate identity. 5-HT ie 
receptors are found in the cortex, hippocampus and striatum.
5-H Î2 Receptors
5-HTg receptors have well recognised, potent selective antagonists (ketanserin,
mianserin and ritanserin). amethyl 5-HT is a selective agonist at these 
receptors. 5-HTg receptors are widely distributed and therefore activity at these 
sites mediate a variety of complex actions. 5-HTg receptors are predominantly
found in the cortex, arteries, veins, platelets and Gl tract. As already discussed, 
phosphatidylinositol is the second messenger system.
5-HT3 Receptors
5-HTg receptors act via Na and K"^  channels to depolarise membranes leading
21to neuronal excitation. The structure of these receptors is now known. 5-HTg 
receptors exist in the brain and in enteric neurones. Antagonist activity at these 
sites, with drugs such as ondansetron and granisetron, proves efficacious in the 
treatment of nausea.
5-HT4 Receptors
The 5-HT4 receptor is a more recent discovery. It was first identified in 1989 in
the brain ^  but is also located in the gastrointestinal system and myocardium. 
It is positively coupled to adenylate cyclase increasing local accumulation of
17
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gastrointestinal motility. In addition, 5-HT. receptors have also been noted in
5-HT5 Receptors
The 5-HTs receptor has recently been cloned in rodent species. Subdivided 
into 5-HTsa and 5-HTsB both receptor subtypes exhibit low affinity for 
sumatriptan and serotonin, distinguishing these two receptors from the human 
5-HT1-like receptor.^®’^ ^
5 -H Ï6 Receptors
These receptors have also been cloned in rodent species and are positively 
coupled to adenyl cyclase.^®’^ ® It is thought they may be involved in brain 
development.
5-HT7 Receptors
5-HT7 receptors were first identified in 1993 from molecular cloning in rat^° and 
human^^ brains. In humans this receptor is predominantly detected in the brain, 
but also in the coronary arteries and in the gastrointestinal tract.^^ The second 
messenger coupling system suggests that the 5-HT7 receptor may be implicated 
in the mediation of vasorelaxation.
VASOACTIVE 5-HT RECEPTORS
5-HT receptors may influence the cardiovascular system by many diverse 
methods. Direct actions on vascular smooth muscle, indirect actions on
18
cAMP and depolarising cell membranes. A lack of selective agonists and 
antagonists at the 5-HT^ receptor has curtailed expansion in our knowledge of it.
5-HT^ receptor activation with cisapride however, results in release of
acetylcholine in the myenteric plexus, probably by an action at a pre-synaptic 
site.^^ 5-HT. receptors therefore appear to play an important role in
4
the cerebral cortex and human right atrium. 5-HT^ agonism on isolated human 
atrial cells elicits a positive inotropic response.
-I
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vascular endothelium or sympathetic nerve terminals, or more complex 
interplays with cardiovascular reflexes may all be implicated in changes in 
vascular tone. These issues are discussed below.
Direct vasoconstriction mediated by 5-HTi receptor stimulation
The presence of a 5-HT^-like mediated vascular constriction was first
demonstrated in the saphenous vein of the dog.^^’^  ^ Subsequent work has 
demonstrated similar responses in a wide variety of arterial and venous 
preparations from many species including humans (See table 1.1).
5-HT'] -like receptors often co-exist however with 5-HT2A receptors in vascular 
beds. In the absence of highly selective b-HT i^ agonists therefore, it can be
difficult to isolate individual receptor properties. The rabbit saphenous vein
preparation appears to be an exception as contractions are mediated purely by 
5-HT^-like receptors .The presence of occult functional 5-HT., activity may
however be overlooked and underestimated. Several tissues may appear 
devoid of 5-HT. mediated vasoconstriction under resting conditions, but may
elicit powerful responses when pre-stimulated with other vasospastic agents.
For example, 5-HT causes isolated rabbit femoral artery rings to contract."^®
Spiperone and ketanserin (5-HT^ receptor antagonists) antagonised these
responses suggesting that the 5-HT response was mediated by 5-HT2 
receptors. A small component of the contraction (10%) was however 5-HT.,
mediated as it was resistant to spiperone and ketanserin. In the presence of the 
thromboxane A^ mimetic U46619, angiotensin II or histamine however,
responses became largely resistant to the effects of spiperone and about 60%
of the total response to 5-HT was mediated by 5-HT1-like receptors."^® This 
suggests a synergistic effect between 5-HT.,-like agonists and thromboxane A^ ^
histamine and angiotensin II. Similar synergy has been observed in rabbit renal 
artery and human coronary arteries.'^^’'^ ® The biochemical basis of this 
synergy is uncertain but may have some connection with the respective
19
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receptor coupling systems as it occurs with other receptors negatively coupled 
to adenylate cyclase. Interestingly thromboxane A2 , histamine (Hi) and 
angiotensin II receptors are all positively coupled to the phosphoinositol 
signalling sys tem.Th is  infers that cells already exposed to phosphoinositol 
drive may react differently on account of competing or complimentary 
influences. The potential importance of this synergistic phenomenon in vivo is 
obvious and should not be ignored when investigating in vitro responses.
Direct Vasoconstriction Mediated by 5-HT2 Receptor Stimulation
Powerful vasoconstrictive effects of 5-HT have been observed in a wide range 
of vessels in many species (See Table 1.2). The availability of ketanserin, a 
potent 5-HTg antagonist, has allowed the functional role of 5-HTg receptors in
these responses to be assessed. Evidence also exists from in vivo studies that 
5-HTg receptors may influence total peripheral resistance via actions on
'resistance arterioles. Transient, 5-HT2 receptor-induced hypertensive responses 
have been noted in the rat.®^ ’®^ Intravenous a-methyl 5-HT (5-HT2 agonist) 
produced dose-related increases in blood pressure in both DOCA-salt 
hypertensive and normotensive rats but the magnitude of response was greater 
In hypertensive rats.®  ^These responses were dose-dependently antagonised 
by ketanserin confirming 5-HT2 mediated vasoconstriction. In anaesthetised rats 
5-MeODMT and TFMMP (partially selective 5-HTi agonists) produced
Ihypotensive effects which were preceded by a ketanserin-sensitive increase in 
blood pressure.®^ These transient hypertensive response were therefore 
ascribed to 5 -HT2 receptor stimulation. In pithed rat preparations, these pressor 
responses are associated with an increase in total peripheral resistance.®"  ^ Cats
,"7
exhibit similar physiology with 5-HT induced pressor responses being 
antagonised by selective 5-HTg antagonists.®®’®® A different effect is observed
in the dog however, with indirect 5-HT induced pressor effects mediated via 5- 
HTg receptor stimulated release of catecholamines from the adrenal
medulla.®^’®®
‘i
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5-HTg receptors overall appear to play a minor role in 5-HT induced changes in
vascular resistance, presumably as they exist in greater density in conductance 
vessels. 5~HT„ mediated vasospasm can occur, however, as demonstrated in
the rabbit renal vascular bed where 5-HT2 receptor activation produced flow 
limiting spasm.®®’^ ® The effect of 5-HTg receptor activation may be influenced by
the presence or absence of atherosclerosis.^^'^"^ For example, in normal 
monkeys serotonin had little effect on mesenteric blood flow. In contrast, 
serotonin virtually abolished blood flow to the colon in atherosclerotic 
counterparts.^^ Also in monkeys, there was a greater than 10-fold increase in
::
constrictor responses to serotonin in the hindlimb of atherosclerotics compared
7 „to normals. This raises the possibility that, in atherosclerotic arteries, 5-HT2 
receptor activation may exacerbate already impaired vascular flow, such that a 
relatively benign vascular response may have more severe implications 
resulting in flow-limiting co n s t r i c t i o n .L o c a l  5-HT administration may even 
result in tissue ischaemia due to collateral circulation vasospasm in hind limb 
vessels of the rat cat ®^ and dog.^^
5-HT RECEPTORS MEDIATING VASORELAXATION DIRECTLY
As previously observed, 5-HT administered in vitro results in prominent 
contractile responses on blood vessels. If however, it is administered slowly to 
anaesthetised animals, the net response is vasodilatation. The mechanism 
behind this was initially unclear, but more recently evidence for a direct
;r
vasorelaxant action has been identified. Histamine contracted sheep and goat
1
pulmonary vein rings will relax in response to submicromolar concentrations of
5-HT.^ ®'^ ® These responses are resistant to morphine and dibenamine and it
was concluded that neither "D" or "M" receptors mediated this vasodilatory
effect. It is only relatively recently that the 5-HT receptor types involved have 
been identified as belonging to the 5-HT.,-like and 5-HT^ classes.®®
I22 ■7,
Smooth Muscle 5-HT-i-like Receptors
i.-:5-HT induced relaxation of tonically constricted isolated blood vessels has been '■i'î
widely reported (Table 1.3) but in some cases, only becomes evident when 5-
'1'HT receptors which mediate vasoconstriction are simultaneously blocked.®’®^ In 
addition, many of the studies have been performed in the presence of intact
::endothelium and therefore some of the responses may be mediated via g
endothelial-derived relaxing factor (EDRF) rather than direct 5-HT actions on
:vascular smooth muscle. A number of endothelium denuded preparations have
been studied and the evidence suggests involvement of the same receptor type
vasorelaxation. This theory is reinforced by the resistance to block by selective
in all tissues.®"^ '®®'®® Although specific agonists and antagonists do not exist for
this receptor, the rank order of potency for a number of agents
,s[carboxamidotryptamine (5-CT) > 5-HT » a  methyl-5-HT (a-Me-5-HT) > ||
sumatriptan] concurred with a single 5-HT'i receptor subtype mediating direct i5-HTg (ketanserin) and 5-HTg (ondansetron, MDL72222) antagonists. Moreover
methiothepin, a non specific 5-HTi antagonist, could block these responses at 
nanomolar concentrations. :
The 5-HT., receptor mediating direct vasorelaxation shares many properties 
with, but is not identical to, the 5-HT., receptor mediating vasoconstriction.
Minor differences in pharmacological properties have allowed clear distinctions 
to be drawn between the two receptor subtypes, and from other 5-HT receptors.
The features which differentiate the 5-HT., receptor mediating vasorelaxation
from that responsible for vasoconstriction are (i) No effect of sumatriptan (ii) j
poor agonist activity of a-Me-5-HT and (iii) antagonism mediated by spiperone 
(5-HT2 antagonist). Equally there is no evidence to implicate this receptor as a 
correlate of any of the central 5-HT receptors. Several studies with a number of 
agents show that this 5-HT., receptor does not meet the recognised criteria for 
classification as 5-HT.,^, 5-HT.,g, 5-HT,^. or 5-HT.,p. This vasorelaxant receptor
has therefore not been defined in terms of a CNS binding site.®"^ '®®
22 I
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In keeping with other 5-HT'i receptors, this receptor also appears coupled to 
cAMP as a second messenger system. In distinction to the others however, 
agonism at this receptor site increases cAMP production (positive 
coupling).®^’®®’®® Cyclic AMP increases four fold in pig venacava in response to 
5-HT and carboxamidotryptamine (5-CT). The time course of this rise is 
compatible with a vasorelaxant action.®® In canine femoral veins and 
mesenteric arteries, this action appears to be associated with an enhanced K"^  
efflux which may theoretically inhibit calcium influx. The exact mechanism here 
remains uncertain however.®®'®^
Smooth Muscle 5-HT4 Receptors
A novel 5-HT receptor, (5-HT^) positively coupled to adenylate cyclase was first
described in brain tissue by Dumuis et al.®^  Its ubiquitous distribution has now 
been acknowledged through identification on peripheral autonomic neurones 
G.l. smooth muscle cardiac muscle and vascular smooth
oro not antîarionîccaH color*ti\/o R_WT ormuscle. 5-HT^ receptors are not antagonised by selective 5-HT^, 5-HT^ or 5 
HT3 receptor ligands.®® The first recognised 5-HT^ antagonist was tropesitron, 
an indole S-HT^ receptor antagonist but more recently GR113808 has been 
utilised to radiolabel 5-HT^ receptors in the b r a i n . T h e  most potent agonist at 
the 5-HT4 receptor is 5-HT itself, but no DMA clone for the receptor has been
identified. The receptor is therefore characterised by rank order of potency and 
resistance to blockade by selective 5-HT^, 5-HT^ and 5-HTg antagonists
(metergoline, ketanserin and ondansetron) respectively. Despite well 
documented cardio-active effects there is a paucity of reports describing 
vascular responses mediated by 5-HT^ receptors. In guineapig ®® ®® ,piglet
and human atrial tissues positive inotropic or chronotropic responses are 
observed. 5-HT^ receptor mediated vascular responses have only been
observed in sheep pulmonary vein ®® where the potent relaxant effect of 5-HT 
was resistant to ketanserin (5-HT2 antagonist), methysergide and methiothepin,
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(non-specific 5-HTi antagonlsts/5-HT2 antagonists) and MDL72222 (5-HTs
antagonist). The responses, however, were competitively antagonised by high
concentrations of tropesitron, as were responses to aMe-5-HT and a novel
agonist BIIVIU8. Together with a lack of efficacy of sumatriptan and 2-Me-5-HT 
these results were in keeping with a 5-HT^ mediated response. 5-CT however,
also behaved as a potent agonist. Unlike 5-HT it was not sensitive to 
tropesitron, but was sensitive to methiothepin.
When high concentrations of tropesitron were applied, initial antagonism of 5-
HT mediated relaxation was lost and sensitivity to methiothepin was then 
observed. The conclusion was therefore that 5-HT^ and 5-HT^ receptors co­
exist in the sheep pulmonary vein and that 5-HT phenomena only become
%
apparent amid high local 5-HT concentrations.
5-HT Receptors Mediating Vasorelaxation tndirectiy
In addition to directly mediated vasorelaxation, 5-HT can also induce 
vasorelaxation indirectly by stimulating release of EDRF. This process was first 
identified in canine and porcine coronary arteries ®® but has since been 
observed in pig venacava and pulmonary arteries.®® The jugular vein in a 
number of species also exhibits a similar p h e n o m e n o n . I n  all of these 
studies, the observed relaxation occurred despite tonic contraction of vessel
Æ.preparations. The implication therefore was that EDRF release had been 
stimulated by 5-HT. Preparations with denuded endothelium are known to 
show augmented contractile responses to serotonin, but this may simply be 
explained by removal of inhibition of release of EDRF.^ ®®'^ ®® A clear distinction 
should therefore be drawn between studies demonstrating direct EDRF 
stimulation and those studies employing denuded endothelium preparations.
Current evidence supports the premise that 5-HT-induced endothelial 
dependent relaxations are mediated by 5-HT^-like receptors. Spiperone (5- 
HTg), ondansetron (5-HTg) and tropesitron (5-HT^) failed to antagonise
■
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endothelium-dependent responses in rings of coronary artery and guinea 
pig jugular vein Methiothepin, however, exhibits potent antagonist activity „ jj
and the order of agonist potency (5-CT > 5-HT > aMe-HT> sumatriptan >8-
hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) > 2-Me-HT) suggests a 5- 
HT^-like receptor profile.^®  ^ Although this receptor is not identical to the 5-HTid
receptor mediating vasoconstriction, major similarities cannot be overlooked.
For example the potency of agonist drugs at these receptors follow the same 
order as the 5-HT^-iike receptor mediating vascular contraction. Furthermore,
the second messenger characteristics appear to overlap. 5-HT-induced 
relaxations of the pig coronary artery are inhibited by pertussis toxin, consistent 
with coupling to a G protein and adenylate cyclase.^^® Negative receptor 
coupling to adenylate cyclase has already been described for the 
vasoconstrictive 5-HT, counterpart.^
The distribution and function of these 5-HT^ receptors within the vascular
system are poorly understood. Invasive haemodynamic studies with 
sumatriptan confirm vasoconstrictor effects, but these responses may be 
dampened by a simultaneous 5-HT^ induced endothelium dependent relaxation.
In anaesthetised beagles, the vasoconstrictor effects of sumatriptan are
heightened when nitric oxide (NO) release is b lo cke d . Th e  overall role of 5- 
HT. receptors in controlling the vasculature therefore remains unknown. A 
similar common identity for these two 5-HT^ receptors is suggested, but the
exact relationship requires further clarification.
Atypical 5-HT-  ^ Receptors on Vascular Endothelium
Before identification of the above described 5-HT^-like receptor on vascular
endothelium, the ability of 5-HT to effect endothelium dependent relaxations via 
an atypical 5-HT receptor had been observed in a number of species and 
tissues.®®'®^ '^ ®®'^ ®® The ability of L-arginine analogues to inhibit such relaxation
suggested that the receptor stimulated NO release. As is the case for the 5-
25
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HT^-like receptor on vascular endothelium, S-HT^ (ketanserin) and
antagonists (MDL72222, ondansetron) are unable to block these responses,
whereas methysergide, methiothepin and cyproheptadine are potent
antagonists.®" ’^ ®^® The pharmacological profile of agonists differs however, 
excluding a 5-HT ,-like characterisation.^^^ A selective agonist (723C86) has %
been identified for this receptor, but no specific antagonist exists.^^® At present
5this atypical receptor does not have a formal allocation in the Bradley
,1
specification scheme."^
Isolated tissue studies have demonstrated the presence of this receptor in 
arteries and veins, but confirmation of an important vascular role is still awaited. 
Intravenous infusions of 723C86 in conscious rabbits produces no consistent 
change in systemic or regional haemodynamics.^^® Further studies are required 'i
to clarify the role of this atypical 5-HT receptor.
5 -HT3 Receptor Mediated Reflex Vasodilatation
Evidence exists for a serotonergic mechanism causing reflex vasodilatation. "Ï:
Human forearm and cat intestinal blood flow studies have recognised 
the involvement of 5-HT receptors in a vasodilator reflex. It has been proposed ■Ithat mechanical stimulation of the intestinal mucosa releases 5-HT from 'C
enterochromaffin cells, which, via a neural reflex results in the secretion of
vasoactive intestinal peptide, a known vasodilator h o r m o n e . A  role for an
unknown 5-HT receptor has been suggested since dihydroergotamine, a
substance with serotonergic properties, inhibits this response.^^^ Low doses of
5-HT cause a rapid transient increase in blood flow which is abolished by the 
selective 5-HT., receptor antagonist, tropisetron, suggesting that 5-HT
receptors may be implicated.
3 "  '  '  '  3 ■Ï:!
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conjecture, as is the premise that 5-HT receptor mediated release of 
prostacyclin plays a role in influencing vascular smooth muscle tone.
HEART RATE RESPONSES TO 5-HT AND RELATED DRUGS
Serotonin can elicit both bradycardic and tachycardie responses.
by ketanserin {5-HT2 antagonist).70
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5-HT Receptors and Prostaglandin Secretion
:5-HT has been observed to stimulate vascular smooth muscle synthesis and 
release of PGI^ (prostacyclin) in cell cultures of bovine aor ta.Stud ies  of 
antagonist potency demonstrate this phenomenon to be 5-HTg receptor
vs
m e d i a t e d . A  similar 5-HT-induced prostacyclin release has been noted in |
intact blood vessels. In the dog saphenous vein, 5-HT responses were 
mimicked by a-Me-5-HT and blocked by ritanserin, again implicating a 5-HT2
re cep to r . I n  the rat aorta, however, methysergide, cyproheptadine and 
mianserin all were effective antagonists, but ketanserin was an exception.
The receptor subtype involved in the rat aorta is therefore a subject of
%
Bradycardia
In the presence of an intact CNS and vagus nerves, 5-HT will produce profound
transient bradycardia in a variety of species. These responses can be
eliminated by vagotomy, spinal section or ganglion blockade.^^®’^^® This
suggests it originates from activation of afferent cardiac neurons (i.e. von
Bezold-Jarisch-like reflex). Intravenous bolus injections of 5-HT,
phenylbiguanide and 2-Me-5-HT (5-HT3 agonist) in anaesthetised rats result in 
transient bradycardia sensitive to a number of 5-HT., receptor antagonists
including MDL72222 and ICS205-390.''®®"''®® 5-HT also elicits bradycardia in the 
rabbit.^® '*®®’ ®^^ Phenylbiguanide (5-HTa agonist) and 5-carboximadotryptamine 
(probably by release of platelet 5-HT) can mimic this response which is 
antagonised by MDL72222 ™, 2 naphthylguanldine and bufotenine but not
28
Rapid bolus injections of 5-HT in the cat cause bradycardic responses sensitive
to bilateral vagotomy, atropine and MDL72222.^®®’ "^^® When injected into the
left ventricle^"^\ left coronary artery^"^^or pericardial sac^ "^ ®, a reflex bradycardia
is also induced which is abolished by MDL72222 (5-HT3 antagonist). Injections
of 5-HT into the ascending aorta produce no bradycardic r e s p o n s e . T h e  
above evidence therefore supports a role for 5-HTg receptors in this cardiac
sensory receptor reflex (von Bezold-Jarisch-like reflex).
Cardiogenic Hypertensive Chemoreflex
A cardiogenic hypertensive chemoreflex that increases efferent vagal and
sympathetic nerve activity is induced by 5-HT in the dog. This leads to an initial 
brief slowing of the heart followed by t a c h y c a r d i a . A  role for 5-HT3
receptors is again supported since ICS205-930 could antagonise this 
cardiogenic hypertensive chemoreflex.^"^®
Central 5-HT^^Mechanism
8-OH-DPAT, a 5-HT.,^ receptor ligand reduces heart rate in normotensive, 
spontaneously hypertensive and induced hypertensive rats. This response is 
antagonised partly by pimozide and fully by atropine plus propranolol, but 
methysergide, methiothepin and cinanserin among others have no effect. 
Extensive studies by Fozard et al have demonstrated the bradycardic and 
hypotensive responses in spontaneously hypertensive rats to be centrally
mediated, and that the central actions of 8-OH-DPAT are mediated by 5-HT 1A 
receptors.^®® In the cat, agents with 5-HT.,^ agonist activity lower heart rate in 
contrast to 5-HT.,g agonists which have no effect.^ ®^ "^ ®^  These studies imply that
bradycardia and hypotension result from increased vagal and decreased 
sympathetic tone secondary to central 5-HT.,^ receptor activation, as discussed
below.
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Pre-Synaptic inhibition of Sympathetic Activity
Preganglionic stimulation of sympathetic nerves in rats results in a positive 
chronotropic response which is inhibited by 5-methoxytryptamine via an 
unidentified receptor/®® In the dog 5-HT can abolish electrically stimulated 
tachycardia/®® Cyproheptadine is ineffective in blocking this response 
excluding a role for 5-HT2 receptors.
Stimulation of Cholinergic Neurons
Isolated perfused hearts of reserpine treated rabbits become bradycardic when
exposed to 5-HT. MDL 72222 abolishes this response, suggesting an influential 
role of 5-HT3 receptors on post ganglionic cholinergic nerve endings.''®® It may
be however that 5-HT3 receptors are located on cardiac vagal ganglia as 5-HT3 
receptors have been identified on parasympathetic ganglia."^’ ®^®
TACHYCARDIC ACTION
A variety of mechanisms are responsible for 5-HT induced tachycardia which is 
a species dependent phenomenon. A discussion of these mechanisms follows:
Tyramine-like action;
Intravenous administration of 5-HT in the spinal guinea-pig results in 
tachycardia which is insensitive to ketanserin, MDL72222 or methiothepin, but 
is antagonised by Q> ad re noreceptor antagonists and by the 5-HT uptake 
inhibitor indalpine. Pretreatment with reserpine failed to modify the first 
response to 5-HT but tachyphylaxis quickly developed to subsequent 
chal lenges.Unl i ke the spinal guinea-pig, isolated guinea-pig atria displayed 
a reserpine insensitive tachycardie response to 5-HT.^ ®® The evidence 
therefore suggests that the chronotropic response to 5-HT in the guinea-pig 
heart arises from stimulation of catecholamine release in a manner akin, but not 
identical, to tyramine. Another possibility is that 5-HT stimulates the release of 
calcitonin gene-related peptide from the guinea-pig sinus node to accelerate the
29
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heart rate7®'^ ®® In isolated dog atria the chronotropic response to 5-HT is 
attenuated by both desipramine and fi adrenoreceptor blockers, suggesting an 
indirect sympathomimetic action7"^ ’ ®^"^ ’'*®® Similar conclusions have been drawn 
using high dose 5-HT in vivo.
5-H Ï2 receptor stimulation
166
5-HT'I Jike receptor stimulation
Trendelenberg demonstrated that lysergide can abolish 5-HT mediated 
tachycardia in cat atria, but that reserpine, dichlorisoprenaline and cocaine were 
all ineffective/®^ He concluded that this cardioactive action was mediated by the 
"D" 5-HT receptor which may belong to either 5-HT'i-like or 5-HT2 type/®® In
kitten atria pre-treated by reserpine, the responses could be blocked by 
methysergide or phenoxybenzamine, but not by ketanserin, MDL72222 or 
yohimbine/®® In cats with sectioned spinal chords, 5-HT induced tachycardia is 
only partially susceptible to blockade by guanethidine, propranolol, burimamide, 
5-HT2 receptor antagonists ®^® or bilateral adrenalectomy despite the possibility
that 5-HT may stimulate catecholamine secretion from the adrenal medulla/®® 
This action of 5-HT is interrupted by mixed 5-HT., and S-HT^ receptor
antagonists (methiothepin, methysergide) and mimicked by 5-CT to confirm that 
5-HT.,-like receptors mediate tachycardia in the cat.®®'^ ®®'^ ®^
In pithed rats 5-HT (100 pg/kg) increases heart rate and blood pressure and
these responses are effectively antagonised by cyproheptadine. In contrast, 
another 5-HT2 receptor antagonist, R50656, suppressed the pressor response,
but not the tachycard ia. In  contrast to 5-HT, 5-CT fails to increase heart rate 
in ganglion blocked rats and the tachycardia induced by 5-HT is ketanserin and 
cyproheptadine sensitive, suggesting a 5-HT2 receptor function.^^® 5-
methoxytryptamine also elicits tachycardia, but 8-OH-DPAT and DOI have no :
effect on pithed, normotensive or spontaneously hypertensive rats. DOI 
exhibited partial agonist activity at 5-HT2 receptors mediating pressor
30
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propranolol/^®
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responses but completely failed to influence heart rate or to antagonise 5-HT 
induced tachycardia/^®’^^ "^  The unexpected findings with DO! and R50656 point 
toward an "atypical" 5-HT receptor modulating chronotropic responses in the
rat. It cannot be ignored however, that 5-HT at high doses (100 pg/kg) may 
increase heart rate via a tyramine-like action sensitive to desipramine or
Serotonin induced tachycardia in anaesthetised dogs is widely r e p o r t e d . A  
concomitant elevation of noradrenaline concentration in coronary sinus and 
venacaval blood is also observed, but this can be abolished by autonomic 
blockade.^®® Later work has shown that 5-HT induced tachycardia in 
vagotomised, cardiac decentralised and ganglion blocked dogs is accompanied 
by raised catecholamine blood levels which can be suppressed by 
cyproheptadine, methysergide, syrosingopine (a catecholamine depleting 
agent) and bilateral adrenalectomy (43% reduction).^®®’ ®^® 5-HT may therefore 
induce tachycardia by 5-HT2 receptor-mediated catecholamine release from the
adrenal medulla in addition to a tyramine-like effect.
5-HT3 Receptor Stimulation
In isolated rabbit atria, 5-HT stimulates noradrenaline release, resulting in 
tachycardia. Extensive studies in perfused heart preparations have 
demonstrated that while reserpine, propranolol, cocaine, MDL72222 and ICS 
205-930 (5-HT3 antagonist) inhibit this tachycardia; desipramine, methiothepin
and methysergide are without effect.^ ®®’ ®^®’^^ ®’^^® The indirect cardio-active 
effect of 5-HT in the rabbit is therefore mediated via 5-HTg receptors stimulating
■release of noradrenaline from post-ganglionic sympathetic nerve terminals. 5- 
HT3 receptors also mediate tachycardia in conscious instrumented dogs.^ ®®
■V;
Î;
■ ::
BLOOD PRESSURE RESPONSES TO 5-HT AND RELATED DRUGS
5-HT exerts a complex triphasic effect on arterial blood pressure consisting of 
rapid, intense but brief hypotension followed by a moderate hypertension and, 
finally, a more sustained hypotension/®®'^®® The late sustained hypotensive 
effect is more potent than either the initial hypotensive effect or the pressor 
response and therefore the term serotonin is actually inconsistent with its 
action/^® As holds for many 5-HT induced responses, the hypertensive phase 
varies largely depending on the species and experimental conditions. In the 
dog, particularly after ganglion blockade, the hypertensive phase is prominent
32
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5-HT4 Receptor Stimulation
In anaesthetised pigs, 5-HT elicits a tachycardia which is insensitive to drugs
affecting autonomic receptors, histamine Hi and H2 receptors, dopamine 
receptors, calcium channels, 5-HT.,-like and/or 5-HTg and 5-HT3 receptors.^®^
■AFurthermore, selective agonists at 5-HT^-like and 5-HT3 receptors do not 
increase heart rate. Therefore, 5-HT-induced tachycardia in the pig is not
mediated via endogenous catecholamines, histamine or calcium transport into 
the SA node, nor does it result from an action on 5-HT.,, 5-HTg or 5-HT3
V 'î ’:receptors.^®^ 5-methoxytyptamine, renzapride and alpha-methyl 5-HT 
mimicked the effects of 5-HT on the pig heart, the responses being antagonised
I:by ICS205-930. This evidence therefore implies that 5-HT-induced tachycardia 
in the pig is controlled by 5-HT^ receptors. 5-HT^ receptors also appear to play Ia role in human atria where a positive inotropic effect is observed.®' ’^®®’®^’’’®® S
Unidentified Mechanisms
In hamster isolated atria, 5-HT increases heart rate probably by combination of 
a direct effect on the myocardium and an indirect effect via the liberation of 
noradrenaline from cardiac sympathetic nerves, since the responses are 
essentially unaffected by phentolamine plus propranolol or 
phenoxybenzamine.^®®’ ®^'^
■?v
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.a1-
' ^VA
33
67,187^  whereas this phase is marginal in the rabbit °^J3G,187^  ^^^139.187^^ . pjgg las- 
®^° These differences may be accounted for by distribution and population 
variations in 5-HT receptor subtypes in different species.
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Initial Transient Depressor Response
The initial hypotensive response to 5-HT arises from an initial bradycardia with
consequent reduction in cardiac output. This occurs secondary to stimulation of 
5-HT3 receptors on afferent cardiac vagal nerves. Some evidence however
suggests a transient 5-HT3 mediated vasodilatation which may arise from an 
axon-like reflex.^ ®®
Pressor Response '■
The pressor phase has been attributed to 5-HTg receptor effects as this phase 
is sensitive to ketanserin and related drugs. The activation of 5-HT receptors 
may occur on the blood vessels as in the rat 131,172-174,186,191  ^ and cat ^6,139,170^ ,. 
on the adrenal medulla to stimulate catecholamine release as occurs in the 
dog 67,159 contractile effects on arteries and veins are generally mediated 
by 5-HTg receptors, although in cranial blood vessels of different species 
(including humans) and in dog saphenous vein, 5-HT.,-like receptors also
'
mediate vasoconstrictor responses.®®’®®’"^®’®^’ ®^®"^®® In some vessels and species 
5-HT.,-like and 5-HT2 receptors appear to co-exist where they both mediate
contractile responses. This appears true in the dog®®'®®'®®'^ ®®'^ ®^''"®® and 
monkey.®®’"^®’’'®®
5-HT may also influence sympathetic nerve activity. Pontomedullary 
serotonergic neural connections and 5-HTg receptors exert an excitatory effect
,,,,,
on pre-ganglionic sympathetic activity.®®® Whether these nerves have a tonic 
influence, however, is doubtful. The 5-HT-induced increase in sympathetic .activity may also involve a 5-HT.,-like receptor. Intrathecal administration of 5-
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CT (but not 8-OH-DPAT) in the rat increases sympathetic activity, an action 
which is not antagonised by ketanserin, MDL72222 or ICS 205930.®°^
Late Depressor Response
Selective 5-HTg or 5-HTg receptors fail to inhibit the late depressor effect of 5-
HT. Methysergide and methiothepin can however abolish this 
r e s p o n s e . 5 - C T  can evoke a similar depressor response which is 
also blocked by methiothepin and methysergide.^^®’^^ ®’’’®® Furthermore, there is 
good correlation between the hypotensive activity of tryptamine analogues and 
their affinity for the 5-HT-like receptor binding site.^ ®^  The late hypotensive 
response therefore appears to be mediated via the 5-HT'i-like receptor, but a
number of different mechanisms are involved depending on experimental 
preparation and species. These mechanisms include central vasomotor 
inhibition, vascular smooth muscle responses, inhibition of noradrenergic 
neurons and release of endothelium-derived relaxant factor (EDRF).
Central Vasomotor Inhibition
CNS injections of 5-HT are known to cause pressor, depressor or biphasic 
responses depending on the site of application, dose used, whether the animals 
were conscious or anaesthetised, normotensive or hypertensive.®®®'®®^  5-HT 
neuronal function appears to vary depending on the site within the CNS. Dorsal 
and median raphe, anterior hypothalamus and ventrolateral medullary raphe 
areas appear associated with pressor responses, whereas midline medullary 
raphe nuclei may elicit pressor or depressor actions.®®  ^®®® Different 5-HT 
receptors seem to mediate the central pressor and depressor responses.®®®
A number of 5-HT' iagonists have been observed to decrease arterial blood
pressure and heart rate.®®® Urapadil is one of these agents, which although it 
also possesses a-adrenergic antagonist activity still relies on 5-HT.,^ agonism
for some of its effects.®®®'®^ ® The role of the CNS in 5-HT.,^ mediated
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.. ■cardiovascular responses has been confirmed in several studies. Urapidil,
‘ ■flesinoxan and 8-OH-DPAT when administered into the cat CNS decrease heart 
rate and blood pressure more potently than when administered 
intravenously.^®®"^®®’®®®’®^®’®^  ^ 5-HT.,^ receptor antagonism abolishes these
responses.®®'"'®®'''®®’®®®'®®® Additionally, 8-OH-DPAT, flesinoxan and/or urapidil 
reduce sympathetic nerve activity 161,152,200.212,213 especially of the renal nerves 
®^"^ , leading to renal vasodilatation.®^®'®^® Hypotension, bradycardia and a 
reduction in renal nerve activity has also been demonstrated to occur following 
5-HT administration into the fourth ventricle of the cat ®®^ as has the centrally-
induced increase in vagal tone in the rat.®®®'®®^ 5-HT may also act at a spinal 
level, with 5-HTg receptors implicated in the inhibitory effect on sympathetic
activity. Intrathecal a-Me-5-HT mimics this effect which is antagonised by 
ketanserin, but unaffected by prazosin, MDL72222 or ICS 205930.®®^
Inhibition of Noradrenergic Neurons
In the isolated dog saphenous vein 5-HT has a dual action on post-ganglionic 
sympathetic neurons. Low concentrations of 5-HT inhibit noradrenaline release ' 
following transmural stimulation, while higher concentrations initiate :
catecholamine release by a tyramine-like reaction.®^  ^The inhibitory effect of 5-
HT and related drugs on transmitter release from post-ganglionic sympathetic
nerves has been confirmed in various organs of different species including
canine and human saphenous vein,®^ ’^®^® canine coronary ®^ ®and carotid
arteries®®®’®®^ and rat kidney®®® vena cava®®®and heart.''®® The involvement of 5- 
HT.,-like receptors is suggested by the high agonist potency of 5-CT and 5-HT
■/
222,223 antagonism by methiothepin metergoline and methysergide
'Ï158,219,222,224 ^ot ketanseun, LY53857 or metoclopramide.^®®'®^® ®®® Obviously 
interference with sympathetic neurotransmission by 5-HT will modify direct 
cardiovascular effects. An example of this occurs in the canine external carotid
-Avascular bed when 5-HT causes vasodilatation when sympathetic vascular tone 
is high and vasoconstriction when it is low.®®® ®®®
,135
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Vascular Smooth Muscle Responses and Release of EDRF
These two mechanisms by which vascular relaxation may be mediated by 5-HT 
have already been discussed earlier in this chapter.
SEROTONIN RECEPTORS ON CORONARY ARTERIES
influencing the response to serotonin.
I
Both 5-HT.j-like and 5-HTg receptors exist in human coronary arteries. As might 
be expected from the foregoing discussion, the role of these two receptors in 
the coronary circulation is equally complex. The actions of serotonin and 
related compounds on the coronary arteries may also vary depending on the 
presence or extent of atherosclerosis. In acute ischaemic syndromes (i.e. 
unstable angina and myocardial infarction) it is known that fissuring of an 
atherosclerotic plaque occurs with subsequent platelet aggregation and 
serotonin release. Serotonin may therefore play an important 
pathophysiological role in such situations. In patients with complex coronary
■Ï:artery lesions, elevated serotonin levels have been observed in the coronary 
sinus.®®® Plasma coronary samples are also capable of inducing canine 
coronary artery vasoconstriction in vitro, an action which is inhibited by 
serotonin receptor antagonists.®®^
In anaesthetised dogs, serotonin causes dose-dependent constriction of
:
coronary arteries when the endothelium has been injured.®®®’®®® In conscious 
dogs with an intact endothelium, serotonin displays a biphasic response with an 
initial vasodilatation, followed by constriction.®®® Isolated coronary artery
“A
segments with an intact endothelium relax in response to serotonin but will 
contract following endothelial removal.®®’®®^ The presence of an intact 
endothelium (e.g. no atherosclerosis) therefore appears an important factor
36
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Human coronary artery responses
In vitro responses using human epicardial coronary artery rings from explanted 
hearts have shown that serotonin causes contraction/® "^"^ The smooth muscle
relative effects of 5-HT.,-like and 5-HTg receptors may vary depending on the 
presence of coronary artery atheroma.
Serotonin administration in vivo displays divergent effects on the coronary
In another study, intracoronary infusion of 5-HT in patients with angiographically
contraction was mediated by both 5-HT.,-like and 5-HTg receptor subtypes but 
the 5-HT receptors were thought to be functionally more important as
ketanserin partly antagonised these responses. A residual contraction (30% of 
the maximum effect) was 5-HT.,-like m e d i a te d I t  was also postulated that the
1
More recently Kaumann and colleagues reassessed the relative participation of 
5-HT.,-like and 5-HTg receptors in human epicardial coronary arteries.®®® They 
found that both constrictor 5-HT.,-like and 5-HTg receptors existed in coronary
arteries and that their relative ratio was not modified by atheroma. In addition, 
they reported the predominance of 5-HT.,-like over 5-HTg receptors in mediating
serotonin-evoked contraction. In the same study they also confirmed selective 
5-HT.,-like mediated contractions with sumatriptan.
1
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arteries.®®® In patients with normal coronary arteries serotonin acted as a 
vasodilator and increased coronary artery blood flow. This effect was 
potentiated by ketanserin, indicating that the vasodilator action of serotonin in 
normal human coronary arteries is non-5-HTg mediated (i.e. possibly 5-HT.,-
like). In patients with coronary atherosclerosis, serotonin-evoked (ketanserin 
sensitive) vasoconstriction and reduced blood flow, suggesting that 
vasoconstriction arises secondary to direct 5-HTg activation.
normal coronary arteries caused a biphasic response in proximal segments, 
with dilatation at low doses and constriction at high doses.®®  ^ In the same
37
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A;:study, intracoronary infusion of 5-HT in patients with coronary artery disease 
caused only vasoconstriction, leading to myocardial ischaemia. In patients with 
stable angina, ischaemia arose from distal (small) vessel constriction, whereas 
patients with variant angina displayed coronary artery spasm at doses of 
serotonin which dilate normal vessels. Ketanserin was unable to attenuate 
neither coronary artery vasospasm nor distal vessel constriction.®®® This 
observation suggests that activation of 5-HT-like receptors, either at hyper­
reactive sites in patients with variant angina, or in the distal epicardial vessel of 
patients with chronic stable angina, may contribute to or cause myocardial 
ischaemia when 5-HT is reieased from aggregating piatelets.
■■I
Two recent studies have confirmed an important role for 5-HT2 receptors when 
vasoconstriction is observed during percutaneous transluminal coronary 
angioplasty (PTCA).®®®’®®^ Following balloon dilatation, coronary artery 
vasoconstriction has been noted distal to the angioplasty site. The degree of
.il;vasoconstriction was related to the amount of serotonin released into the
circulation®®® and was attenuated, at least partly, by ketanersin in both studies.
It therefore must be assumed that both 5-HT.,-like and 5-HTg receptors are i
implicated in serotonin-induced human coronary artery vasoconstriction.
The clinical importance of 5-HT.,-like receptors in mediating coronary artery
vasoconstriction has been highlighted with the use of sumatriptan, a selective 5- 
HT -like agonist, in the treatment of acute migraine. Isolated case reports of
coronary spasm with angina ®®®, myocardial infarction ®®®and ventricular
fibrillation®"^ ® following sumatriptan have raised concerns over its use in patients
with ischaemic heart disease. Coronary artery vasoconstriction following
intravenous®"^  ^and subcutaneous®"^® sumatriptan has been observed, but
detailed EGG monitoring following sumatriptan administration revealed that 99% 
had no EGG changes.®"^ ® 5-HT.,-like agonism with sumatriptan may therefore
unmask underlying coronary artery disease.
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Despite initial claims of selective intracranial vasoconstriction, sumatriptan has 
also been shown to exert vasopressor responses on the systemic and 
pulmonary circulation.®"^  ^ A relative percentage increase in pulmonary artery 
pressure greater than the change in systemic arterial pressure by a factor of 2-3 
may suggest greater density of 5-HT.,-like receptors in the pulmonary compared
to the systemic circulation.®"^ ® The number of patients, however, was small and 
may therefore not be truly representative. The effects of 5-HT., agonism on left
ventricular function in vivo have not been studied.
SUMMARY
The effects of serotonin on the cardiovascular system are therefore complex, 
comprising tachycardia or bradycardia, hypotension or hypertension and 
vasoconstriction or vasodilatation. The eventual response depends on a
'■'Anumber of factors including species, vascular bed under study, and dose 
employed. As the effects of serotonin are receptor mediated, the net effect will 
rely on the relative densities of 5-HT receptor subtype population within the 
vascular bed under study. The lack of suitably selective antagonists and 
agonists has limited progress in the investigation of serotonin-mediated ’’t
responses. Present knowledge implies that 5-HT acts on seven main classes of
■A;.
receptors, but these subtypes are defined in terms of functional pharmacology 
rather than agonist/antagonist potency orders. Increased understanding of the
Aroles of each receptor can only be expected when more selective agents
ëbecome available.
7
IThe physiological role of 5-HT remains controversial, with a plethora of in vitro 
findings which may bear no clinical or in vivo relevance. The pathophysiological 
role for 5-HT has however been identified in a number of clinical settings
a:namely, migraine, acute myocardial ischaemia and nausea/vomiting.
'iHeightened awareness of 5-HT pharmacology may promote further therapeutic A
interventions in these areas.
:
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This thesis will investigate some aspects of the cardiovascular actions of 
serotonergic agents, looking particularly at the role of 5-HT.,-like and 5-HTg
receptors in vivo. The specific aims are listed below.
6. To examine whether sumatriptan induces 5-HTib/d vasoactive effects on the 
peripheral circulation using forearm blood flow plethysmography.
AIMS
1. To investigate the mechanism of the rise in pulmonary artery wedge 
pressure following sumatriptan injection and determine whether this is 
secondary to an acute increase in afterload or due to negative inotropic 
effects.
2. To examine the possibility that sumatriptan has a greater 5-HTi induced 
vasopressor response in the pulmonary compared to the systemic 
circulation.
3. To assess whether systolic time intervals may be a potential non-invasive 
tool to investigate the haemodynamic effects of 5-HTi agonists.
4. To assess whether the 5-HTib/d agonist, naratriptan has a similar in vivo 
pharmacological profile to sumatriptan.
5. To investigate the haemodynamic effects of eletriptan, a 5-HTio agonist with 
limited 5-HTib activity, and comment on whether the absence of 5-HTib 
activity potentially alters drug pharmacodynamics.
40
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7. To investigate the effect of sumatriptan on plasma noradrenaline levels.
8. To assess whether ketanserin, a 5-HT2 antagonist, has vasodilator 
properties on the coronary arteries and if so, to infer on the possibility of 
basal serotonergic tone in patients with stable angina symptoms.
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ARTERY/VEIN
Saphenous Vein
Basilar Artery
Umbilical Artery 
Pulmonary Artery
Coronary Artery
SPECIES
Rabbit
Human
Sheep
Dog
Primate
Human
Human
Human
Bovine
Human
REFERENCE NO.
34
35,36
37
38.39
38.39
40
41
42 
42
43-45
Table 1.1 Tissues in which 5-HT'i-like receptors mediate vascular contraction
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ARTERY/VEIN
Rabbit
Dog
Cat
Pig
Rat
Human
* Part contribution from 5-HT'i-like receptors
Table 1.2 Tissues in which 5-HT2 receptors mediate vascular contraction.
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SPECIES REFERENCE NO.
Aorta 49
:3:=
_
Carotid Artery 50 -1A
Carotid Artery 51 1
Femoral Artery 51 1
Gastrosplenic Vein 52 1
ÏAMiddle Cerebral Artery 53
Saphenous Vein 54 ■1
Carotid Artery 50 1
Coronary Artery 55 1
Pulmonary Artery 56 J
Basilar Artery 57 a
Jugular Vein 58
■A:%Mesenteric Vein 59
Femoral Artery 60 1
Temporal Artery 61 s
Coronary Artery* 43 :A
44
SPECIES VEIN RECEPTOR TYPE REFERENCE
Cat Saphenous vein 5-HT '] -like 54
Rabbit Jugular vein 5-HT'I-like 84,105
Neonatal Pig Vena Cava 5-HTi-like 85,86
Sheep Pulmonary Vein 5-HTi-like 5-HT4 78,80
Table 1.3 Tissues in which 5-HT mediates vasorelaxation directly.
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RECEPTOR AGONIST ANTAGONIST
45
1
■AIiof
5 -H T ia
5 “H T ib
5-HT
8-OH-DPAT
Urapidil
5-HT
5-CT
Sumatriptan
Naratriptan
Methiothepin 
Methysergide 
Metergoline 
WAY 100135
Methiothepin
Metergoline
I
..a::;’-
;:>■A'
5-HTic
5-HTi,
5-HT2
5-HT
a-Methyl-5-HT
5-HT
5-CT
Sumatriptan
Naratriptan
Eletriptan
5-HT
a-Methyl-5-HT
Mianserin
Methysergide
Methiothepin
Metergoline
Mesulergine
Methiothepin
Methysergide
Metergoline
Ketanserin
Ritanserin
Spiperone
Methiothepin
Metergoline
Mesulergine
Methysergide
Cyproheptadine
”1
f : :
5-HT
5 -HT4
5-HT
2-Me-5-HT
5-HT
Cisapride
Ondansetron 
Granisetron 
T ropisetron 
MDL 72222 
ICS 205-930
GR113808 
Tropesitron 
ICS 205-930
«
5-CT= Carboxamidotryptamine
Table 1.4 Serotonin receptor agonists and antagonists.
'■fi'
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NH2
5- HYDROXYTRYPTAMINE
H
N(CH3)
SUMATRIPTAN
NARATRIPTAN
H
Figure 1.1 Structural formulae of 5-hydroxytryptamine, sumatriptan and 
naratriptan.
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TRYPTOPHAN
Tryptophan
>  5-HYDROXYTRYPTOPHAN
Hydroxylase
L -Amino Acid 
Decarboxylase L -Amino Acid 
Decarboxylase
TRYPTAMINE 5-HYDROXYTRYPTAMINE
Figure 1.2. Synthesis Of 5-Hydroxytryptamine (5-HT)
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CHAPTER 2
METHODS.
.£|i
f
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The Ethics Committee of The West Glasgow Hospitals University NHS Trust 
approved studies. Each patient was issued an appropriate information sheet
'1
49
METHODS 
Patient Groups
All patients in this thesis were studied during coronary arteriography performed 
for diagnostic purposes with a view to selection of patients for coronary 
intervention by angioplasty or coronary artery bypass surgery. All vasoactive 
therapy other than sublingual glyceryl trinitrate was discontinued 24 hours Ibefore study.
■
Standard exclusion criteria were used to exclude women of child bearing 
potential and patients with an unstable clinical substrate including myocardial 
infarction within 3 months, unstable angina, cardiac arrythmias and
hypertension (diastolic BP >95 mmHg). Patients with a coronary artery stenosis 
>50% were excluded from the studies involving sumatriptan, eletriptan and 
naratriptan on account of potential coronary vasoconstrictor properties of 5-HTi 
agonists. Patients in the ketanserin study were not subject to exclusion on the
Ibasis of coronary artery anatomy. Ketanserin can however prolong the QT
interval particularly in the presence of hypokaleamia. Patients were therefore |fnot enrolled if they had a prolonged QT interval or were concurrently taking 
potassium-losing diuretics.
and written informed consent was obtained.
I
■I
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SVR = 80(A-RA) dyne.s.cm-5 A = mean arterial pressure (mmHg)
PVR = 80(PA-PAW1 dyne.s.cm‘ 5 PA = mean pulmonary artery pressure
C.O. PAW = mean pulmonary artery wedge
pressure (mmHg)
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Central Haemodynamic Monitoring
Routine left ventricular angiography and selective coronary arteriography were 
performed by the conventional Judkin technique. After the diagnostic procedure, 
a pigtail catheter was retained in the aorta to measure systolic and diastolic 
blood pressures, and in turn could be introduced into the left ventricle (LV) to 
measure LV systolic and end diastolic pressures (LVEDP). To allow the 
calculation of peak rate of left ventricular pressure rise (ôp/ôt), the left 
ventricular pressure tracing was expanded to lOOmm.s"^ and d i g i t i s e d . T o  
measure pulmonary artery systolic (PASP) and diastolic (PADP) pressures, 
right atrial pressure (RAP) and occluded wedge pressures (PAWP), a 7f balloon
flotation catheter (Swan Ganz) was positioned in the pulmonary artery. Hard I
copies of systemic, pulmonary and left ventricular pressure tracings were
obtained at baseline and at 10 minute intervals until stable. Following 
administration of placebo, pressures were recorded. Thereafter active drug was 
administered and pressure recordings were obtained at regular intervals for 15- 
40 minutes depending on the individual protocol for each drug.
Cardiac outputs were measured by the thermodilution technique, a mean value 
of at least 3 measurements at each timepoint. The total systemic vascular
f;resistance (SVR) and pulmonary vascular resistance (PVR) were calculated 
from the undernoted formulae.
0.0. RA = mean right atrial pressure
(mmHg)
■li.
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As drug administration was performed on an open basis in all studies, pressure 
tracings were analysed by a blinded observer.
Systolic Time interval Estimation
The systolic time intervals (STI’s) were measured from a simultaneous recorded 
electrocardiogram and aortic pulse wave tracings (Figure 2.1). This allowed the 
calculation of total electromechanical systole (EMS) from the onset of the QRS 
to the incisural notch on the arterial tracing. The left ventricular ejection time 
(LVET) was measured from the upstroke of the arterial tracing until the trough of 
the incisural notch. The pre-ejection period (PEP) was derived by subtracting 
the LVET from the total electromechanical systole. This represents the interval 
from the onset of electrical depolarisation until the onset of mechanical ejection. 
The ratio of the PEP over LVET was calculated (PEP/LVET). All STI values 
were then corrected for heart rate according to the regression formula in table 
2 .1.
Quantitative Coronary Angiography
After base-line measurements, placebo and active drug were administered via 
an intravenous cannula in the right antecubital fossa (ketanserin, eletriptan) or 
subcutaneously into the deltoid region of the right arm (naratriptan). Quantitative 
angiography was performed on right and left coronary arteries. The chosen 
artery was determined after visualisation of the coronary artery system in the 
standard views. A projection was chosen that allowed simultaneous 
visualisation of the coronary artery system and the diagnostic 6 French catheter 
which was used for reference calibration. Serial angiograms were obtained with 
a Siemens angioscope C arm. X-ray tube to patient distance was fixed to 
maintain identical magnification. Non-ionic contrast medium (Ultravist) 4-7 ml 
was injected by hand into the coronary artery under study. Recordings of the
51
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angiograms were stored on digital tape and analysed on a Siemens 
Angiographic Workstation (AWOS v4.0) or on a Cardiotrace software package 
with automatic edge detection. End diastolic frames from the third or fourth 
cardiac cycle were stored for analysis and several corresponding segments 
were identified along the lengths of the artery. Two blinded observers measured 
coronary artery diameter at these sites using the automated edge detection 
programme. Absolute values were obtained by using the 6 French catheter 
diameter (1.98mm) as a calibration factor. Stenotic areas in the arteries were 
also identified and the stenotic index (percentage) automatically calculated by
Vthe computer.
Reproducibility Study
Reproducibility of the methodology to measure coronary artery dimensions was 
assessed in 15 additional patients (8M, 7F) undergoing diagnostic coronary 
angiography. Immediately after the diagnostic angiogram, a second 
angiographic run was performed in a manner identical to that described above. 
Angiograms were stored on digital tape and coronary artery dimensions were 
measured by 2 observers on the software analytical system. A total of 53 
coronary artery segments were measured (see table 2.1), with a mean (sd) 
diameter of 3.2 ± 0.6 mm. Mean (sd) intraobserver variability was 0.13 ±
0.13mm (subject 1) and 0.13 + 0.12mm (subject 2). Mean interobserver 
variability was 0.14 + 0.15 mm. The coefficient of variation was calculated for
.
each observer using the technique described by B l a n d . T h e  intra-observer 
coefficients of variation were 5.3% (observer 1) and 4.8% (observer 2). The 
inter-observer coefficient of variation was 5.2%.
7
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STUDY LIMITATIONS
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Patient numbers
The individual studies in this thesis involved small patient numbers and this may 
have resulted in type 1 or type 2 errors. In those studies, which failed to show a
I
significant change in coronary artery diameter, the possibility of type 2 errors 
should not be overlooked. Due to catheter laboratory constraints, coronary 
artery protocols were restricted to 10 patients. Assuming a 20% change in 
coronary artery diameter to be clinically relevant, this would require 
approximately 18 patients to detect such a change with 90% probability 
however.
Patient selection
It is important to recognise that the responses to each of the serotonergic 
agents in these studies are likely to have been influenced by by the functional 
state of the endothelium. Patients with modest coronary artery atherosclerosis 
are likely to have dysfunctional endothelium and could therefore respond 
differently to subjects with completely normal coronary angiograms. Other 
factors also associated with endothelial dysfunction include cigarette smoking, 
hypercholesterolaemia, diabetes and the post-menopausal state. The 
prevalence of factors predisposing to endothelial dysfunction in each of the 
chapters is discussed below but it is impossible to say with certainty that the 
endothelium was dysfunctional in all of these patients as assessment of 
endothelial dependent relaxation was not made for each individual. This is an 
important limitation as many of the subjects in this thesis may fall into the 
category of Syndrome X which is associated with angiographically normal 
coronary arteries but endothelial abnormalites. In addition, smoking status was
■I
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unknown in a number of patients and some of the earlier studies were 
performed prior to widespread assessment of serum cholesterol in patients with 
suspected coronary artery disease and therefore cholesterol levels were not 
recorded for all individuals.
Chapters 4 & 5:- Nineteen of 28 patients (68%) had known potential causes of 
endothelial dysfunction. This included 14 patients with mild coronary artery
Chapter 3:- A total of 5 patients (50%) had known factors predisposing to 
endothelial dysfunction. Two patients had minor coronary artery disease and a 
further 3 were post-menopausal women not on hormone replacement. 
Cholesterol levels and smoking status were not known for these patients and 
there were no diabetics.
disease. Smoking status was not documented in all patients. Ten patients were
post-menopausal of which 5 also had mild coronary artery disease. Cholesterol 
levels were unknown and there were no diabetics. •4
Chapter 6 :- Eight of 10 patients had factors predisposing to endothelial 
dysfunction. One patient had minor coronary artery disease, 2 patients were 
current smokers and 4 patients were post-menopausal. One further patient was 
diabetic, post-menopausal and hypercholesterolaemic.
Chapter 7:- Six often patients (60%) had known potential causes of endothelial 
dysfunction. Two patients had mild coronary artery disease. Four patients were 
post-menopausal of which 3 and 2 respectively were also hypertensive and
54
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hypercholesterolaemic. Two further patients were post-menopausal but were on 
hormone replacement. Smoking status was not recorded.
METHODOLOGICAL LIMITATIONS
Limitations of ôP/ôt measurement
55
Chapter 8:- Nine often patients (90%) had factors predisposing to endothelial 
dysfunction. Eight had coronary artery disease (4 of which were current 
smokers, a further 3 were post-menopausal and 3 were hypercholesterolaemic). 
One patient with normal coronary arteries was a diet controlled diabetic and 
hypercholesterolaemic.
Chapter 9:- All subjects in this chapter were normal healthy volunteers with no 
known factors predisposing to endothelial dysfunction. i
%
The use of fluid filled catheters/ transducer systems to measure haemodynamic 
pressures has inherent sources of error.^ "^ ® Accurate measurement of pressure
waves requires a frequency response range of 20Hz but commonly used 
pressure measurement systems with 6F catheters attached to standard strain 
gauge manometers have frequency responses less than 10Hz. In addition,
■V
motion of the catheter within the left ventricle or against the wall of the ventricle Ican cause artifact. Micromanometer catheters, which have a pressure
- i :transducer mounted at the catheter tip, have superior harmonic properties and 
are therefore less susceptible to measurement error. Ideally therefore, a
-micromanometer system for ÔP/Ôt measurement should have been employed Ibut this would have had both cost and time implications (micromanometers
?require meticulous calibration).
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Other possible invasive methods of measuring LV function during this study 
would include measuring LV volumes, stroke volume and ejection fraction in 
response to placebo and sumatriptan injection. This would however involve 
repeated left ventricular angiography which is not without risk (eg. air embolus, 
excessive x-ray contrast and ventricular dysrhythmias). Ejection fraction could 
be measured non-invasively by radionuclide ventriculography but this would 
obviously entail radiation exposure. Trans-thoracic echocardiography can 
quantify LV ejection fraction but this requires high quality recordings with
'precise visualisation of the endocardial border which is not possible in all 
subjects.
Limitations of STI methodology
The technique for measuring systolic time intervals in this study was
a
unconventional and could be criticised. The intention was to assess whether 
STI may represent a potential non-invasive method of assessing the 
cardiovascular effects of serotonergic drugs and this would obviously require 
confirmation using conventional non-invasive approaches. The use of fluid filled 
catheters/ transducers to measure aortic pressures is open to the same 
criticism applied to that for ôp/ôT assessment (see above). In addition, the 
inherent transmission delays through the catheters results in the absolute 
values of the STl’s being slightly longer than those obtained externally. 
Nonetheless a directional change may be evident.
Using the convential technique of simultaneous electrocardiography, 
phonocardiography and carotid pulse wave tracings would provide more
accurate absolute values for the STI. This however, relies upon precise
variation of 10-15% for this technique have been reported.
'■1
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identification of a) the onset of ventricular depolarisation on the EGG b) the 
early high frequency components of A2 and c) the incisural notch on the carotid 
tracing, which are all common sources of error.
Limitations of venous occlusion plethysmography methodology
.In conventional venous occlusion plethysmography studies, active drug is given 
intra-arterially and the contralateral arm is used as a simultaneous control for
■ I
forearm blood flow. In chapter 9 however, sumatriptan was administered f
subcutaneously and therefore two study days were required. Although
Istrenuous efforts were made to standardise experimental conditions, it is
gpossible that biological variation may have occurred between both study days
'and this may have influenced results. Problems with reproducibility of
measurement of forearm blood flow have been described but coefficients of
I
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Segment Observer 1 Observer 1 Observer 2 Observer 2
Run 1 Run 2 Run 1 Run 2
1 3.7 3.3 3.3 3.0
2 3.1 3.0 2.8 2.6
3 3.1 2.9 3.1 3.04 3.1 3.0 2.9 3.3
5 3.0 3.2 3.0 3.06 5.2 5.9 5.1 5.67 3.2 4.0 3.0 3.48 2.1 2.0 2.0 2.2
9 3.7 3.9 3.7 3.910 4.8 4.6 4.6 4.911 3.2 3.1 3.2 3.212 2.5 2.4 2.5 2.7
13 2.6 2.5 2.7 2.6
14 3.7 4.0 3.9 4.1
15 3.0 3.1 2.6 2.416 2.9 2.7 2.9 2.917 2.3 2.4 2.4 2.318 1.7 1.9 2.0 1.9
19 3.8 3.9 3.9 4.020 4.3 4.5 4.4 4.4
21 3.4 3.4 3.4 3.5
22 2.2 2.4 2.1 2.5
23 2.5 2.5 2.4 2.8
24 2.1 2.1 2.1 2.4
25 3.1 3.0 3.1 3.0
26 3.5 3.6 3.5 3.827 1.9 1.8 1.9 1.728 3.4 4.0 3.4 4.0
29 3.0 2.9 3.2 3.1
30 2.4 2.2 2.4 2.631 4.1 4.0 3.9 3.932 2.1 2.0 2.1 2.0
33 3.6 3.6 3.4 3.5
34 3.3 3.3 3.3 3.3
35 3.3 3.3 3.3 3.3
36 2.4 2.5 2.6 2.537 1.8 1.9 1.7 1.938 2.3 2.4 2.2 2.139 4.3 4.4 4.3 4.440 4.0 4.1 4.1 4.041 5.1 4.9 5.0 5.042 3.4 3.8 3.7 3.5
43 3.4 3.5 3.7 3.544 3.0 2.9 2.9 2.745 3.5 3.2 3.5 3.0
46 3.8 4.2 3.8 4.4
47 3.8 3.7 3.6 3.7
48 3.5 4.0 3.7 4.049 2.9 2.8 3.0 2.850 2.0 1.8 1.9 1.951 3.3 3.5 3.2 3.252 3.3 3.4 3.2 3.253 3.6 3.6 3.8 3.6
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PWONO
AORTICPRESSURE
LV PRESSURE
ECG
Figure 2.1: Simultaneous tracing of electrocardiogram, 
phonocardiogram, left ventricular and aortic pressure tracings. LVET= left 
ventricular ejection time, PEP= pre-ejection period, QS2= total 
electromechanical systole.
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CHAPTER 3
THE HAEMODYNAMIC EFFECTS OF SUMATRIPTAN, A SELECTIVE 5- 
HTib/d a g o n is t .
60
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'iSerotonin, sumatriptan and their role in migraine.
Sumatriptan, a selective 5-HT ib/d receptor agonist, is the prototype and first 
clinically available 5-HTi agonist, which is effective in the treatment of acute 
migraine. Fifty years ago, serotonin (5-HT) was isolated and identified as a 
vasoconstrictor substance.^ Since then the effects of serotonergic compounds 
on the cardiovascular system have been extensively studied. During the 1960’s ■1? 
i'levidence accumulated that 5-HT played a role in migraine. Sicuteri showed that
methysergide, a non specific 5-HT antagonist could reduce the frequency and 
severity of migraine headache. "^^® Kimball et al subsequently relieved acute 
migraine pain by intravenous injection of 5-HT.^®° Intravenous serotonin 
however, was associated with side effects of nausea, dyspnoea, faintness and
"Iparaesthesia. Urinary 5-hydroxy indole acetic acid (5-HIAA), the main 
metabolite of 5-HT was later found to be elevated during acute migraine 251
IIn 1983 it was reported that dilatation of the frontal branches of the superficial 
temporal artery contributed to the pain of acute migraine in one third of patients 
and, in a further third of patients, vasodilatation of the carotid circulation was Iimplicated.^^^ The search for a 5-HT agent which could abolish these 
vasodilator responses and thereby relieve migraine pain without unacceptable 
side effects was therefore stepped up. Sumatriptan (GR43175) is an analogue 
of 5-HT with selectivity for the 5-HTi receptor subtype.^®'^®’'^ °’^^ ’^^ ^^  This receptor
■S.occurs in a number of vascular beds in several species and agonist activity is 
known to cause vasoconstriction in vitro (see table 1.1).
I
s '
Of clinical relevance for the acute treatment of migraine, sumatriptan constricts 
human isolated basilar artery."^ ® More interestingly, a selective vasoconstriction
61
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has been observed in the carotid circulation of the anaesthetised cat^ ®^  and
Cardiovascular Side Effects of Sumatriptan
The side effect profile of sumatriptan is favourable. Given subcutaneously, 
adverse events such as tingling (9%), pressure sensation (6%), flushing (6%)
dog.^ ®"^  In the beagle dog, intravenous sumatriptan produced a dose-dependent
■Irise in carotid vascular resistance with negligible effect on heart rate or blood 
pressure suggesting a selective action on the carotid circulation.^^"^ Similarly, 
sumatriptan and ergotamine caused dose-dependent reduction in cardiac 
output through arteriovenous anastamoses.^®^ Whereas ergotamine caused 
increases in diastolic BP and total peripheral resistance, sumatriptan did not, 
again implying that sumatriptan had a selective action on the carotid 
vasculature. There is therefore sound rationale for the use of sumatriptan in iacute migraine.
The efficacy of sumatriptan in acute migraine and cluster headache has been 
evaluated in a number of large double blind controlled t r i a l s . R e s p o n s e  
rates in the order of 60-80% can be expected after subcutaneous sumatriptan 
but the mechanism of action is uncertain. Friberg et al have reported migraine 
pain associated with middle cerebral artery dilatation.^^® This could be reversed 
by sumatriptan suggesting that vasodilatation is responsible for the headache 
and that sumatriptan induced vasoconstriction results in relief of symptoms. 
There is evidence however that the anti-migraine activity of sumatriptan relates 
not only to vascular receptor properties but also on an ability to modulate 
release of certain neuropeptides responsible for neurogenic inflammation 
(plasma protein extravasation and va sod i I atatio n ). ^ 0^.251
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and tightness (3%) occur more commonly than with placebo.^^^The mechanism 
of these side effects is uncertain. Life-threatening side effects have however 
occurred following administration of sumatriptan. Isolated case reports of 
coronary spasm with angina,m yocard ia l infarction and ventricular 
fibrillation '^^® together with the 3-6% incidence of chest pressure and tightness 
have raised cardiovascular safety concerns.
These adverse events suggest that the effects of sumatriptan are not confined 
to the intracranial circulation in humans. There is evidence that this is indeed 
the case. Systolic and diastolic blood pressure rose by a mean of 12 and 
lOmmHg respectively after subcutaneous administration of sumatriptan.^®® The 
effect was evident within 10 minutes of administration and persisted for 30-60 
minutes. Vasoconstrictor responses have been noted from invasive recordings 
of systemic and pulmonary arterial pressure following intravenous and 
subcutaneous sumatriptan in patients undergoing diagnostic cardiac 
catheterisation.
In these two studies, systemic arterial pressure rose by 16-20% with 40-58%
increases in mean pulmonary arterial pressure (MPAP). Furthermore there was 
a 14-16% reduction in coronary artery diameter implying an additional ■f:
vasoconstrictor response in the coronary circulation. An additional rise in the
pulmonary arterial wedge pressure (PAWP) was also observed after 
sumatriptan. The increase in PAWP was postulated to be secondary to 
pulmonary venoconstriction but direct measurement of the left atrial or left
ventricular end diastolic pressure (LVEDP) was not made and therefore a
4
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reduction in left ventricular contractility could not be excluded as the cause of 
the rise in PAWP.
The effect of sumatriptan on standard haemodynamic parameters was therefore 
investigated further in 10 patients undergoing diagnostic cardiac catheterisation, 
paying particular attention to the possibility of a negative inotropic action. 
Simultaneous measurement of the PAWP and LVEDP was performed and the 
peak rate of left ventricular pressure rise (SP/Ôt) was also established allowing 
the mechanism of the rise in PAWP to be more fully evaluated.
4Ï
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METHODS 
Patient Group
Ten patients (3 male, 7 female, mean age 49+/- 9 years) were studied. 
Exclusion criteria and description of the methodology were as reported in 
chapter 2 (pages 49-50). Table 3.1 summarises the study protocol.
;  ,v
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TIME (mins) -10 0 10 20 30 40 50 60
Coronary angiogram *
Placebo injection *
Sumatriptan 6mg s.c. *
6 lead EGG * * * * * * * *
Cardiac
Haemodynamics
* * * * * ie * *
Table 3.1. Study protocol: The haemodynamic effects of sumatriptan.
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Data analysis
A baseline value was obtained for each haemodynamic parameter by averaging 
two observations. As any response occurred within 10 minutes and persisted for 
the 40 minute study period, the average of the haemodynamic recordings at 10, 
20, 30 and 40 minutes after sumatriptan injection were used to summarise the 
response to sumatriptan.
Results are summarised in table 3.2 and in figures 3.1 to 3.6.
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Statistics
Post-placebo and post-sumatriptan results were compared with baseline 
measurements using a paired t-test/confidence interval as the data appeared 
normally distributed.
RESULTS
Electrocardiography
There were no changes in the duration of standard EGG intervals (PR,QRS, QT 
and QTc) and no changes in EGG morphology as assessed from the hard icopies of six lead EGG’s taken at 10 minute intervals throughout the study.
Heart Rate
Mean (sd) baseline heart rate was 66 (8) beats per minute. After placebo, mean 
change in heart rate was 0.7bpm (95%GI -1.6 to 3.0, p=0.6). Mean change in 
heart rate after sumatriptan was 3.8bpm (95%GI -0.2 to 7.8, p=0.15).
"f
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Cardiac Output
Mean baseline cardiac output (0.0.) was 5.1(0.9) l.m in'\ No significant change 
occurred after either placebo or sumatriptan. After sumatriptan, mean change in 
cardiac output was -0.1 l.min'\ (95% C.l. -0.3 to 0.1, p=0.09).
Pulmonary Artery Wedge Pressure (PAWP)
Mean (sd) baseline PAWP was 6.5 (2.5)mmHg. No significant change occurred 
after placebo injection but PAWP rose on average by 2.2mmHg after 
sumatriptan (95% C.l. 0.5 to 3.9, p=0.045).
T
Systemic Arterial Pressure
Baseline systolic (SAP), diastolic (DAP) and mean (MAP) aortic pressure were 
118(19)mmHg, 63.3 (8.7)mmHg and 87 (11 )mmHg respectively. After placebo
Iinjection, no significant changes occurred. Following sumatriptan, SAP rose 
significantly by a mean of 23mmHg (95% C.l. 18 to 28, p=0.00001). DAP rose 
on average by lOmmHg (95% C.l. 5.4 to 14.6, p=0.03). MAP rose on average
by 14mmHg (95% C.l. 11.2 to 16.8, p=0.00002).
yPulmonary Arterial Pressure
ÎBaseline mean pulmonary artery systolic (PASP), diastolic (PADP) and mean 
(MPAP) pulmonary artery pressures were 24.3 (5.6)mmHg, 8.7 (2.9)mmHg and
:S14.6 (4.0)mmHg respectively. After placebo injection, no significant change in y
PASP or PADP occurred but MPAP fell by O.SmmHg (95% c.l. 0.3 to 1.3,
, V
p=0.02). Following sumatriptan injection, PASP rose on average by 3.0mmFlg 
(95% C.l. 1.1 to 4.9, p=0.024), PADP by 2.0mmHg (95% C.l. 0.6 to 3.4, 
p=0.05) and MPAP by 2.0mmHg (95% C.l. 0.6 to 3.4, p=0.039).
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Right Atrial Pressure (RAP)
Mean (sd) baseline RAP was 4.8 (2.4)mmHg. No significant change occurred 
after placebo injection but RAP rose after sumatriptan by an average of 
1.3mmHg (95% C.l. 0.5 to 2.1, p=0.02).
Left Ventricular End Diastolic Pressure (LVEDP)
Mean (sd) baseline LVEDP was 7.2 (2.6)mmHg. No significant change occurred 
after placebo injection. After sumatriptan injection, LVEDP rose by an average 
of 4.4mmHg (95% C.l. 3.0 to 5.8, p=0.0005).
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Peak Rate of Left Ventricular Pressure Rise (ôP/ôt)
Mean (sd) baseline ÔP/ôt was 2304 (823)mmHg.s'\ No significant change 
occurred after placebo. Sumatriptan injection resulted in a non significant mean 
change in ôP/ôtof -187mmHg.s‘  ^ (95%C.I. -335 to -39, p=0.24).
Systemic Vascular Resistance (SVR)
Mean (sd) baseline SVR was 1326 (70) dyne.s.cm ®. After placebo, SVR rose 
on average by 129 dyne.s.cm ® (95% C.l. 82 to 176, p=0001). Mean increase 
from placebo after sumatriptan injection was 237 dyne.s.cm ® (95% C.l. 165 to 
309, p=0.0003).
iPulmonary Vascular Resistance (PVR)
Mean (sd) baseline PVR was 119 (21) dyne.s.cm^®. No significant change 
occurred after placebo injection but sumatriptan injection was associated with a 
mean increase in PVR of 23.3 dyne.s.cm'® (95% C.l. 8.1 to 38.5, p=0.02).
■ .
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DISCUSSION
These results show that subcutaneous injection of sumatriptan causes arterial 
vasoconstriction in extracranial vascular beds, in keeping with previous in vivo 
human studies. '^^^’®'^ ® In the absence of changes in cardiac output and heart 
rate, it is assumed that the pressor responses are due to a direct sumatriptan 
induced vasoconstrictor effect. Procedure related effects cannot be fully 
excluded but this appears unlikely.
. i
The observed 20% increase in systemic arterial pressure and 18% rise in SVR 
in this study is entirely consistent with previous invasive haemodynamic findings 
following intravenous or subcutaneous sumatriptan.®^^’^ "^  ^ In the treatment of 
acute migraine with sumatriptan, significant changes in blood pressure, as 
measured non invasively, have not been consistently r e p o r t e d . S o m e  
observers have however noted sumatriptan induced pressor responses in 
migraineurs.®®® The present study confirms the systemic vasoconstrictive effects 
of sumatriptan. I
■I
In agreement with previous findings, a sumatriptan-induced pulmonary 
vasopressor effect was also observed. Intravenous sumatriptan to a total dose 
of 48pg.kg"^ caused a 53% rise in PASP, 77% rise in PADP and 58% rise in 
MPAP. "^^  ^ Subcutaneous injection of 6mg sumatriptan increased PASP and 
PADP by 40% and 33% respectively. Pulmonary vascular resistance rose by 
400/  ^242 1^  present study PASP,PADP and total PVR rose by 12%, 23% 
and 20% respectively. The rise in pulmonary arterial pressures and PVR is of a 
smaller magnitude than previously recorded and may simply reflect biological 
variation. Previous studies showing an increase in PAP greater than the change
y:
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in systemic arterial pressure by a factor of 2-3 may suggest a greater density of 
5-HTi receptors in the pulmonary compared to the systemic circulation. The 
current findings cannot refute this idea but pooling of the current results with 
those in the 2 previous studies '^^ ’^^ ^^  has been performed in chapter 4.
Equipotent systemic and pulmonary vasopressor effects were observed in this 
study. The reason for this disparity is not immediately evident as the individuals 
in all 3 studies were selected from the same clinical substrate. This study group 
included a higher percentage of females (70% compared to 40% in both 
previous studies). In addition, baseline values of aortic and pulmonary artery 
pressures were slightly lower in the present compared to the previous studies. 
Pulmonary artery wedge pressure increased from a mean placebo value of 
6mmHg to a maximum of 9.3mmHg (55%) compared with the 80% increase 
(8.7mmHg to 15.6mmHg) in the previous subcutaneous study. '^^ ® Simultaneous 
measurement of the LVEDP showed a rise of a similar degree to the PAWP and 
it may be that the change in PAWP is a reflection of the rise in LVEDP rather 
than a pulmonary venoconstrictive effect.
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The rise in LVEDP could be secondary to increased afterload or reflect a
snegative inotropic effect. A negative inotropic effect has not previously been
■noted with serotonergic agonists and studies with human ventricular muscle 
preparations show a lack of functional 5-HT receptors in terms of contractile 
e f f e c t s . H u m a n  atrial preparations, however, elicit a 5-HT4 mediated positive |
inotropic effect. A negative inotropic action of sumatriptan seems unlikely in 
view of the above and the lack of a significant change in the peak rate of left 
ventricular pressure rise (ôP/ôt). It is therefore assumed that the rise in LVEDP
f
"y#s,
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and PAWP are a consequence of the acute increase in afterload. The minor 
non-significant reduction in ôP/ôt could therefore reflect the ventricular response
70
I
to raised aortic pressure and is unlikely to be of clinical significance.
Right atrial pressure also rose following sumatriptan. The acute increase in 
pulmonary artery pressure seen in this study would be expected to raise right 
ventricular end diastolic pressure (cf LVEDP) hence accounting for the increase
.
in RAP. The rise in RAP exceeded the magnitude of the rise in MPAP however,
(28% versus 17%) and it may be that part of the rise in RAP reflects systemic 
venoconstriction in addition to pulmonary artery vasoconstriction. In vitro, 
sumatriptan contracts human saphenous veins.®®’®® In high doses, applied 
locally, sumatriptan also induced venoconstriction in the hand veins of 
migraineurs.®®'  ^ This effect was blocked by ketanserin and was not evident
■;
following a standard clinical dose of 6mg subcutaneously. This ketanserin- 
sensitive response was therefore postulated to be 5-HT2 mediated as a 
consequence of high local concentrations following intravenous injection.
In summary, a standard clinical dose of 6mg sumatriptan (s.c.) caused 
equipotent vasopressor responses in the systemic and pulmonary circulation.
Left ventricular end diastolic pressure and pulmonary artery wedge pressure 
both increased after sumatriptan with no effect on the peak rate of left 
ventricular pressure rise (5P/5t) excluding a negative inotropic action of 
sumatriptan. The rise in right atrial pressure raises the possibility of an 
additional venoconstrictive action. There is no evidence that any of these effects 
are of clinical significance.
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Mean
baseline
value
(S.D.)
Mean
change after 
placebo 
(95% C.l.)
P
Value
Mean change 
after sumatriptan 
(95% C.L)
P value
HR (bpm) 66 (8) 0.7 (-1.6 to 
3.0)
0.6 3.8 (-0.2 to 7.8) 0.15
CO (l.min"') 5.10(0.9) 0.2 (-0.5 to 
0.1)
0.12 -0.1 (-0.3 to 0.1) 0.09
SAP (mmHg) 118(19) 3.0 (-0.3 to 
6.3)
0.12 23 (18 to 28)* 0.00001
DAP (mmHg) 63.3 (8.7) 2.4 (0.3 to 
4.5)
0.07 10.0 (5.4 to 14.6)* 0.03
MAP
(mmHg)
87(11) 1.6 (-0.4 to 
3.6)
0.18 14(11 to 17)* 0.00002
SVR
(dyne.s.cm®)
1326 (70) 129 82 to 
176)
0.001 336 (282 to 420)* 0.00004
PASP
(mmHg)
24.3 (5.6) -0.4 (-1.2 to 
0.4)
0.35 3.0 (1.1 to 4.9)* 0.024
PADP
(mmHg)
8.7 (2.9) -0.4 (-1.1 to 
0.3)
0.27 2.0 (0.6 to 3.4)* 0.05
MPAP
(mmHg)
14.6(4.0) -0.8 (-0.3 to -  
1.3)
0.02 2.0 (0.6 to 3.4)* 0.039
PVR
(dyne.s.cm®)
119(21) 2.3 (-13.3 to 
17.9)
0.78 23.3 (8.1 to 38.5)* 0.02
PAWP
(mmHg)
6.5 (2.5) -0.5 (-1.4 to 
0.4)
0.48 2.2 (0.5 to 3.9)* 0.045
LVEDP
(mmHg)
7.2 (2.6) 0.5 (-0.2 to 
1.2)
0.25 4.4 (3.0 to 5.8) 0.0005
ôP/Ôt
(mmHg.s'^)
2304
(823)
-123 (-336 to 
90)
0.32 -187 (-335 to 
-39)
0.24
RAP (mmHg) 4.8 (2.4) ”0.4 (-1.1 to 
0.3)
0.26 1.3 (0.5 to 2.1)* 0.02
Table 3.2: Cardiac haemodynamics at baseline and changes after placebo and 
sumatriptan injection. Figures given in parentheses represent 95% confidence 
intervals for the mean change from baseline. In each case statistical 
comparisons are made with baseline values.
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Figure 3.1 Mean arterial pressure (MAP) changes after placebo 
and sumatriptan injection. Each line represents an individual
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Figure 3.2 Mean pulmonary arterial pressure (MPAP) at 
baseline and after placebo and sumatriptan injection.Each line 
represents an individual.
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Figure 3.3 Left ventricular end diastolic pressure (LVEDP) at 
baseline and after placebo and sumatriptan injection. Each line 
represents an individual.
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Figure 3.4 Peak rate of left ventricular pressure rise (dP/dt) at 
baseline and after placebo and sumatriptan. Each line 
represents an individual.
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Figure 3.5 Mean (sd) pulmonary (PVR) and systemic (SVR) 
vascular resistance after placebo and sumatriptan injection.
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Figure 3.6 Mean (sd) left ventricular end diastolic pressure 
(LVEDP) and pulmonary artery wedge pressure (PAWP) 
after placebo and sumatriptan injection.
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CHAPTER 4
RELATIVE EFFECTS OF SUMATRIPTAN ON THE PULMONARY AND 
SYSTEMIC CIRCULATIONS.
75
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INTRODUCTION
Early studies addressing the pharmacodynamics of sumatriptan suggested a
selective vasoconstrictive effect on the intracranial vasculature. In isolated 
vascular preparations, it was shown to cause constriction of dog and primate 
basilar arteries.^®’^ ®’ ®^® Human isolated basilar artery rings were also found to 
constrict in response to sumatriptan."^® In addition to in vitro constriction of 
cranial vessels, in vivo experiments also confirmed vasoconstriction. In 
anaesthetised intact animals, it caused vasoconstriction of feline^ ®® and 
canine^ ®"^  carotid arterial circulations. When given intravenously to 
anaesthetised beagle dogs, sumatriptan produced a dose dependent increase 
in carotid vascular resistance with little or no effect on heart rate or blood 
pressure thus implying a selective vasoconstrictor action on the canine carotid 
circulation.^®"  ^Vasoconstrictor responses were resistant to blockade by 
ketanserin (5-HT2 antagonist), MDL72222 (5-HT3 antagonist) and phentolamine 
(a-adrenoceptor antagonist ) but were sensitive to methiothepin (5-HTi and 5- 
HT2 antagonist) which confirmed a 5-HTi mediated response.
Similarly, sumatriptan caused constriction of feline carotid vessels.^®® In this 
study, both sumatriptan and ergotamine caused dose-dependent reduction in 
the proportion of cardiac output passing through arteriovenous anastomoses 
(AVA’s). Ergotamine, unlike sumatriptan however, was also associated with 
increases in diastolic blood pressure and total peripheral resistance suggesting 
that the effect of sumatriptan on the carotid vasculature was selective. Further 
evidence of a selective vasoconstriction was also obtained in this study. Using 
15pm radiolabelled microspheres the vasoconstrictor effect was shown to be 
highly localised within the carotid circulation, in particular to carotid
76
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animals, Neilsen et ai in 1989, assessed toe-arm systolic gradients in man 
using strain gauge plethysmography and concluded that intravenous 
sumatriptan had no effect on peripheral arteries in humans.
not, as first thought, confined to the cranial circulation. A non-invasive study
noteworthy.
•rf:
arteriovenous anastomoses. In addition to a selective vasoconstrictor action in
;|
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Subsequently however, evidence arose to suggest that 5-HTi receptors were
demonstrated that sumatriptan could cause femoral artery vasoconstriction in 
humans.^®® Direct invasive evidence of sumatriptan’s extracraniai activity was
confirmed in three studies which revealed both systemic and pulmonary 
vasoconstrictor a c t i o n s . T h e s e  studies measured arterial pressure 
changes in response to sumatriptan in patients undergoing diagnostic cardiac 
catheterisation. Systemic arterial pressure rose by 16-20% with pulmonary 
artery pressure rising by 40-58%. This relative 2-3 fold percentage increase in 
pulmonary artery pressure compared to the rise in systemic arterial pressure 
raised the possibility of a more pronounced effect on the pulmonary circulation. 
The inference therefore followed that 5-HTi receptors were more densely 
distributed in the pulmonary circulation.^"^^
There is a school of thought which considers 5-HT, released from pulmonary 
neuroendocrine cells and platelets, to be implicated in pulmonary hypertension 
secondary to hypoxia.^®® This being the case, 5-HTi receptors may have a 
pathophysiological role in pulmonary hypertension and therefore information on 
the density of 5-HTi receptors within the pulmonary circulation would be
77
S
78
The relative effects of sumatriptan on the systemic and pulmonary circulation
were therefore more closely re-examined in 28 patients whose results have 
been reported in 3 previous trials with similar study protocols.^ "^ '^^ "^ '^^ ®® The 
intention was to obtain more information on the density and clinical relevance of 
5-HTi receptors in the respective circulations.
{
STATISTICS
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METHODS
The protocol was as described in chapter 2 (pages 49-50) In brief, 28 patients 
were studied with mean arterial pressure (MAP) and mean pulmonary artery 
pressure (MPAP) being recorded at baseline, following placebo injection and at 
10 minute intervals following sumatriptan administration. Twenty patients 
received 6 mg sumatriptan by subcutaneous injection and 8 received
intravenous sumatriptan (maximum dose 48 fj/kg). The ratio of MPAP:MAP was 
calculated for each time point.
For each individual, a baseline value was obtained for MAP and MPAP by 
averaging two baseline observations. As any response occurred within 10 
minutes and persisted for the 40 minute study period, the average of the 
haemodynamic recordings at 10, 20, 30 and 40 minutes after sumatriptan 
injection were used to summarise the response to sumatriptan. Post-placebo 
and post-sumatriptan results were then compared with baseline measurements I
using a paired t-test/confidence interval as the data appeared normally 
distributed.
7Ï
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RESULTS
Table 4.1 shows the MAP and MPAP for each individual at baseline and after 
sumatriptan injection.
DISCUSSION
The observed rise in both mean systemic and pulmonary arterial pressures 
following sumatriptan administration was to be expected as these observations
mean systemic arterial pressure occurred after sumatriptan injection. Mean 
pulmonary arterial pressure rose by 26% however, consistent with the previous
' 1
■IMean arterial pressure (MAP)
Baseline mean (sd) MAP was 96 (13)mmHg. Mean (95%C.I.) increase after 
placebo injection was 0.36mmHg (-1.9 to 2.6, p=0.74). After sumatriptan
injection, the mean (95% C.l.) rise in MAP was Ilm mHg (7.5-15, p<0.0001).
I
Mean pulmonary arterial pressure (MPAP)
Baseline mean (sd) MPAP was 16 (6.6) mmHg. After placebo injection, the 1
mean (95% C.l.) change in MPAP was -0.4mmHg (-1.5 to 0.7, p=0.43). Mean
increase in MPAP following sumatriptan injection was 4.2mmHg (2.5-5.9,
p<0.0001)
Ratio of MPAP:MAP
Baseline mean MPAP:MAP ratio was 0.171 (0.07). No significant change was 
observed after placebo injection [mean change -0.005 (-0.02 to 0.005, p=0.3)j. 
Sumatriptan caused a significant increase in MPAP:MAP with a mean (95%C.I.) 
rise of 0.02 (0.008-0.03, p=0.0023)
had been noted in all 3 individual studies.^ "^ *^^ "^ ’^^ ®® Overall an 11% increase in
:S
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observation of an approxinoate 2- fold relative percentage increase in pulmonary 
arterial pressure compared to the increase seen in the systemic circulation after 
sumatriptan.
J
When precontracted with the thromboxane mimetic U46619 (10nm) however, 
sumatriptan was able to induce further contraction which was competitively 
antagonised by methiothepin (5-HTi and 5-HT2 antagonist) but was resistant to
80
The significant increase (12%) in the ratio of MPAP:MAP suggests a greater 
effect of sumatriptan on the pulmonary in comparison to the systemic 
circulation. It is assumed that the effects of sumatriptan are mediated via 5-HTi 
agonism and it could therefore be inferred that 5-HTi receptors exist in greater 
density in the pulmonary circulation. Alternatively, 5-HTi may play a functionally 
more important role in the pulmonary circulation in humans but confirmatory 
evidence of this is lacking in the scientific literature.
Studies in bovine species have demonstrated that sumatriptan constricts 
pulmonary but not mesenteric arteries, implying a lack of functional 5-HTi 
receptors in the bovine mesenteric circulation.^^® The physiology and 
pathophysiology of the bovine pulmonary vasculature is poorly understood. 
However, there is evidence that 5-HT induced pulmonary vasoconstriction is 
mediated via 5-HT2 receptors.^^^ Under conditions of basal tone, ketanserin (5- 
HT2 antagonist) competitively inhibited 5-HT induced vasoconstriction in 
isolated bovine pulmonary artery rings.^^^ This observation, together with the 
fact that sumatriptan displayed little or no agonist activity under these basal 
conditions suggested a 5-HT2 receptor mediated response.^^^ I
81 4:
ketanserin.^^^ These results suggest that, in the absence of vascular tone, 
serotonin induced constriction is mediated by 5-HT2 receptors whilst with tone 
present, 5-HTi receptor mediated vasoconstriction becomes evident in bovine
implicated in pulmonary hypertension. Interestingly the response to sumatriptan
heart disease and pulmonary hypertension^^"^ and in chronic hypoxic pulmonary 
hypertension.^^® It may be that there is hypersensitivity to 5-HTi receptor 
stimulation in patients with pulmonary hypertension and endothelial dysfunction.
In such cases serotonin-induced vasoconstriction could play a role in the 
pathogenesis of the disease and there is additional supportive evidence to
.'4 -suggest a role for serotonin. Increased plasma concentrations and turnover of 
serotonin have been observed in primary pulmonary hypertension^^® and in 
children with pulmonary hypertension secondary to congenital heart disease.^^^
In addition, appetite suppressant drugs with serotonergic activity such as 
dexfenfluramine and fenfluramine have been associated with an increased risk 
of pulmonary hypertension.^^®
■■■!>pulmonary arteries. Both 5-HTi and 5-HT2 receptors may therefore be
1
was augmented by L-NAME and endothelial removal, manoeuvres which 
remove the influence of nitric oxide (NO).^^^ Responses to 5-HT however, were :s;
. 4-
not augmented by L-NAME or endothelial removal. This indicates that, in bovine 
pulmonary arteries, the potentiating effect of removal of NO influence is specific
: : :
to 5-HT1 receptor activation. Similar facilitatory effects have been reported 
between a-adrenoceptors and endothelial removal in rabbit pulmonary 
arteries.
The clinical relevance of these findings is unclear, however. Endothelial 
abnormalities and dysfunction have been observed in patients with congenital
81 I -  .
paucity of selective 5-HTi antagonists and no agent is currently suitable for 
clinical use. If and when a 5-HTi antagonist becomes clinically available, its 
effects on the pulmonary vasculature will have to be established, particularly in 
individuals with elevated pulmonary artery pressures.
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Ketanserin, a 5-HT2 antagonist, has been shown to reduce pulmonary vascular 
resistance following cardiac surgery and in a study of 14 patients with 
pulmonary hypertension secondary to systemic sclerosis.^®^ Its use in the 
treatment of protamine induced pulmonary hypertension has also been 
reported^®®, implicating a potential role for serotonin and 5-HT2 receptors in the 
pathogenesis of pulmonary hypertension. In another study of 20 patients with
:
primary pulmonary hypertension, however, ketanserin had only modest 
pulmonary vasodilator effects of doubtful clinical significance and of similar 
magnitude to conventional vasodilators.^®"  ^ In 7 patients with hypoxic pulmonary 
hypertension, ketanserin had no effect on pulmonary artery pressure.^®® These
1
contradictory results prevent firm conclusions being drawn over the role of 
serotonin, particularly 5-HT2 receptors, in the pathogenesis of pulmonary 
hypertension.
It must be recognised that pulmonary hypertension is not a single disease entity 
but has multiple aetiologies, the pathogenesis of which may be equally varied. 
The finding that sumatriptan appears to have a greater pulmonary than 
systemic vasoconstrictor effect implies that 5-HTi receptors are perhaps more 
densely distributed in the pulmonary circulation. Whether these 5-HTi receptors 
have a pathogenetic role in pulmonary hypertension is unclear but the 
aforementioned discussion has highlighted the potentiating effects of
endothelial function on 5-HTi receptor responses. Unfortunately there is a
-,   ..
BASELINE POST SUMATRIPTAN
Table 4.1. Mean arterial pressure (MAP), mean pulmonary arterial 
pressure (MPAP) and MPAP:MAP ratio at baseline and following 
sumatriptan injection
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Subject MAP MPAP MPAP:
MAP
ratio
MAP MPAP MPAP:
MAP
ratio
1 116 18 0.155 126 30 0.238
2 90 9 0.1 105 13 0.123
3 110 35 0.318 118 39 0.331
4 100 19 0.19 100 23 0.230
5 100 14 0.140 102 15 0.147
6 110 16 0.145 121 19 0.157
7 100 14 0.140 120 18 0.150
8 100 14 0.140 145 24 0.166
9 90 30 0.333 95 34 0.358
10 75 13 0.173 94 14 0.150
11 106 14 0.132 114 18 0.158
12 92 16 0.174 111 19 0.171
13 82 10 0.122 92 13 0.141
14 76 19 0.250 87 22 0.253
15 87 13 0.149 98 14 0.143
16 74 10 0.135 90 15 0.167
17 85 13 0.153 105 14 0.133
18 105 23 0.219 117 20 0.171
19 100 18 0.180 106 21 0.198
20 100 17 0.170 92 14 0.152
21 88 12 0.136 87 14 0.161
22 100 10 0.10 110 14 0.127
23 108 12 0.111 136 30 0.221
24 80 16 0.20 92 20 0.217
25 107 11 0.103 119 18 0.151
26 128 14 0.109 141 21 0.149
27 88 14 0.159 93 18 0.194
28 95 33 0.347 100 44 0.440
I
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Haemodynamic
parameter
Mean
(sd)
baseline
value
Mean (95%C.I.) 
change after 
placebo
P value Mean (95%C.I) 
after
sumatriptan
P value
MAP (mmHg) 96 (13) 0.36 (-1.9 to 2.6) 0.74 11 (7.5 to i 5) <0.0001
MPAP (mmHg) 16(6.6) -0.4 (-1.5 to 0.7) 0.43 4.2 (2.5 to 5.9) <0.0001
MPAP: MAP 0.171
(0.07)
-0.005 (-0.02 to 
0.0005)
0.3 0.02 (0.008 to 
0.03)
0.0023
Table 4.2 Haemodynamic parameters at baseline and following placebo and 
sumatriptan injection. In each case comparisons are made with baseline values.
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Figure 4.1 Percentage change in MPAP:MAP ratio for each 
subject after sumatriptan injection
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CHAPTER 5
THE EFFECT OF SUMATRIPTAN ON SYSTOLIC TIME INTERVALS
86
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INTRODUCTION
e je c tio n .L a te r attempts were then made to elucidate the relationship between
Measurement of STI’s: Methodology
blood (stroke volume, cardiac output), the capacity to generate force (ie the
HISTORICAL PERSPECTIVE
In the mid nineteenth century Ludwig studied arterial and venous pulse contours 
and how they varied in differing disease states.^ ®® Garrod in 1874 noted the y
inverse relationship between heart rate and the duration of left ventricular
duration of systole and cycle length and to apply this measurement as a i
surrogate of cardiac performance in man.^ ®®'^ ®® By the 1920’s Wiggers began to 
realise the full potential of systolic time intervals (STI’s) when he was able to 
more clearly delineate the phases of systole.^®®’^ ®^ Katz and Feil then applied
electronic recordings to determine the phases of systole in the presence of LV 
diseases.^ ®^ "^ ®"^  In 1942, Blumberger reported extensive studies on the systolic 
intervals in a wide variety of cardiac disorders.
With the subsequent development of direct measures of LV function, the
%
significance of systolic time intervals in man could be related to ventricular 
performance on a more quantitative basis and the measurement of STI’s
became more popular during the 60’s and 70’s. More recently, rapidly 
advancing, non-invasive ultrasound techniques have aliowed greater 
appreciation of cardiac performance in disease states, but the measurement of 
STl’s still represents a sensitive and valid method of assessing cardiovascular 
function.
Ventricular performance can be assessed by the ability of the ventricle to pump
87 ?:
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maximal rate of left ventricular pressure rise [maximal ôP/ôT]), the ability to 
shorten with each contraction (ejection fraction), the temporal relationships of 
contraction (systolic time intervals) and combinations of these variables. Most 
tests of ventricular function deal with stroke volume-cardiac output or force.
The systolic time intervals are the only tests for which the sole measure of
ventricular function is time.
-
The three basic STI’s are the pre-ejection period (PEP), the left ventricular 
ejection time (LVET) and the total electromechanical systole (EMS or QS2). 
There are several methods of measuring STI’s but regardless of methodology, 
meticulous detail must be applied to recording techniques to avoid 
misinterpretation. In the most widely employed technique, STI’s are obtained 
from simultaneous, fast lead recordings (100 mm/sec) of the electrocardiogram, 
the phonocardiogram and the carotid pulsation. The EGG lead which most 
clearly displays the onset of ventricular depolarisation is selected. The 
phonocardiogram is placed over the upper précordium in an area which 
provides a clear view of the initial high frequency aortic components of the
i
second heart sound (A2). A filter system should be employed to eradicate lower
frequency (< 100 Hz) sounds. Carotid arterial pulsation is recorded with a 
funnel shaped pick up attached by polythene tubing to a pressure transducer. 
Again it is crucial that the rapid upstroke and pointed, single incisural notch on 
the carotid pulse tracings are clearly discernible. Failure to obtain a sharp 
incisural notch is a common source of error and is likely to occur if carotid pulse 
tracings are small. #
I
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The QS2 interval is measured from the onset of ventricular depolarisation to the 
first high frequency vibration of A2. The LVET is measured from the beginning 
upstroke to the trough of the incisural notch of the carotid pulse tracing (Figure 
2.1). The PEP is that interval from the beginning of ventricular depolarisation to
the beginning of LV ejection. Subtracting the LVET from OS2 therefore derives 
the PEP. The PEP consists of the electromechanical interval plus the
isovolumetric contraction time. Except in the presence of left ventricular 
conduction delay, (e.g. left bundle branch block) the electromechanical interval J :
is relatively constant. Therefore, variations in PEP usually reflect changes in 
isovolumetric contraction time. Measurement of the isovolumetric contraction 
time itself is subject to variability and is dependent on where the first high 
frequency components of the second heart sound are found.
.j:
STI’s can also be derived from simultaneous fast speed EGG and 
haemodynamic pressure recordings obtained using fluid filled catheters in the 
aorta. In this situation, the incisural notch of the aortic pressure tracing 
corresponds exactly with the initial vibrations of A2.^ ®® Using this technique, the
.y
incisural notch can be readily identified and the difficulty in identifying the
:
variable first components of A2 can be circumvented. In addition, the incisural 
notch is often more difficult to identify in small carotid pulse wave tracings 
obtained externally, a problem not encountered when aortic pressure recordings 
are invasively obtained. There are however problems using fluid filled catheters 
to obtain aortic pressure tracings, namely the inherent transmission delays 
through the catheters. In this situation the absolute values of the STI’s are 
slightly longer than those obtained externally.
-i::
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In applying STI measurements, corrections must be made for heart rate. When 
corrected for heart rate, the STI’s are suffixed with the letter I (hence PEP 
becomes PEPi etc). The linear regression equations for this are detailed in table 
5.1. At rates below 110/min, the PEP and LVET shorten proportionately as 
heart rate increases. In the normal range of heart rates, the ratio of PEP/LVET 
is often employed as a measure of LV function when either the PEP or LVET 
may both be within normal limits.
Systolic Time Intervais in Clinical Pharmacology
To evaluate the effect of drugs on the CVS requires sensitive, exact and valid 
methods, which preferentially should be non-invasive. STI fit these criteria and 
have been widely employed in the investigation of pharmacological agents. 
Changes in inotropy, preload and afterload produce characteristic alterations in 
the STI's (see table 5.2).^ ®®'^ ®®
Positive inotropic drugs, which cause little or no change in afterload, will shorten 
isovolumic contraction time and hence will also shorten the PEP. In this 
situation LVET shortens and, as a result, QS2 will also decrease. Conversely, 
negative inotropic drugs, which prolong isovolumic contraction time, will prolong 
the pEp_296-299 LVET is generally shortened by both negative and positive 
inotropes.^®®’^ ®^ In the presence of negative inotropes there are directionally 
opposite changes in the PEP (increases) and LVET (decreases), and the 
duration of systole (QS2) remains relatively constant. QS2 is therefore an 
insensitive marker of a negative inotropic action. Because positive inotropes 
shorten both PEP and LVET, a reduction in QS2 is the most sensitive STI 
marker in detecting positive inotropic stimulation. A positive inotropic effect is
90
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■itherefore suggested by a shortening of OS2. Since negative inotropes will 
prolong PEP but shorten LVET, an increase in the PEP:LVET ratio is indicative 
of a negative inotropic effect.^ ®®’^ ®^ STI's can therefore be used to non- 
invasively assess the inotropic effects of cardiovascular agents.
distinguished from pressor agents on account of their differing effects on the 
LVET.
Sumatriptan and systolic time intervals
As discussed above, systolic time interval estimation can be used to non- 
invasively assess the cardiovascular activity of drugs. Invasive haemodynamic
91
Caution must however be exercised in the interpretation of STI’s, particularly 
when acute changes in afterload or preload occur.^“° Acute Increases In 
afterload prolong the PEP but have no effect or slightly prolong the LVET.
Overall, drugs which acutely increase afterload, will therefore also increase the
PEPiLVET ratio ( as do negative inotropes). Negatively inotropic drugs can be
Augmented ventricular filling (increased pre-load) results in an increase in
T:stroke volume. This is accompanied by a prolongation of the LVET and an 
abbreviation of the PEP, hence the PEP;LVET ratio decreases. A decrease in 
pre-load (reduced ventricular filling) will produce opposite changes in PEP,
LVET and PEP:LVET, namely increases in PEP and PEP:LVET ratio with a 
reduction in LVET. Systolic time intervals are therefore ideally suited for 
studying the cardiovascular actions of pharmacologic agents being able to 
distinguish negative inotropy from positive inotropy and acute changes in 
afterload from those occurring when preload is altered.
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studies have obvious limitations, restricting the potential for clinical studies. A 
reliable non-invasive tool to evaluate the effects of 5-HTi agonists would 
therefore be welcome. This would open up the possibility of performing serial 
studies. The aim of the study was therefore to assess the effects of sumatriptan 
on the duration of the systolic time intervals and to relate these alterations to 
changes in haemodynamic variables measured invasively.
PATIENTS AND METHODS
Haemodynamic tracings were analysable for twenty-six patients (14M, 12F, age 
49+10 yrs) who had participated in three previous sumatriptan haemodynamic 
studies.^ "^ '^^ "^ '^ Eighteen patients received subcutaneous placebo
followed by subcutaneous sumatriptan 6mg. Eight patients received a lOminute 
intravenous infusion of placebo followed by a lOminute intravenous infusion of 
sumatriptan to a total maximum dose of 48pg.kg.min"\ Aortic pressure tracings 
were recorded at baseline, following placebo and at lOminute intervals for 
40minutes. Systolic time intervals were calculated for each timepoint as 
described in chapter 2 (page 51).
DATA ANALYSIS
For each individual, a baseline value was obtained from two averaged 
observations. As any response occurred within 10 minutes and persisted for the 
40 minute study period, the average of the recordings at 10, 20, 30 and 40 
minutes after sumatriptan injection was used to summarise the response to 
sumatriptan.
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Statistics
Post-placebo and post-sumatriptan results were compared with baseline
'measurements using a paired t-test/confidence interval as the data appeared 
normally distributed.
RESULTS
Results are shown in figure 5.1 and in Table 5.3. Figures given in parentheses
ELECTROCARDIOGRAPHY
There were no changes in ECG morphology as assessed from the hard copies 
of six lead ECG’s taken at 10 min intervals throughout the study.
represent the 95% confidence intervals for the mean change from baseline.
1
HEART RATE
Baseline heart rate was 68 (SD13.5) per minute. After sumatriptan, heart rate 
decreased by 4.6 bpm (1.3 -8, p = 0.0094).
3:SYSTEMIC ARTERIAL PRESSURES
Mean baseline values for systolic arterial pressure (SAP), diastolic arterial 
pressure (DAP) and mean arterial pressure (MAP) were 124, 73 and 94mmFig,
■respectively. There was no significant change between baseline and placebo 
values. After sumatriptan, systolic arterial pressure rose by 19 mmHg (14.5 -
23.6, p=0.0001). Diastolic arterial pressure rose by 6.9 mmHg (3.9 - 9.8,
p=0.0001). Mean arterial pressure increased by 11.5 mmHg (8.6 -  14.3, p =
0 .0001).
SYSTOLIC TIME INTERVALS
There were no significant differences between baseline and placebo values.
Mean baseline (heart rate corrected) values for the systolic time intervals were; 
total electromechanical systole (EMS) 585ms, pre-ejection period (PEP) 163ms
yand left ventricular ejection time (LVET) 423ms. Mean baseline PEP/LVET ratio
93
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was 0.387. After sumatriptan administration, EMS rose significantly by 25ms 
(17-33, p=0.0001), PEP by 14ms (8-21, p=0.0002) and LVET by 11ms (5-16, 
p=0.0006). PEP/LVET ratio rose after sumatriptan by 0.023 (0.007-0.04, 
p=0.009). See figure 5.1.
DISCUSSION
The present study assessed the measurement of systolic time intervals as a 
potential non-invasive marker for the effects of sumatriptan on the 
cardiovascular system. Conventionally, STI's are measured from simultaneous, 
fast recording, (i.e. paper speed > 100 mm/sec) of the electrocardiogram, 
phonocardiogram and carotid arterial pulsation. In this study STI's were 
calculated using high quality, fast paper speed arterial tracings and EGG 
recordings. A phonocardiogram was not recorded as STI measurements were 
based on invasive pressure recordings. The onset of the second heart sound 
(A2) was therefore not recorded in this set up and so total electromechanical 
systole cannot be denoted by the conventional nomenclature (QS2) but for 
purposes of this discussion wiil be referred to as EMS, The advantage of 
employing the sharp inscription of the incisural notch of the aortic pressure 
tracing as a marker of A2 in this protocol is that the difficulty in identifying the 
variable first high frequency components of A2 are not encountered.
The absolute duration of the systolic intervals in this study is longer than in 
those protocols utilising phonocardiograms as there is an inherent conduction 
delay in fluid filled catheters which will lead to a prolongation of the pre-ejection 
period and total electromechanical systole. The PEP consists of two sub 
intervals; electromechanical delay and isovolumic contraction time (ICT). In the 
absence of conduction disturbances (QRS < 90ms) the ICT and PEP are 
closely correlated.^®® in this study no sequential changes in ECG morphology
94 «
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pressure.®®  ^Angiotensin infusion, an agent with almost exclusive changes in
afterload however, causes increases in QS2 and PEP, but with a reduction in
ricre
and in response to drugs with negative inotropic effects.
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were noted and it is therefore assumed that the change in PEP reflects 
prolongation of ICT.
?
This study demonstrates that sumatriptan, in clinically relevant doses, 
significantly prolongs EMS, PEP and LVET with a consequent rise in the 
PEP/LVET ratio.. The observed increase in PEP and PEP:LVET in response 
to sumatriptan may have occurred secondary to a negative inotropic effect or 
due to an acute rise in afterload. Analysis of the overall change in all STI’s 
allows the precise mode of action to be established. Negative inotropes would 
be expected to decrease LVET without significant effect on the EMS, a pattern 
observed by Boudoulas et al when studying the negative inotropic effects of 
lidocaine.®®  ^ Acute increases in afterload however prolong the EMS and LVET 
as well as the PEP and PEPiLVET and this pattern resembles closely the 
change in STI’s following sumatriptan injection. Also against a negative 
inotropic action is the lack of a previous invasive study to show a significant 
change in the peak rate of rise of LV pressure (ôP/ôt) following sumatriptan.^®®
These STI changes are therefore consistent with a sumatriptan-induced 
increase in afterload as witnessed by the rise in systemic arterial pressures.
:
Increases in afterload induced by intravenous injection of methoxamine are, like 
sumatriptan, accompanied by a lengthening of the PEP, QS2 and LVET.®®'* 
Shaver et al maintained heart rate constant with atrial pacing during 
methoxamine infusion, thereby preventing reflex bradycardia and noted an
approximate 1 ms increase in LVET for each mmHg rise in systolic arterial
LVET.®®® Increases in PEP:LVET are seen with acute in reases in afterload
■71
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The effect of sumatriptan on pre-load is less clear. Increases in left ventricular 
end-diastolic pressure (LVEDP) and pulmonary artery wedge pressure (PAWP) 
may be accounted for by increases in pre-load and afterload.^®® A prolongation 
of EMS following sumatriptan is also in keeping with an increase in pre-load but 
the PEP would normally shorten as pre-load increases. It is therefore assumed 
that, although sumatriptan may augment pre-load, the over-riding effect seems
to be an increase in afterload.
Invasive haemodynamic studies of serotonergic compounds have obvious 
limitations and therefore the use of systolic time intervals as a non-invasive 
marker of haemodynamics has appeal. For example, the duration of action of 
serotonergic compounds can be assessed utilising the ST! changes as 
physiological markers of the pharmacological activity. In this study the STI 
changes were evident within 10 mins, in keeping with a sumatriptan tmax of 5-20 
mins^ ®^  and a 15 min response rate of 74% in cluster headache.^®^ The duration 
of the response in this study was maintained to at least 40 mins, consistent with 
sumatriptan’s 1 hour anti-migraine response rate of 77%.^ ®®
In conclusion, it has been shown that sumatriptan induces changes in STI’s 
consistent with its effect on afterload, and that the measurement of systolic time 
intervals may represent an accurate, non-invasive method of investigating the 
influence of serotonergic compounds on the cardiovascular system. This 
requires confirmation in a protocol that measures STI using a phonocardiogram, 
carotid arterial waveforms and the electrocardiogram.
I'I
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Systolic interval Sex STI-lndex
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Standard deviation
1.;v31
t
■1,3
I
I
002 Male
Female
PEP
LVET
Male
Female
Male
Female
QS2i = -2.1HR + 546 
QS21 = -2.0 HR + 549
PEPi = -0.4 HR + 131 
PEP, = -0.4 H R +133
LVET, = -1.7 H R + 413 
LVET, = -1.6 H R + 418
14
14
10
11
10
10
Table 5.1 Linear regression equations for systolic time intervals in both sexes. 
QS2 ~ Total electromechanical systole, PEP = pre-ejection period, LVET = Left 
ventricular ejection time, HR = Heart rate.
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Systolic Interval Increase Decrease
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PEP
LVET
tAfterload
iPn^oad
Negative inotropes
tPreload 
tAfterload 
Aortic stenosis
tAfterload 
tPreload 
Positive inotropes
tPreload
Positive inotropes 
Negative inotropes
OS2 tAfterload
LBBB
Positive inotropes
PEP:LVET Negative inotropes Positive inotropes
LV dysfunction
Table 5.2 Factors affecting the STI’s. LBBB = Left bundle branch block
■a:
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Mean
Baseline
(SD)
Mean change after 
placebo (95% C.l.)
P value Mean change after 
sumatriptan (95% 
C.l.)
P value
HR (bpm) 68 (14) -2 (-4.5 to 0.2) 0.069 -4.6 (-8 to -1 .3 ) 0.0094
SAP{mmHg) 124 (18) 2 (-0.9 to 4.5) 0.17 19 (14.5 to 23.6) 0.0001
DAP(mmHg) 73(11) 0.7 (-1.4 to 2.7) 0.5 6.9 (3.9 to 9.8) 0.0001
MAP{mmHg) 94 (14) 0.6 (-1.6 to 2.8) 0.58 11.5 (8.6 to 14.3) 0.0001
EMS(ms) 585 (38) 3 (-4 tolO) 0.43 25 (17 to 33) 0.0001
PEP(ms) 163 (32) -0.7 (-6.8 to 5.4) 0.81 14(8 to 21) 0.0002
LVET(ms) 423 (29) 3.5 (-1.5 to 8.5) 0.16 11 (5 to i 6) 0.0006
PEP/LVET 0.39 (084) -0.006 (-0.02to 0.01) 0.48 0.02 (0.01to0.04) 0.0088
TABLE 5.3: Arterial pressure and systolic time interval changes following
placebo and sumatriptan. Baseline values are expressed as mean 
(SD). Figures given in parentheses represent 95% confidence 
intervals for the mean change from baseline.
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Figure 5.1 Mean (95%C.I.) increases in systemic arterial pressure and 
systolic time intervals after sumatriptan injection.
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Figure 5.2 Systolic (SAP) and diastolic (DAP) arterial pressures (s.d.) following
placebo and sumatriptan
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Figure 5.3 Systolic time interval changes (s.d.) 
after placebo and sumatriptan
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CHAPTER 6
THE EFFECT OF SUBCUTANEOUS NARATRIPTAN, A 5 -H T ib /d AGONIST ON 
THE SYSTEMIC, PULMONARY AND THE CORONARY CIRCULATIONS
102
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INTRODUCTION
long-lasting increases in carotid vascular resistance with parallel reductions in 
carotid blood flow.^°® Although a 92% increase in carotid vascular resistance and 
44% decrease in carotid blood flow were elicited by naratriptan, no significant
103
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Naratriptan, an analogue of sumatriptan, is a selective 5-HT ib/id agonist. Although 
the efficacy of sumatriptan in acute migraine is well e s ta b lis h e d 256,259 oral
bioavailability (14%) and short duration of action {iH = 2 hrs) are recognised 
lim ita tions,N aratriptan, however, has high oral bioavailability (60-70%) and a 
longer duration of action = 6 hrs), making it a potentially more attractive anti- 
migraine compound.
The biological pre-clinical profile of naratriptan has been established in a number 
of carefully controlled in vitro trials reported in the one paper.^°^ Naratriptan has 
high affinity for human recombinant 5-HTib and 5-HTio receptors, having six fold 
and three fold higher affinity respectively than sumatriptan at these two 
receptors.^°^ Affinity for 5-HTia and 5-HT3 receptors is low. In isolated dog basilar 
and middle cerebral artery, naratriptan was approximately equipotent with 
serotonin, but roughly three fold more potent than sumatriptan. Maximal 
contraction was similar for all 3 agonists, however. In dog isolated basilar artery,
methiothepin, but not ketanserin, antagonised naratriptan-induced contractions,
Iindicating a 5-HTi mediated effect. In human isolated coronary arteries,
■■I,
naratriptan produced a maximum contractile effect one-third that of serotonin, but 
was four times more potent than sumatriptan, although the maximum contraction 
elicited was similar for sumatriptan and naratriptan. Ï
In vivo experiments in anaesthetised dogs, naratriptan caused dose-dependent
104
change in blood pressure was observed. This suggests that, like sumatriptan, 
naratriptan causes a selective vasoconstriction of the carotid vascular bed in 
dogs.^ "^  ^Naratriptan, was again more potent (approximately two fold) than 
sumatriptan.
METHODS
The study protocol is summarised in table 6.1. Ten subjects (2 M, 8 F, age range 
44-69 yrs) undergoing diagnostic cardiac catheterisation were studied. Exclusion 
criteria are documented in chapter 2. Haemodynamics were measured in an 
identical manner to that described for sumatriptan in chapter 2 (pages 49-50)
104
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In summary, naratriptan has a pre-clinical profile similar to that of sumatriptan, but 
is approximately three to six fold more potent at 5-HT ib and 5-HT id receptors. It is 
obviously impossible to accurately extrapolate results from in vitro experiments 
and from other species to the clinical situation, hence the need for controlled 
clinical trials. In humans, sumatriptan has been shown to cause vasopressor 
responses in the systemic and pulmonary circulation, with an additional 14-16% 
reduction in coronary artery diameter.^"^ ’^^ "^  ^ Given the pharmacodynamic pre- 
clinical similarities between sumatriptan and naratriptan, one might also expect
: :naratriptan to induce systemic, pulmonary and coronary vasoconstriction.
The effect of naratriptan (1.5 mg s.c.) on cardiac haemodynamics and coronary 
circulation was therefore assessed in 10 patients undergoing diagnostic cardiac 
catheterisation. The experimental model was based on that previously applied to 
sumatriptan.
a
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TIME (mins) -20 -10 0 10 20 30 40
Coronary angiogram ■k * * * * k *
Baseline
measurements
*
Placebo injection k
Naratriptan 1.5mg s.c. *
6 lead ECG * k k * * k k
Cardiac
Haemodynamics
k k k k k k k
Table 6.1 Study protocol. The haemodynamic effects of naratriptan.
Quantitative Coronary Angiography
Quantitative coronary angiography was performed on 2 right and 8 left coronary 
arteries. The procedure has been described in chapter 2 (page 51). Ten proximal 
(one from each patient), 8 mid and 9 distal sites were identified. Two blinded 
observers measured coronary artery diameter at these sites using the automated 
edge detection programme.
Data analysis
A baseline value was obtained for each haemodynamic parameter by averaging 
two observations. As any response occurred within 10 minutes and persisted for 
the 40 minute study period, the average of the haemodynamic recordings at 10, 
20, 30 and 40 minutes after naratriptan injection were used to summarise the 
response to naratriptan. Similarly when assessing coronary artery diameter 
responses to naratriptan, the average of the artery diameter at 10, 20 and 30 
minutes was used as a summary measure of the response.
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106 SStatistics
Post-placebo and post-naratriptan results were compared with baseline 
measurements using a paired t-test/confidence interval as the data appeared 
normally distributed.
RESULTS
Results are summarised in Tables 6.2 and 6.3. Figures given in parenthesis 
represent 95% confidence intervals for the mean change from baseline. I
Heart Rate and Cardiac Output
No significant change in mean heart rate (95%C.I. -2.5 to 3.8 bpm, p=0.64) was 
observed with a base-line rate of 67(S.D.8) and post-naratriptan rate of 68 (S.D.8) 
beats/min. Cardiac output was 5.62 (S.D.0.9) L/min at baseline and 5.69 (S.D.1.0)
L/min post-naratriptan (95%C.I. -0.33 to 0.47, p=0.70).
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Systemic Arterial Pressure
Mean baseline values for systemic arterial pressure (SAP), diastolic arterial 
pressure (DAP) and mean arterial pressure (MAP) were 135 mmHg, 70 mmhg 
and 96 mmhig respectively. No significant change from baseline was observed 
after placebo injection. Following naratriptan injection, SAP, DAP and MAP had a 
mean (95%C.I.) rise of 14.8 (7.6 to 22.0, p= 0.0015), 6.3 (3.9 to 8.7,p=0.0002) and 
12.4 (7.0 to 17.8,p=0.0007) mmhg respectively. K
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Systemic Vascular Resistance
Mean baseline SVR was 1314 dyne.s.cm’®. No significant change was observed 
after placebo but SVR rose on average by 163 dyne s.cm’® (95%C.I. 74 to 253, 
p=0.003) after naratriptan.
Pulmonary Arterial Pressure
Mean baseline values for pulmonary arterial systolic pressure (RASP), pulmonary 
arterial diastolic pressure (PADP) and mean pulmonary arterial pressure (MPAP) 
were 23.7 mmHg, 8.2 mmHg and 14.1 mmHg respectively. No significant change 
was observed after placebo injection. Following naratriptan injection PASP, PADP 
and MPAP rose by 4.4 mmHg (95%C.I. 2.0 to 6.9,p=0.003), 2.6 mmHg (95%C.I. 
0.7 to 4.4, p=0.012) and 3.5 mmHg (95%C.I. 2.4 to 4.7, p=0.0001) respectively.
Pulmonary Vascular Resistance (PVR)
Mean baseline PVR was 97 dyne.s.cm ®. No significant change was observed 
after placebo but PVR rose by 19 dyne.s.cm ® (95%C.I. 3 to 34, p=0.025) after 
naratriptan.
Pulmonary Artery Wedge Pressure (PAWP)
Mean baseline PAWP was 7.3 mmHg. No significant change occurred after 
placebo, but PAWP rose on average by 2.1mmHg (95%C.I. 1.9 to 2.4, p“ 0.009) 
after naratriptan.
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0.08cm (95%C.I. -0.27-0.11, p=0.37).
108
Right Atrial Pressure (RAP)
Mean baseline RAP was 6.2 mmHg. No significant change occurred after placebo 
but following naratriptan injection, RAP rose on average by 0.8mmHg (95% C.l.
0.2 to 1.3, p=0.01).
1
Coronary Artery Dimensions
■
Coronary arteries were divided into proximal, middle and distal segments. One 
artery measurement from each individual was used for baseline comparisons. No 
significant differences were observed between naratriptan and placebo or baseline 
values (See Table 6.2 and Figure 6.3). Mean baseline proximal coronary artery
diameter was 3.70cm. After naratriptan, mean change in artery diameter was -
Plasma Drug Concentrations
Mean plasma naratriptan concentrations at 10 and 20 mins post dosage were 
17.15 (S.D. 5.9) ng/ml and 17.83 (S.D. 2.05) ng/ml respectively.
■1
Adverse Events
Adverse events were reported by 5 subjects (50%). Four subjects reported chest 
discomfort, which occurred within 5 minutes of naratriptan injection. These events 
were described as mild or moderate in severity and spontaneously resolved after 
10 minutes. One subject experienced a headache classified as serious and the 
patient was therefore detained in hospital overnight. This headache commenced
■170 mins after naratriptan injection and resolved 9 hrs later. Whether the 
headache was related to naratriptan or not is uncertain. No patients had an 
elevated creatinine kinase following naratriptan injection.
108
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DISCUSSION
receptors with approximately 6 and 3 fold higher affinity than sumatriptan, 
respectively for these s u b t y p e s . I n  anaesthetised beagle dogs, naratriptan 
displayed a similar profile of action to sumatriptan, but was about two fold more
109
These results show a clinically non-significant, vasopressor response in the 
systemic and pulmonary circulation after subcutaneous naratriptan administration. 
The response occurred within 10 mins of injection and persisted for the 40 min 
study period. The rise in total systemic and pulmonary vascular resistance without 
a change in heart rate and cardiac output suggests that the pressure changes are 
consequent upon a direct vasoconstrictor effect. It is assumed that the 
haemodynamic effects are drug related although procedure related effects cannot 
be excluded.
I
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These responses were to be expected as naratriptan exhibits similar 
pharmacological properties to sumatriptan.®®®'®®® Subcutaneous administration of 
naratriptan up to a dose of 10 mg has been associated with statistically significant 
increases in mean and systolic blood pressure up to 13 and 15 mmHg respectively 
(Glaxo Group Research). The rise in mean systemic arterial pressure in this study 
(12%) was of lesser magnitude than the 20% increase observed with sumatriptan 
6 mg subcutaneously.^"^^ Pulmonary artery pressure changes following naratriptan 
injection were of a similar magnitude to sumatriptan-induced changes, with an 
approximate 30-40% rise accompanying injection of either agent. "^^  ^ As seen with 
sumatriptan, the relative percentage increase (32%) in pulmonary artery pressure 
following naratriptan was greater than systemic pressure changes (12%), again 
suggesting the possibility of a greater density of 5-HTi receptors in the pulmonary
circulation. Naratriptan has high affinity for human cloned 5-HT ib and 5-HT id
%
I
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In vivo therapeutic doses of sumatriptan have previously been noted to cause a 
14-16% reduction in coronary artery diameter®"^ ’^®"^® raising concerns that this may
no
'-s.,; 
%
110
potent at vascular 5-HTi receptors.®®® In a range of isolated vascular tissue 
preparations used to study 5-HTi receptor mediated effects, naratriptan was found
■
to be four times more potent than sumatriptan.®®  ^ More recently, naratriptan has
displayed greater potency compared to sumatriptan at recombinant rabbit 
saphenous vein 5-HTib receptors.®®® Human isolated coronary arteries contract in 
response to both naratriptan and sumatriptan, but naratriptan is approximately four 
times more potent than sumatriptan in this respect, although the maximum 
contraction is similar.®®®
be associated with rare serious cardiac adverse events.®®®’^ ®® In this small study, 
naratriptan in a therapeutic dose of 1.5 mg subcutaneously, had an insignificant 
effect on the coronary arteries similar to that of placebo. The reason for this is 
unclear, but may relate to a relative dose difference or reflect minor differences in 
receptor subtype interaction between the two drugs.
The functional state of the endothelium may be important, as the presence of 
atherosclerosis, resulting in dysfunctional endothelium, has been shown to
■ "
influence coronary artery responses to serotonergic agonists.55,229,233,235,309.312 
patients in this study and in the previous sumatriptan studies,®' '^*’®'^ ® had normal or 
near normal coronary arteries but may still have had occult endothelial dysfunction 
which contributed to the observed differences between the two drugs.
Interestingly, a recent in vitro study found sumatriptan less potent than other 
triptans in contracting isolated human coronary arteries with functional 
endothelium.®'’®
111 g
The effect of naratriptan and other triptans on diseased coronary artery segments :
would be of interest but presently all triptans are contraindicated in patients with, 
or at risk of, coronary artery disease. Assessment of coronary artery blood flow 
would also be desirable, but was not part of the present study. Preliminary 
evidence in migraineurs, however, suggests that naratriptan induced changes in 
myocardial perfusion are substantially less than those seen with ergotamine.®^"^
IFour of the patients reported sensations of chest heaviness or tightness without 
significant ECG changes, rise in creatinine kinase or reduction in coronary artery 
diameter. One individual’s ECG showed inverted T waves in leads 1 and AVL at 
baseline. This normalised at 30 mins post naratriptan in lead 1 but had reverted to 
the baseline state the following day and was not considered to be of clinical 
concern. These non-specific findings are similar to experience with sumatriptan.
In summary, naratriptan, like sumatriptan and other 5~HTiagonists, has been 
shown to cause vasoconstrictor responses in the systemic and pulmonary 
circulation, presumably via direct 5-HTi receptor agonism. Unlike sumatriptan, 
however, no significant effect on coronary artery dimensions was observed in this
'study. This may relate to relative dose or potency differences of the two drugs or 
may be a reflection of differing endothelial function among subjects. These 
findings, however, could have therapeutic importance and may widen the clinical 
application of this group of compounds depending on the results of future studies 
and clinical observation.
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Mean 
baseline 
value (S.D.)
Mean 
change 
after 
placebo 
(95% C.l.)
P
Value
Mean change 
after
sumatriptan 
(95% C.l.)
P value
HR (bpm) 67 (8) -1.9 (-4.0 to 
0.16)
0.59 0.67 (-2.5 to 3.8) 0.64
CO (l.min-^) 5.62 (0.9) 0.14 (-0.19 
to 0.48)
0.35 0.07 (-0.33 to 
0.47)
0.7
SAP (mmHg) 135 (31) -0.44 (-10.7 
to 9.8)
0.92 14.8 (7.6 to 
22.0)*
0.0015
DAP (mmHg) 70(13) -0.11 (-3.2 
to 3.0)
0.94 6.3 (3.9 to 8.7)* 0.0002
MAP
(mmHg)
96(18) 1.1 (-3.6 to 
5.8)
0.6 12.4 (7.0 to 
17.8)*
0.0007
SVR
(dyne.s.cm®)
1314(330) “16 (-94 to 
62)
0.65 163 (74 to 253)* 0.003
PASP
(mmHg)
23.7 (7.1) 0 (-1.7 to 
1.7)
1.0 4.4 (2.0 to 6.9)* 0.003
PADP
(mmHg)
8.2 (3.6) 0.4 (-1.5 to 
2.3)
0.65 2.6 (0.7 to 4.4)* 0.012
MPAP
(mmHg)
14.1 (4.6) 0.2 (-1.2 to 
1.5)
0.78 3.5 (2.4 to 4.7)* 0.0001
PVR
(dyne.s.cm®)
97 (38) 0.2 (-21 to 
22)
0.98 19 (3 to 34)* 0.025
PAWP
(mmHg)
7.3 (3.9) 0.1 (-0.7 to 
0.9)
0.75 2.1 (1.9 to 2.4)* 0.009
RAP (mmHg) 6.2 (2.9) 0.3 (-0.4 to 
1.1)
0.35 0.8 (0.2 to 1.3)* 0.01
Table 6.2 Cardiac haemodynamics at baseline and changes after placebo and 
naratriptan injection. In each case comparisons are made with baseline values.
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Mean
(S.D.)
baseline
diameter
(mm)
Mean change 
after placebo 
(95%C.I.)
P
value
Mean change after 
naratriptan (95%C.l.)
P
value
Proximal
segments
(n=10)
3.70 (0.63) -0.06(-0.15to
0.02)
0.12 -0.08(-0.27 to 0.11) 0.37
Middle
segments
(n=8)
2.63 (0.73) -0.15(-0.38to
0.07)
0.15 -0.10(-0.29 to 0.08) 0.23
Distal
segments
(n=9)
1.65 (0.37) -0.04(-0.12to
0.04)
0.3 -0.15(-0.36to0.04) 0.09
Table 6.3 Mean coronary artery diameter (mm) at baseline and following 
placebo and naratriptan injection. In each case comparisons are made with 
baseline values.
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Figure 6.1 Mean arterial pressure (MAP) at baseline and after 
placebo and naratriptan injection. Each line represents an
individual.
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Figure 6.2 Mean pulmonary artery pressure (MPAP) at 
baseline and after placebo and naratriptan injection. Each 
line represents an individual.
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Figure 6.3 Proximal coronary artery diameters at baseline 
and after placebo and naratriptan injection. Each line 
represents an individual.
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Figure 6.4 Mean arterial (MAP) and mean pulmonary arterial 
pressure (MPAP) changes after placebo and naratriptan
injection.
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CHAPTER 7
THE EFFECT OF ELETRIPTAN, A 5-HTm AGONIST, ON THE SYSTEMIC, 
PULMONARY AND CORONARY CIRCULATIONS.
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INTRODUCTION
Symptomatic relief is gained in 70-80% of acute migraine attacks treated with 
sumatriptan, the prototype and first clinically available 5-HTi agonist.^^®’^ ®^
However, as discussed earlier in this thesis, its use is complicated by limited 
oral bio-availability and by side effects which include chest tightness in 
approximately 3-5% of p a tien ts .T he re  is conclusive evidence from both in 
vitrQ 2^,48 y/^ o24i,242 g^udios, that the cardiovascular effects of sumatriptan i
are not confined to the cranial circulation as was originally thought. These 
extra-cranial vascular actions may be responsible for some of the more serious 
adverse reactions to sumatriptan.^^®' "^^®
I
■ÿ
Eletriptan is a “second generation” 5-HTi receptor agonist. It is a potent and 
selective agonist at the 5-HTid receptor subtype and is currently in clinical 
development for the acute treatment of migraine. There is some evidence that 
eletriptan has greater cranioselectivity than sumatriptan and this is of potential
interest in terms of cardiovascular safety. In both in vitro and in vivo pre-clinical 
studies, eletriptan has shown lower potency than sumatriptan to cause 
coronary artery vasoconstriction but remains equipotent in tissues believed to 
reflect anti migraine activity (Pfizer Central Research data). For example, both "3
sumatriptan and eletriptan are potent constrictors of isolated canine saphenous Iveins but eletriptan was approximately 2 fold more selective for saphenous
vein compared to the coronary artery. On the contrary, sumatriptan displayed
1.7 fold selectivity for the coronary artery compared to the saphenous vein. f
In vivo, in the anaesthetised dog, eletriptan demonstrated a statistically :ïsignificant 5-fold selectivity for reduction in carotid artery blood flow relative to
:::
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the reduction in left circumflex coronary artery diameter. This compared 
favourably with sumatriptan which demonstrated a non-significant 2-fold 
selectivity for carotid blood flow reduction (Pfizer Central Research data).
119
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These data infer that, in the anaesthetised dog, for a given reduction in carotid 
artery blood flow (a surrogate marker of potential anti-migraine efficacy), less 
coronary artery constriction is induced by eletriptan than sumatriptan. This 
suggests a potential increase in the selectivity of eletriptan over sumatriptan for 
the target vascular territory but the vasoactive effects of serotonergic 
compounds are notoriously species dependent and these results cannot be 
extrapolated to the clinical setting.
Î
Within the proposed clinical dosing range (16.7 -102 mcg/kg i.v and 1.5- 30mg 
p.o.) eletriptan displays approximately linear increases in plasma concentration 
with dosing. Eletriptan has been evaluated in over 100 volunteers and over 
200 migraine patients. Preliminary studies revealed that intravenous doses of 4-
50-102 mcg/kg (over 15 minutes) and oral doses of 5,20 and 30mg were well Itolerated and efficacious in acute migraine. Only 2 episodes of chest pain were 
reported, one by a 68 year old woman 2 hours after dosing with 20mg orally
fand after prolonged and severe vomiting. The other episode of chest pain ■ >
occurred in a volunteer after dosing with 120mg orally (Pfizer Central Research 
data).
Bearing in mind the favourable pre-clinical profile of eletriptan, the effects on 
the human vasculature require to be established in vivo to ascertain whether 
theoretical advantages might be translated into a potentially safer anti-migraine
I t
compound. In this chapter the effects of intravenous eletriptan on the systemic.
120
pulmonary and coronary circulation were therefore established in a similar 
clinical model to that applied to sumatriptan and naratriptan.
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METHODS
The study protocol is summarised in table 7.1. Ten patients (2M;8F; mean age 
51, range 39-75) were studied. Exclusion criteria were as discussed in chapter
2 (page 49). After initial baseline readings had been taken, a placebo infusion 
of 16ml of 0.9% saline was administered via an antecubital vein at 96ml/hr for 
10 minutes. Five minutes after completing the placebo infusion, eletriptan was
sinfused through the same cannula at a rate of 3.33mcg/kg/min for 15 minutes 
(total dose 50mcg/kg). This concentration was chosen in order to achieve 
plasma levels similar to those found after a 40mg oral dose of eletriptan.
Measurements continued for a 30 minute “wash out” period after cessation of 
the eletriptan infusion. Haemodynamic pressure recordings and quantitative 
coronary angiography were performed in a manner identical to that described 
in chapter 2 (pages 49-51 ).
Statistical Anaiysis
A mean placebo value for each parameter was calculated from the average of S
13
3 recordings during the placebo infusion. Similarly, a mean eletriptan value for 
each parameter was calculated from the haemodynamic recordings during
:eletriptan infusion. During the wash out phase, a mean wash out value was 
also established for each haemodynamic variable. Measurements during 
placebo infusion, during eletriptan infusion and after eletriptan infusion were 
then compared to baseline values by t-test. All results are expressed as 95%
confidence intervals and significance levels are stated.
:::'1
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RESULTS 
Haemodynamic Variables
Pulmonary Arterial Pressure
pulmonary artery diastolic pressure (PADP) and mean pulmonary artery
respectively. Mean (95%C.I.) changes following eletriptan infusion were: PASP
121
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There were no significant differences between baseline and placebo values for 
any of the haemodynamic variables. Results are summarised in table 7.2.
I
Heart Rate
3ÏMean (s.d.) heart rate at baseline was 69 (9.5) bpm. After eletriptan infusion, 
the mean change in heart rate was -1 bpm (95%C.I. -1.6 to 3.6, p=0.6)
vît
Cardiac output (C.O.)
Mean (s.d.) baseline 0.0. was 5.8 (1.3) l.min"\ After eletriptan infusion 0.0 . 
fell significantly by an average of 1.0 l.min"  ^ (95%O.I. 0.4 to 1.6, p=0.018).
Systemic Arterial Pressure
Mean (s.d.) baseline values for systolic arterial pressure (SAP), diastolic
arterial pressure (DAP) and mean arterial pressure (MAP) were 131 
(25.7)mmHg, 69 (12.3)mmHg and 91 (14.8) mmhg respectively. Mean 
(95%O.I.) changes following eletriptan infusion were: SAP 4.3mmHg (-5.8 to 
14.4, p=0.5) : DAP 4.6mmHg (-0.7 to 9.9, p=0.1) : MAP 7mmHg (-0.7 to 9.9,
tp=0.09).
Mean (s.d.) baseline values for pulmonary artery systolic pressure (PASP),
■I
pressure (MPAP) were 21 (4)mmHg, 8 (2.1)mmHg and 14 (2.7)mmHg
'■i
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1.1mmHg (-1.5 to 3.7, p=0.5): PADP 3.4mmHg (-1.2 to 8.0, p=0.2) : MPAP 
0.6mmHg (-2.1 to 3.1, p=0.7).
Mean (s.d.) baseline PAWP was 8.1 (3) mmHg. Mean (95%C.I.) change after 
eletriptan infusion was O.GmmHg (-1.0 to 2.2, p=0.5).
Right Atrial Pressure (RAP)
Mean (s.d.) baseline RAP was 5.0 (2.1) mmHg. Mean (95%C.I.) change after 
eletriptan was 0.9mmHg (-0.3 to 2.1, p=0.2)
Pulmonary Vascular Resistance (PVR)
Pulmonary Artery Wedge Pressure (PAWP)
I
j
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Systemic Vascular Resistance (SVR)
Mean (s.d.) baseline SVR was 1221 (232) dyne.s.cm'^. After eletriptan 
infusion, SVR rose significantly by an average of 298 dyne.s.cm"® (95%C.I. 
161-435, p=0.004).
I
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Mean (s.d.) baseline PVR was 70 (33) dyne.s.cm ®. Eletriptan infusion was 
associated with a significant increase in PVR. The mean maximum rise was 31 Idyne.s.cm"® (95%C.I. 9-53, p=0.03).
:
Coronary effects
During eletriptan infusion, one subject developed a segmental constriction in 
the proximal right coronary which was accompanied by mild chest tightness 
but no ECG changes. The constriction persisted to a lesser degree after the 
end of the eletriptan infusion, as did the chest tightness, which was later
relieved by sub-lingual nitrates. Two experienced independent cardiologists
122
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felt that catheter induced spasm could not be excluded as a cause of the 
segmental constriction. Statistical analysis of the coronary dimensions was 
performed including this subject.
123
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Mean (s.d.) baseline coronary artery diameters were 2.96 (0.59)mm, 2.40 
(0.81 ) mm and 2.20 (0.58)mm for proximal, middle and distal coronary artery 
segments respectively. No significant changes occurred during or after 
eletriptan infusion. Mean (95%C.I.) change in proximal coronary segments 
was -0.11mm (-0.44 to 0.22, p=0.5). Corresponding figures for mid and distal 
segments were 0.16mm (-0.16 to 0.32, p=0.38) and -0.09mm (-0.29 to 0.11,
p=0.45) respectively.
.1;
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DISCUSSION
Unlike sumatriptan and naratriptan, eletriptan failed to elicit significant 
increases in systemic or pulmonary arterial blood pressure in this small group 
of patients. If vasoconstrictive effects are a class action of the triptan group of 
5-HTi agonists, then increases in arterial and pulmonary pressures might have
been expected following the administration of eletriptan. It is unclear therefore
/:why no such effect was seen with eletriptan. The patients in this study came 
from an identical clinical substrate to those in the sumatriptan and naratriptan 
studies and different patient characteristics seem an unlikely explanation.
Relative dose differences between the respective drugs could provide an 
explanation. The dose of eletriptan in this study (total dose 50mcg/kg i.v.) was 
toward the lower end of the proposed clinical dosing range (16.7 -102 mcg/kg) 
and it may be that in relatively low doses, eletriptan has little effect on the
AI124
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pulmonary or systemic circulation whilst maintaining anti-migraine efficacy.
This possibility has been discussed with regard to the differing actions of
■v'naratriptan and sumatriptan on coronary artery dimensions (see chapter 6). ;/
There is evidence that the anti-migraine activity of sumatriptan relates not only 
to vascular receptor properties but also on an ability to modulate release of 
certain neuropeptides responsible for neurogenic inflammation (plasma protein I  
I
extravasation and vasodilatation).^®°’^ ®^ The dose response curves for these
two properties may differ such that sumatriptan induced inhibition of 
neurogenic inflammation occurs at a lower dose than that required to produce 
vasoconstriction. Interestingly, sumatriptan selectively inhibited plasma 
extravasation in the dura mater of the rat and guinea pig at doses that did not 
increase systemic arterial pressure.^®^
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IAlthough no effect was seen on systemic or pulmonary arterial pressure, both I
systemic and pulmonary vascular resistance increased after eletriptan infusion.
SVR rose by 24% from baseline with a 44% rise in PVR. As seen with both 
sumatriptan and naratriptan, the percentage rise in PVR exceeded that for f
SVR in keeping with the possibility that 5-HTi receptors are more densely 
distributed within the pulmonary circulation. Eletriptan however, was 
associated with a statistically, but not clinically, significant 17% decrease in
■cardiac output, it is possible that the observed increases in both SVR and PVR 
are a reflection of this reduction in cardiac output as cardiac output is the 
denominator in the formulae required to calculate SVR and PVR.
ventricular pressure rise (ôP/ ôt) as seen in chapter 3. Assessment of STI
sumatriptan (see chapter 5) but this is more likely to reflect an acute increase 
in afterload rather than a negative inotropic effect.
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In the absence of changes in heart rate, the reduction in cardiac output seen 
after eletriptan could be attributed to a reduction in stroke volume. Negative 
inotropic effects of 5~HTi agonists have not been reported however. 
Sumatriptan (6mg s.c.) had no significant effect on maximal rate of left
■
I
responses has however shown an increase in the PEP:LVET ratio after
Sumatriptan has vasoconstrictor properties on the coronary circulation as 
evident from the 14-16% reduction in coronary artery diameter seen after both 
intravenous^"^^ and subcutaneous^"^^ injection. Neither naratriptan nor eletriptan
,1have been observed to share this property. Possible reasons for the disparity %
between naratriptan and sumatriptan in this regard have previously been 
discussed. Similar arguments may explain the difference between eletriptan 
and sumatriptan.
Eletriptan is a potent S-HTm agonist, which in animal models shows coronary 
constriction, but at a dose four times higher than sumatriptan. Higher 
selectivity for non-coronary vascular beds is seen in animal studies and this is
,«■ 
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compatible with the lack of coronary effects in the present study. These 
findings may be explained by eletriptan’s 13-fold selectivity for the 5-HT id 
receptor subtype over the 5-HT ib subtype (Pfizer Central Research). Although 
receptor subtypes in the human coronary artery are not well delineated, there 
is evidence that the 5-HTte but not the 5-HT id subtype is expressed in canine 
coronary arteries and saphenous veins, both vessels being commonly used as
I
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models for vascular responses in human coronaries. Recent evidence also 
suggests that coronary artery spasm in variant angina may be mediated by the 
5-HTib receptor subgroup.^^®
Clearly one subject experienced a marked segmental constriction of the right 
coronary artery during eletriptan infusion which could either be due to a direct 
drug effect or due to catheter related spasm. Catheter induced spasm is often t:
seen in the proximal right coronary artery, although in this case the timing of
the constriction seems to correlate well with the drug infusion. However, 
segmental constriction of this type has not been described previously with 5- 
HTi agonists.
Current 5-HTi agonists are contra-indicated in patients with known ischaemic 
heart disease and are recommended to be used with caution in those with 
conditions predisposing to coronary artery disease. This data and receptor 
selectivity studies provide theoretical evidence to suggest that eletriptan may 
be the 5-HTi agonist of choice in patients with coronary risk factors but no 
overt coronary artery disease, it must not be overlooked however that the 
patients in this study had normal or near normal coronary arteries.
It is well recognised that, in vivo, the effects of serotonin agonism on human 
coronary arteries is dependent on the presence or absence of 
atherosclerosis.^^^’ In one study, serotonin acted as a vasodilator and 
increased coronary artery blood flow in patients with normal coronary 
arteries.^^^ In another study, intracoronary serotonin caused vasodilatation of
angiographically normal coronary arteries at low doses but vasoconstricted at
126
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higher doses. In subjects with atherosclerosis however, intracoronary 5-HT 
caused only vasoconstriction. In another study in patients with stable angina, 
ketanserin (S-HTz antagonist) was unable to attenuate serotonin induced 
coronary artery spasm indicating that 5-HTi receptor activation may be
y
im p l i c a te d . A  similar study assessing the effect of eletriptan on diseased 
coronary arteries would therefore be required to confirm claims that eletriptan 
has potentially enhanced cardiovascular safety.
In summary, eletriptan, unlike sumatriptan, did not cause significant 
vasoconstriction in the systemic, pulmonary or coronary vasculature. Whether 
this relates to relative differences in 5-HT ib and 5-HT id receptor subtype 
selectivity between the two drugs is unclear.
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Table 7.1 Study protocol: The haemodynamic effects of eletriptan
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Variable Baseline
(S.D.)
Mean change 
(95% C.l.) after 
placebo
P
value
Mean change 
(95% C.l.) after 
eletriptan
P
value
HR (bpm) 69 (9.5) -2 (-5.6 to 1.6) 0.91 - 1 (-1.6 to 3.6) 0.6
C.O.
(I.min'^)
5.8 (1.3) -0.24 (-0.49 to 
0.01)
0.13 -1.0 (-0.4 to -1.6)* 0.018
SAP (mmHg) 131 (25.7) -7.8 (-15.3 to -  
0.3)
0.1 4.3 (-5.8 to 14.4) 0.5
MAP
(mmHg)
91 (14.8) 0.6 (-5.9 to 7.1) 0.9 7.0 (-0.7 to 9.9) 0.09
DAP (mmHg) 69(12.3) 0.6 (-3.8 to 5.0) 0.8 4.6 (-0.7 to 9.9) 0.1
RASP
(mmHg)
21 (4) -0.9 (-3.5 to 1.7) 0.5 1.1 (-1.5 to 3.7) 0.5
MPAP
(mmHg)
14 (2.7) -0.8 (-3.3 to 1.7) 0.6 0.6 (-2.1 to 3.1) 0.7
PADP
(mmHg)
8.0 (2.1) -0.1 (-1.9 to 1.7) 0.9 3.4 (-1.2 to 8.0) 0.2
PAWP
(mmHg)
8.1 (3.0) 0.1 (-2.0 to 2.2) 0.9 0.6 (-1.0 to 2.2) 0.5
RAP (mmHg) 5.0 (2.1) 0.07 (-1.19 to 
1.33)
0.68 0.9 (-0.3 to 2.1) 0.2
SVR
(dyne.s.cm"®)
1221 (232) 38 (-115 to 192) 0.66 298(161 to 435)* 0.004
PVR
(dyne.s.cm®)
70 (33) 14 (-12 to 40) 0.4 31 (9 to 53)* 0.03
Table 7.2. Haemodynamic variables at baseline, after placebo and maximal 
change after eletriptan infusion.
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Figure 7.1 Mean arterial pressures (MAP) at baseline and 
after placebo and eletriptan infusion. Each line represents an
individual.
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Figure 7.2 Mean pulmonary artery pressures (MPAP) at 
baseline and after placebo and eletriptan infusion. Each line 
represents an individual.
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Figure 7.3 Proximal coronary artery diameters at baseline 
and after placebo and eletriptan infusion. Each line represents
an individual.
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Figure 7.4 Systemic vascular resistance (SVR) and pulmonary vascular 
resistance (PVR) responses to placebo and eletriptan infusion.
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CHAPTER 8
THE EFFECT OF KETANSERIN, A S-HTj ANTAGONIST, ON THE 
SYSTEMIC, PULMONARY AND CORONARY CIRCULATIONS. :
II
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INTRODUCTION 
Clinical Pharmacology of Ketanserin: 
Systemic Circulation
Ketanserin is a selective S-HTz antagonist with additional, though weaker 
antagonist activity at a-adrenoreceptors.^^^ This 5-HT2 receptor is present in 
most systemic arterial smooth muscle and ketanserin can competitively inhibit 
serotonin induced smooth muscle contraction.^^® in isolated mesenteric arterial 
strips from hypertensive, compared to normotensive rats, the response to 
serotonin is a u g m e n t e d . i n c r e a s e d  responsiveness to serotonin has also 
been consistently reported in patients with essential hypertension®^® and Mehta 
& Mehta in 1981 suggested this may arise on account of increased platelet 
activation in such patients.®^^Stott et ai in 1988 also noticed enhanced 
serotonin induced platelet aggregation in untreated patients with essential 
hypertension compared to a normotensive control group.®^ ® It remains 
uncertain whether this observed increase in platelet aggregation in 
hypertensives is a contributing factor to, or a consequence of the disease 
process. Nonetheless, there is evidence for a pathophysiological role of 
serotonin in hypertension.
Further support implicating serotonin in hypertension Is the documented 
hypotensive effects of ketanserin in hypertensive patients. Given intravenously 
to hypertensive patients, ketanserin rapidly reduced systemic arterial blood 
pressure as measured non-invasively.®^®’®®®’®®®’®®'^  Typically, a 10mg 
intravenous bolus of ketanserin caused an approximate 20mmHg drop in blood 
pressure. The hypotensive action was age-related with greater blood pressure 
drops in the older (> 60 year old) population.®®® For example in patients under
133
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60 years old, a 10% decrease in blood pressure was noted, the corresponding 
figure in over 60 year oids being 20-25%.®®® Given orally in smail studies, 
ketanserin has also been shown to have hypotensive properties similar to 
thiazides, metoprolol or captopril.®®®'®®® Given iong term (2-3 months) 
ketanserin 20-40 mg bd reduced diastolic blood pressure by 13- 
18mmHg.®® ’^®®®
Pulmonary Circulation
Not surprisingly, serotonin also has effects on the pulmonary vasculature. The 
isolated human pulmonary artery contracts when exposed to serotonin®®® and 
this has led to speculation that serotonin may be implicated in some forms of 
pulmonary hypertension. For example, in adult respiratory distress syndrome 
there was a correlation between the serum concentration of serotonin and the 
pulmonary vascular pressure gradient.®®® in experimental pulmonary 
embolism, rises in pulmonary arterial pressure have been accompanied by 
increased plasma serotonin concentrations and ketanserin®®  ^and 
methysergide®®® could inhibit the rise in pulmonary arterial pressure.
Ketanserin has also been shown to reduce pulmonary vascular resistance in 
14 patients with pulmonary hypertension secondary to systemic sclerosis.®®® In 
two other small studies however, ketanserin had only modest or no pulmonary 
vasodilator effects in patients with primary®®"^  or hypoxic®®® pulmonary 
hypertension. The role, if any, of serotonin in pulmonary hypertension therefore 
remains unclear.
Ketanserin has consistently been shown, however, to have hypotensive effects 
on the pulmonary circulation following coronary artery bypass grafting.®^® Van
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der Star re et al for example, noted reductions in pulmonary artery systolic 
pressure (-9%), pulmonary artery diastolic pressure (-27%) and pulmonary 
vascular resistance (-32%) in 20 patients whose pre-treatment pulmonary 
artery pressures and pulmonary vascular resistance were within normal 
limits.®®® This suggests that serotonin influences resting tone within the 
pulmonary circulation as well as in some conditions with pathologically 
increased pulmonary vascular tone.
Coronary Circulation
Serotonin may play an important pathophysiological role in acute coronary 
syndromes such as unstable angina or myocardial infarction. In patients with
:
complex coronary artery lesions, elevated serotonin levels have been
135
observed by sampling blood from the coronary sinus.®®® Blood samples from 
the coronary sinus are also capable of inducing canine coronary artery
vasoconstriction in vitro - an action which can be attenuated with serotonin
■
antagonists.®®^ Serotonin constricts coronary artery rings from explanted 
human hearts, an action mediated by both 5-HTi and 5-HT2 receptors.
As a 5-HT2 antagonist, ketanserin may therefore have the ability to influence in 
vivo coronary artery responses. Two recent studies have confirmed an 
important role for 5 -HT2 receptors in mediating coronary artery 
vasoconstriction during percutaneous transluminal coronary angioplasty 
(PTCA).®®®’®®^ During angioplasty, the degree of coronary artery 
vasoconstriction was related to the quantity of serotonin liberated®®® and was 
attenuated, at least partly, by ketanserin.
;
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During angioplasty, it is assumed that endothelial injury induces platelet 
aggregation with subsequent serotonin release resulting in vasoconstriction. 
Under resting, stable conditions, however, levels of serotonin are likely to be 
low such that serotonin may have little influence on coronary artery tone. 
Whereas ketanserin has been shown to be effective at times of serotonin 
release®®®'®®^ , its in vivo effects on human coronary arteries under resting 
conditions remain unknown.
In this chapter, ketanserin was used as a pharmacological agent to investigate 
the role of 5-HT2 receptors on the coronary circulation under resting, stable 
conditions. The effect of ketanserin on the systemic and pulmonary circulation 
was also examined. Haemodynamic assessments were made using direct 
invasive recordings of aortic and pulmonary arterial pressures. With regard to 
the systemic circulation in particular, this technique obviates the 
methodological difficulties of measuring blood pressure by cuff 
sphygmomanometer (eg Korotkoff sounds, digit preference).
METHODS
invasive investigations were performed in 10 patients (7 male, 3 female, mean 
age 57 + 6 yrs). The protocol is summarised in table 8.1. Exclusion criteria 
and quantitative coronary angiography were as described in chapter 2 (pages 
49-51). Coronary angiograms and haemodynamic tracings were analysed by a 
blinded observer.
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TIME (mins) -20 -10 0 5 15
Coronary angiogram * * * * *
Baseline measurements *
Placebo injection *
Ketanserin lOmg i.v. *
6 lead ECG * * * * *
Cardiac
Haemodynamics
* * * * *
Table 8.1 Study protocol: The haemodynamic effects of ketanserin. 
Statistics
Data are expressed as mean (s.d.). The effect of placebo and ketanserin i.v. 
boius on central haemodynamics was analysed for each haemodynamic 
response using a paired t-test/confidence interval analysis. No significant 
differences were identified between baseline and post-piacebo values. 
Significant differences between post-placebo values and post-ketanserin 
values (p < 0.05) are highlighted by an asterisk.
RESULTS
See tables 8.2 and 8.3 and figures 8.1, 8.2 and 8.3.
Heart Rate and Electrocardiography
There was no significant change in ECG morphology following ketanserin 
injection. Mean heart rate was 68 (16) bpm after placebo injection. Five 
minutes after ketanserin, heart rate rose by a mean of 2.7 (95%C.l. 0.6-5.4,
p=0.06)
137
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■■■Cardiac output
No significant differences were observed between baseline and piacebo vaiues 
nor between the two post ketanserin vaiues. Mean (s.d.) cardiac output was 
5.4 (1.1) L/min after placebo. Fifteen minutes post ketanserin the mean change 
in C.O was 0.3 (95%C.I. -0.2 to 0.8, p = 0.42).
138
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Systemic arterial pressure
No significant change was evident between baseline and placebo values 
Mean (s.d.) systolic arteriai pressure (SAP), diastolic arterial pressure (DAP) 
and mean arterial pressure (MAP) following placebo were 143 (17), 74 (11) 
and 101 (12) mmHg respectively. Five minutes after ketanserin, SAP had 
falien by a mean of 21 mmHg (95%C.i. 14.5-27.5, p=0.002). Simiiarly, DAP feil 
significantly by an average of 8 mmHg (5.8-10.2. p=0.0001). Five minutes after 
ketanserin, MAP had fallen by 12mmHg (7.9-16.1, p=0.0006).
Pulmonary artery pressures
No significant changes were observed between baseiine and placebo values. 
Mean (s.d.) pulmonary artery systolic pressure (PASP), pulmonary artery 
diastolic pressure (PADP) and mean pulmonary artery pressure (MPAP) were 
22.3 (3.5), 8.2 (3.4) and 14.3(2.8) mmHg respectively after placebo injection. 
Significant decreases in PADP and MPAP, but not PASP were observed 
fifteen minutes after ketanserin. PADP fell by 1.5mmHg (95% C.l. 0.3-2.7, 
p=0.04). MPAP fell by 2.4mmHg (95% C.l. 0.7-4.1, p=0.028). PASP fell by a 
mean of 2.2mmHg (95% C.l. -0.4 to 4.8, p=0.1 ).
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Pulmonary artery wedge pressure
There was no significant change between baseline and placebo values. Mean 
pulmonary artery wedge pressure (PAWP) was 7.5 (10) mmHg after placebo 
and had fallen significantly 15 minutes after ketanserin by an average of 2 
mmHg (95% C.l. 1.0 -3.2, p=0.011).
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Right atrial pressure
There was no significant difference between placebo and baseline values. 
Right atriai pressure (RAP) was 5.4 (2.4) mmHg following piacebo injection 
and mean change after ketanserin was 0.7mmHg (95% C.i. -0.6 to 2.0, p= 
0.35).
Systemic vascular resistance
There was no significant difference between placebo and baseline values. 
Mean systemic vascular resistance (SVR) was1463 (256) dyne s cm after 
placebo and fell by 233 (95% C.l. 88-378, p=0.018) dyne s cm  ^five minutes 
after ketanserin.
Pulmonary vascular resistance
There was no significant difference between piacebo and baseline values. 
Pulmonary vascular resistance (PVR) fell significantly from a baseline of 111 
(37) dyne.s.cm  ^by a mean of 33 (95%C.I. 14-52, p=0,009) dyne.s.cm  ^five
minutes after ketanserin.
"i
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CORONARY ARTERY DIMENSIONS
No significant change in mean proximal, mid or distal coronary artery
140
dimensions was observed between baseiine and placebo values. Neither was
I
there a change in the mean stenotic index between the baseline value and 
after placebo injection.
%
Proximal coronary artery segments
Mean (s.d.) diameter of the proximal coronary artery segments after placebo
.was 4.14 (0.7) mm. Five minutes after ketanserin injection, mean change in 
coronary artery diameter was -0.06mm (95%C.i. -0.1 to 0.22, p=0.45).
*
Middle coronary artery segments
Mean diameter of the mid coronary artery segments after placebo injection 
was 2.39 (0.42)mm. Five minutes after ketanserin injection, mean change in 
coronary artery diameter was 0.06mm (95%C.i. -0.25 to 0.13, p=0.56).
Distal coronary artery segments
Mean diameter of the distal coronary artery segments after placebo injection 
was 1.33 (0.34)mm. Five minutes after ketanserin injection, mean change in 
coronary artery diameter was -0.02mm (95%C.I. -0.12 to 0.16, p=0.84).
Coronary artery stenotic index
Mean coronary artery stenosis after piacebo injection was 78 (13)%. Five 
minutes after ketanserin injection, mean change in coronary artery stenotic 
index was -2% (95%C.I. -6  to 2, p=0.37).
■
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DISCUSSION
antagonism of both 5-HT2 and a-receptors.®®®’®®® A central mechanism of 
action seems less likely as the hypotensive effect of ketanserin is not
141
Ketanserin 10 mg intravenously has been shown to have a vasodilator 
response in the systemic and pulmonary circulations. In the absence of 
changes in heart rate or cardiac output, the fall in systemic and pulmonary 
arteriai pressures and in systemic and pulmonary vascular resistances can be 
attributed to a direct vasodilator effect. In general, the effects of ketanserin 
occurred early after intravenous injection and had often resolved within 15 
minutes. This study identified a 10-15% reduction in systemic arteriai 
pressures, with changes of similar magnitude in the pulmonary circulation. 
These results are similar to previously reported haemodynamic changes 
following intravenous ketanserin.®^ ®'®®® It is assumed that these effects are 
mediated via 5-HT2 and/or a-adrenergic receptor antagonism although non 
drug induced changes (eg. ionic contrast media) cannot be fully excluded.
There is evidence that the anti-hypertensive effect of ketanserin relies on both 
of these mechanisms. Ritanserin, a 5-HT2 antagonist with much weaker a- 
receptor properties fails to reduce blood pressure when given intravenously to 
hypertensive patients, whereas ketanserin does.®®® On the contrary, the 
pressor response to the a-agonist phenylephrine is not reduced by the i.v. 
administration of hypotensive doses of ketanserin, although it was markedly 
reduced by equivalent doses of the potent a-antagonist prazosin.®®"^  The
observation that ritanserin greatly enhances the anti-hypertensive effect of
small doses of prazosin on the spontaneously hypertensive rat supports the 
theory that ketanserin produces an anti-hypertensive effect due to combined
I
2,;l-
142
accompanied by reduced noradrenaline levels, unlike clonidine and 
methyldopa.®®  ^Interestingly, the fall in systemic arteriai pressure was not 
associated with a reflex increase in heart rate, a finding consistent with 
previous reports.®^®’®®®
Ketanserin has been noted to have pulmonary vasodilatory effects in 
hypertensive patients undergoing coronary artery bypass surgery. Van den 
Broucke and colleagues observed a significant 5-6% reduction in pulmonary 
artery pressure, 5% reduction in pulmonary artery wedge pressure and an 8% 
decrease in pulmonary vascular resistance following successive i.v. bolus 
doses of ketanserin to a maximum of 30mg.®®^  Van der Star re et al reported a 
13% decrease in systolic arterial pressure and a 9% decrease in pulmonary 
artery systolic pressure after an i.v. bolus of lOmg ketanserin followed by a low 
dose infusion.®®® Corresponding fails in total systemic (17.5%) and pulmonary 
vascular resistances (32%) were noted. Richter et al reported a 35% reduction 
in systemic vascular resistance, but interestingly there was no significant 
change in pulmonary vascular resistance following iOmg intravenous 
ketanserin.®^®
This study demonstrated approximately equipotent vasodilator responses on 
the pulmonary and systemic circulation, the magnitude of the responses being 
comparable to previous findings. ®^®'®®^ This suggests that 5-HT2 receptors are 
equally distributed in the systemic and pulmonary circulations in humans.
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Coronary artery responses
This study revealed no significant effect of ketanserin on coronary artery 
dimensions. Both 5-HTi-like and 5-HT2 receptors exist in coronary arteries, 
although the role of these two receptors on the coronary circulation is complex 
and not fully understood. In vitro responses using human epicardial coronary 
artery rings from explanted hearts have shown that serotonin causes 
c o n t r a c t i o n . A s  ketanserin partially attenuated these responses, it was 
assumed that 5-HT2 receptors were functionally more important with a residual 
contraction (30% of the maximum effect) being 5-HTrlike mediated.
Kaumann et al, however, have reported the predominance of 5-HTrlike over 
5-HT2 receptors in mediating serotonin-evoked contractions.®®® In vivo 
serotonin displays divergent effects on the coronary arteries, acting as a 
vasodilator in normal arteries and a vasoconstrictor in the presence of 
coronary atherosclerosis.®®® Serotonin evoked vasoconstriction in diseased 
coronary arteries is ketanserin-sensitive, suggesting that vasoconstriction is a 
5-HT2-receptor mediated phenomenon.®®® Two more recent studies have 
confirmed an important role for 5-HT2 receptors when vasoconstriction is 
observed during percutaneous transluminal coronary angioplasty
I'-
(PTCA).®®®’®®^ Following bailoon dilatation, vasoconstriction distal to the 
angioplasty site is frequently noted. The degree of vasoconstriction is related 
to the amount of serotonin released into the circulation®®® and in both of the 
above studies ketanserin attenuated, at least partly, this vasoconstriction.
."-iI
In theory, therefore, one might have expected a significant change in coronary 
artery dimensions in the present study. There are a number of reasons, 
however, why such an effect was not observed. In the absence of platelet
-i
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aggregation and in a group of patients with stable symptoms, circulating levels 
of serotonin are likely to be low and, consequently, 5-HT2 receptors may 
exhibit minimal influence on resting coronary artery tone. Furthermore, all 
patients in this group were taking aspirin which may have modified platelet 
function. An identical study in patients with unstable angina (and presumably 
higher plasma serotonin levels), may have demonstrated a significant 
vasodilator response to ketanserin. Nonetheless, patients with coronary artery 
atherosclerosis have locally elevated serotonin concentrations and ketanserin 
could theoretically have interacted.®®® The route of administration or dose of 
ketanserin employed in the present study (10 mg i.v.) may have been 
insufficient to effect a response. Golino et al ®®®'®®® used a higher dose of 
ketanserin (0.25 mg/kg) to inhibit coronary artery vasospasm following PTCA.
In the other study investigating the effects of 5-HT2 antagonism during 
coronary angioplasty, ketanserin was administered by the intracoronary 
route.®®^
The observed non-significant reduction in proximal coronary artery dimensions 
is probably a reflection of the decrease in afterload following ketanserin 
administration. A direct vasoconstrictive action of ketanserin seems very 
unlikely in view of its known pharmacological properties and that of 5-HT2 
receptors. Attenuation of vasodilator tone could explain the minor reduction in 
coronary artery diameter, but this is not a strong possibility. Serotonin can 
influence vascular tone indirectly by stimulating release of endothelium derived 
relaxant factors (EDRF). This action, however, appears to be mediated by a 5- 
HTrlike mechanism as 5-HT2 (ketanserin) and 5-HT3 (ondansetron) receptor
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antagonists failed to biock these responses, whereas methysergide and 
methiothepin (non-selective 5-HT antagonists) are potent antagonists.®"^ '^ ®®
In summary, equipotent vasodilator responses were seen in the systemic and 
pulmonary arterial circulations following an intravenous dose of 10 mg 
ketanserin. No significant change in coronary artery diameter or coronary 
artery stenotic index was observed after ketanserin. Further studies assessing I
the effects of ketanserin on coronary artery tone at times of platelet 
aggregation are indicated. Such agents may have therapeutic applications in Ithe treatment of myocardial infarction and unstable angina or during PTCA.
I
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BASELINE PLACEBO
Maximum change 
after ketanserin 
(95%C.I.)
P value
HR (bpm) 68.8+16.6 68+16.3 -2.7 (-0.3 to -5.1) 0.06
SAP (mmHg) 137+17.3 143+16.6 -21(-14.5to -27.5) 0.002*
DAP (mmHg) 71.6+9.9 73.6+10.5 -8 (-5.8 to -10.2) 0.0001*
MAP(mmHg) 98+10.9 101+11.7 -12 (-7.9 to 16.1) 0.0006*
PASP (mmHg) 22.7+2.95 22.3+3.5 -2.2 (-4.8 to 0.4) 0.1
PADP (mmHg) 8.1+2.98 8.2+3.35 -1.5 (-0.3 to -2.7) 0.04*
MPAP(mmHg) 14.3+3.28 14.3+2.78 -2.4 (-0.7 to -4.1) 0.028*
SVR(dyne.s.c.nT°) 1394+239 1463+256 -233 (-88 to -378) 0.018*
PVR(dyne.s.c.m'®) 111+37 99+30 -33 (-14 to -52) 0.009*
PAWP(mmHg) 6.8+3.1 7.5+2.3 -2 (-1.0 to -3.2) 0.011*
RAP(mmHg) 4.6+2.2 5.4±2.4 0.7 (-0.6 to 2.0) 0.35
CO(L/mm'^) 5.54+1.09 5.41+1.09 0.3 (-0.2 to 0.8) 0.42
Table 8.2 Mean haemodynamic values at baseline and after placebo and 
ketanserin injections. Baseline and placebo figures are expressed as mean + 
S.D. * =statisticaily significant compared to placebo.
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Proximal 
segments 
(n = 12)
Mid 
segments 
(1 = 8)
Distal 
segments 
(n = 6)
Stenotic 
segments 
(n = 6)
Baseline 4.16(0.79) 2.55 (0.43) 1.45 (0.26) 77.5
(13.4)%
Placebo 4.14 (0.74) 2.39 (0.42) 1.33 (0.34) 77.7
(12.5)%
5 mins 
post
ketanserin
4.08 (0.68) 2.45 (0.37) 1.32 (0.30) 75.3
(12.1)%
Table 8.3 Mean (s.d.) coronary artery dimensions at baseline and after 
placebo and ketanserin injection. No significant differences were identified.
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Figure 8.1 Mean arterial pressure (MAP) at baseline and after 
placebo and ketanserin injection. Each line represents an
individual.
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Figure 8.2 Mean pulmonary artery pressure (MPAP) 
at baseline and after placebo and ketanserin injection. 
Each line represents an individual.
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Figure 8.3 . Coronary artery responses at baseline and 
after placebo and ketanserin injections. Each line 
represents a measured point in a proximal coronary artery.
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Figure 8.4 Mean arterial pressure (MAP) and mean pulmonary 
arterial pressure (MPAP) responses to placebo and ketanserin.
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Figure 8.5 Systemic vascular resistance (SVR) and pulmonary 
vascular resistance (PVR) responses to placebo and ketanserin.
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CHAPTER 9
THE EFFECT OF SUMATRIPTAN ON FOREARM BLOOD FLOW
151
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INTRODUCTION
As previously discussed in chapter 1, serotonin influences the vascular system 
in a complex manner. It can cause both vasodilatation and vasoconstriction 
depending on the dose, species, type of blood vessel and on the presence or 
absence of several physiological or pathological f e a t u r e s ^ I n i t i a l  
studies of the effect of serotonin on the cardiovascular system were performed 
in vitro or on animal preparations. In the last decade, however, Blauw and 
colleagues have assessed the role of serotonin in the human forearm vascular 
bed Employing the technique of venous occlusion plethysmography 
(see below) they found that 5-HT induced a biphasic vascular response 
Within a few minutes of commencement of serotonin infusion, a transient, rapid 
vasorelaxation was observed. This was succeeded by a sustained 
vasodilatation with lower doses (< 10 ng/kg/min) and a vasoconstriction at the 
highest dose of 5-HT (80 ng/kg/min). Maximal vasodilatation was 60-70% with 
a maximum constriction of 34%.
£
The initial response was elicited in a dose-independent fashion and was not 
blocked by propranolol or ketanserin, suggesting that neither the beta- 
adrenoreceptor nor the S-HTz receptor was involved. 5-HT-induced release of 
EDRF could have been implicated, but a dose-dependent response would 
have been expected in that Alternatively an interaction with the
cholinergic nervous system could have occurred 4^7.348 ^  thii-d potential 
mechanism involved in the 5-HT-induced vasorelaxation is the inhibition of 
noradrenaline release by an action of pre-synaptic 5-HT receptors on the 
sympathetic nerve terminals The sustained vasodilator response was
also resistant to 5-HT2 receptor blockade with ketanserin, indicating that 5-HT2
152
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hypertensive effects of ketanserin).
vasodilatation in the human forearm via the “NO pathway” ®^^ ’^ ®^ but the precise 
nature of the 5-HT receptor subtype involved is uncertain. The effect of
153
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receptors were not involved in the vasodilator response to serotonin. At 
vasoconstrictive doses of serotonin, however, ketanserin was an effective 
antagonist. Taken together, these results suggest that serotonin-evoked 
vasoconstriction via 5-HT2 receptor agonism, whilst vasodilatation ensued 
through an agonist action at some other unknown 5-HT receptor. Interestingly, 
the arterial effects of serotonin were not age related (c.f. the anti- I
Initially it was thought that serotonin induced vasodilatation was mediated by a 
5-HTi-like receptor. As new 5-HT receptors were identified in the early 1990’s, 
however, evidence pointed to a 5-HT3 or 5-HT4 receptor-mediated 
phenomenon, as 1CS205-930 (a mixed 5-HT3/5-HT4 antagonist) attenuated 
this vasodilator response^^°. The serotonin-induced vasodilatation was later 
challenged with ondansetron and granisetron (5-HT3 receptor antagonists) 
without effect, thereby implying that the 5-HT4 receptor exerted a significant 
role in the human forearm vascular bed Subsequent work by the same 
authors revealed that the serotonin-induced vasodilatation was mediated by 
the nitric oxide (NO) pathway on account that N-monomethyl-L-arginine 
(NMMA), an inhibitor of nitric oxide synthase, abolished the response^^°. A 
functional role for the 5-HTia receptor was excluded as flesinoxan, a 5-HTia 
receptor agonist, decreased forearm vascular resistance only slightly, and at 
high doses^^\
1
It appears that 5-HTiJike receptors on the vascular endothelium mediate
■if
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sumatriptan, a 5-HTid/ib agonist on forearm blood flow is therefore of interest 
in elucidating which 5-HTi receptor subtype(s) influence forearm vascular 
resistance in the human.
:
MEASUREMENT OF FOREARM BLOOD FLOW USING MERCURY STRAIN Ï
d
GAUGE PLETHYSMOGRAPHY
Mercury strain gauge plethysmography has been used to measure volume 
changes in human limbs for over 40 years. Blood flow can be measured on 
cylindrical parts such as the calf or forearm, using venous occlusion 
plethysmography. Measurements are made in a draught-free room at a 
constant temperature (usually 25°C). With the patient relaxed in a supine 
position, a venous occlusion cuff is wrapped around the arm above the elbow, 
another pneumatic cuff is wrapped around the wrist. A mercury-in-silastic 
strain gauge is positioned so that it encircles the forearm at its widest part.
The gauge should then be applied with approximately 10g tension. Excess 
tension in the gauge retards forearm expansion and should therefore be
avoided. In practical terms, the gauge should be approximately 2 cms shorter
■than the forearm circumference.
■
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Once the plethysmograph has been balanced and a stable base-line is noted
;i
on the recorder, the wrist cuff is inflated well above the systolic blood pressure.
At this point the base-line usually requires adjusting and after 30-45 seconds, 
recordings can then be made. Whilst recording, the arm cuffs are rapidly 
inflated to approximately 40 mmHg (higher than venous pressure, but below
Iarterial diastolic pressure). This produces a slope deflection above the base­
line (see figure 9.1 ) which can later be quantified. Several recordings should
154 /I
using the number of divisions corresponding to a X% resistant change is 
known, blood flow can be calculated using the undernoted formula.
Flow (ml/100ml tissue/min) = slope (divisions per mm)
calibration (divisions per X% volume change)
subcutaneous placebo injection and on the other 6 mg subcutaneous
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be made at each time point by repetitive inflation and deflation of the arm cuff. 
After recordings have been completed, the wrist cuffs are deflated. A rest
period of several minutes is required to allow hyperaemia to subside before 
subsequent recording.
%
CALCULATION OF BLOOD FLOW
Blood flow can be calculated from the venous occlusion tracings by 
determining the slope of the flow curve. Provided that an electric calibration I
Problems with reproducibility of measurement of forearm blood flow have been 
described, but coefficients of variation of approximately 15% have been 
reported. :
:METHODS
Ten healthy male volunteers attended on two study days. In conventional 
venous occlusion plethysmography studies, active drug is given intra-arterially 
and the contralateral arm is used as a control for forearm blood flow. In this
study, however, sumatriptan was administered subcutaneously and therefore
.two study days were required. On one occasion the subject received
sumatriptan on a double-blind basis. Studies were performed at the same time
156
of the day, under fasted conditions and at a constant room temperature 
between 24 and 26°C.
During a 30 minute stabilisation period, forearm blood flow and blood pressure 
were measured at 10 min intervals. Two blood flow measurements were then 
taken and the mean of these was taken as the baseline value. A subcutaneous 
injection of placebo or sumatriptan was then administered on a double-blind 
basis. Forearm blood flow (a mean of 5 sequential measurements) and blood 
pressure were then measured at approximately 7min intervals for 35 mins. 
Blood sampling for catecholamines were taken through an i.v. cannula in the 
right antecubital fossa at base-line and at all time intervals thereafter. The 
study protocol is summarised in table 9.1.
TIME (mins) -10 0 7 14 21 28 35
Baseline
measurements
*
Placebo/sumatriptan
injection
*
Forearm blood flow 
measurement
* * * * * * *
Blood pressure * * * ■k * k k
Table 9.1 Study protocol: The effects of sumatriptan on forearm blood flow 
Data analysis and statistics
A baseline value was obtained for forearm blood flow and blood pressure by 
averaging two observations. The response to placebo and sumatriptan was 
taken as the average of the forearm blood flow and BP recordings at 
7,14,21,28 35 minutes after injection. The effect of placebo and subcutaneous
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sumatriptan on forearm blood flow was then analysed using a paired t- 
test/confidence interval analysis in the same manner as in the other studies.
RESULTS
A summary of the results is displayed in table 9.2. 
Heart Rate
the left arm was 4% (95%CI -4  to 11, p=0.28). On the sumatriptan treatment
j
I
Mean (sd) baseline heart rate on the placebo treatment day was 64 (9) bpm 
and on the sumatriptan treatment day was 66 (9) bpm. Mean change in heart
rate was -2 bpm (95% Cl -4 to 0, p=0.032) after placebo. On the sumatriptan 
treatment day, mean change in heart rate after sumatriptan was -2 bpm (95% 
01 -4 to 1, p=0.08).
Blood pressure
On the placebo treatment day, mean (sd) baseline systolic blood pressure 
(SBP) and diastolic blood pressure (DBP) were 118 (6) mmHg and 62 (10) 
mmHg respectively. Mean changes in SBP and DBP after placebo injection 
were 1 mmHg (95%CI -2 to 4, p=0.47) and 0 mmHg (95%CI -2 to 3, p=0.85) 
respectively. On the sumatriptan treatment day, the corresponding baseline 
values of SBP and DBP were 122 (5) and 61(10) mmHg. Mean changes in 
SBP and DBP after sumatriptan injection were 6 mmHg (95% 01 2 to 10, 
p=0.01) and 6 mmHg (95% 01 3 to 9, p=0.001) respectively.
Change in forearm blood flow
II
On the placebo treatment day the mean percentage change (from baseline) in 
forearm blood flow in the right arm was -1% (95% 01 -9  to 6, p=0.68) and in
157
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day, mean percentage change (from baseline) in forearm blood flow in the right 
arm was 18% (95% Cl -5  to 41, p=0.11 ) and in the left arm was 7% (95% Cl -  
24 to 38, p=0.63).
Plasma noradrenaline levels
On the placebo treatment day, mean (sd) baseline plasma noradrenaline was 
0.69 (0.2) nmol.r\ Mean change in plasma noradrenaline after placebo 
injection was 0.004 nmol.l'^ (95%CI -0.05 to 0.06, p=0.87). On the 
sumatriptan study day, mean (sd) baseline plasma noradrenaline was 0,64 
(0.17) nmol.r\ Mean change in plasma noradrenaline after sumatriptan 
injection was -0.16 nmol.M (95%CI -0.25 to -0.08, p=0.0027).
Discussion
Sumatriptan (6mg subcutaneously) produced expected changes in blood 
pressure. The blood pressure increases seen were of a smaller magnitude 
than that seen in chapters 3,4 and 5 presumably because, in those chapters, 
arterial pressure was measured invasively rather than by an automated cuff 
method. Although statistically significant, these blood pressure changes were 
not of clinical concern.
No clinically or statistically significant change in forearm blood flow was 
observed. This may have been due to a lack of functional vasoactive 5-HTi 
receptors within the forearm and there is supportive evidence for this. 
Naratriptan, given subcutaneously, at both therapeutic and supratherapeutic 
doses, had no significant effect on forearm blood flow in an almost identical 
p ro to c o l .O n  the contrary however, intra-arterial sumatriptan reduced
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forearm blood flow in a dose dependent fashion indicating the presence of 
sumatriptan-sensitive 5-HTib/d receptors in the human forearm.^®"^
IThe lack of effect on forearm blood flow in this protocol may reflect the route of 
drug administration. Sumatriptan was administered subcutaneously in this
study to maintain consistency and allow comparison throughout the whole
thesis. In addition, initial advice from Glaxo Group Research indicated that 
sumatriptan was unsuitable for intra-arterial administration. Intra-arterial
■administration has the obvious advantage of isolating the forearm circulation 
from systemic effects. In addition, the contralateral arm can be employed as a 
control and therefore only one study day is required. Administering sumatriptan 
subcutaneously means that systemic endocrine or hormonal effects could 
ensue which in turn may influence vascular tone in the forearm. Two study
'ÎIdays are also required and biological variation may arise despite efforts to f
maintain standard experimental conditions,
'y
Î
Sumatriptan injection caused no significant change in forearm blood flow but 
was associated with a reduction in plasma noradrenaline levels. As previously 
stated, intra-arterial sumatriptan causes dose dependent reductions in forearm 
blood flow so a similar effect following subcutaneous sumatriptan might 
have been expected. A reduction in plasma noradrenaline levels (as seen 
here) could however result in a vasodilator response with subsequent negation 
of a direct 5-HTib/d mediated vasoconstrictor effect. This may explain the 
apparent lack of effect of sumatriptan on forearm blood flow in this study. 
Interestingly, inhibition of noradrenaline release by an action on pre-synaptic 5-
160
HT receptors on sympathetic nerve terminals has previously been proposed as 
a mechanism of 5-HT induced vasodilatation^®" ’^^ ^^ .
An inhibitory effect of 5-HT and related drugs on transmitter release from post 
ganglionic sympathetic nerves has been confirmed in a number of various 
organs in different species (see Chapter 1- Inhibition of noradrenergic neurons, 
page 35). This effect appears 5-HTi receptor mediated as suggested by the 
high agonist potency of 5-HT and 5-CT^^ '^^^  ^and antagonism by methiothepin, 
metergoline and methysergide^®®’^ ^^ ’^ ^^ ’^ ^^  but not by ketanserin, LY53857 or 
metoclopramide.^^®’^ ®^'^ ^^
Interestingly, one individual (myself, SH) had a pronounced vasodilator 
response to sumatriptan (see figure 9.2). Unfortunately plasma noradrenaline
capacity and venous outflow (emptying rate) using this apparatus but this was 
not part of the present study. This is a potential area of future research.
/ |
S.
I
e
&
Ï
levels were not obtained in this individual so it is unclear whether an
7 .
exaggerated fall in plasma noradrenaline occurred. Blood pressure increased
in this individual from a baseline of 114/79 mmHg to a peak of 130/85 seven 
minutes after sumatriptan administration but this rise was not exceptional. 
Chest and neck pressure was experienced after sumatriptan by this subject but 
4 other subjects also experienced this typical side effect of sumatriptan.
iIt is impossible to comment on whether sumatriptan-induced effects on the 
venous circulation occurred in this study. It is possible to measure total venous
■161
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In summary, sumatriptan 6mg s.c. increased blood pressure slightly but had no 
effect on heart rate or forearm blood flow. Sumatriptan injection was however 
associated with a reduction in plasma noradrenaline levels and this may have 
counteracted a direct 5-HTib/d receptor mediated effect on the forearm
i;
vasculature. 4'
:
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Mean change from 
baseline after 
placebo (95% C.l.)
P value Mean change 
from baseline 
after
sumatriptan 
(95% C.l.)
P value
HR (bpm) -2 (-4 to 0) 0.032* -2 (-4 to 1) 0.08
SBP(mmHg) 1 (-2 to 4) 0.47 6 (2 to 10) 0.01*
DBP(mmHg) 0 (-2 to 3) 0.85 6 (3 to 9) 0.001*
Percentage 
change in right 
forearm flow
-1 (-9 to 6) 0.68 18 (-5 to41) 0.11
Percentage 
change in left 
forearm flow
4 (-4 to 11) 0.28 7 (-24 to 38) 0.63
Plasma
noradrenaline
(nmol/l)
0.004 (-0.05 to 0.06) 0.87 -0.16 (-0.25 to — 
0.08)
0.0027*
Table 9.2 Mean changes in forearm blood flow, heart rate, blood pressure and 
plasma noradrenaline after placebo and sumatriptan injection. *  = significant 
compared to baseline.
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Figure 9.1 Diagram of limb blood flow assessment using mercury strain gauge 
plethysmography.
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Figure 9.2 Mean percentage change in forearm blood 
flow (from baseline) after placebo and sumatriptan 
injection. Each individual is represented by adjacent
columns.
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CHAPTER 10
DISCUSSION
166
In humans, the S-HT-i and 5-HT2 receptor subtypes have greatest direct
167
IISerotonin was first recognised over 50 years ago. initially thought to have
;,S,
purely vasoconstrictor properties, serotonin is now known to have important 
physiological and pathophysiological roles in the cardiovascular system,
■|
platelet function, gastrointestinal motility, mood, appetite regulation and in 
acute migraine.
Knowledge of serotonin receptor function is rapidly changing and updating with 
current consensus recognising 7 main receptor subtypes, many of which i
themselves have subclassifications.
1
The effect of serotonin on any tissue is species dependent and may differ 
between in vitro and in vivo preparations. Hence it is impossible to extrapolate
-results from laboratory animals or isolated human artery preparations to the
:clinical situation. The need for detailed in vivo human studies is therefore
'
apparent. f
influence on the cardiovascular system. Additional neurally mediated effects on Ithe cardiovascular system are influenced by 5-HT3 receptors. This thesis
looked predominantly at the in vivo role of the 5-HT'i and 5-HT2 receptors in
the human cardiovascular system. As this involved predominantly invasive 
techniques, studies had to be limited to small numbers and therefore are open |
to criticism. Nonetheless, the findings of the present studies provide important 
insights into the role of S-HT-j and 5-HT2 receptors in humans.
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SUMATRIPTAN
Sumatriptan, a 5-HT-] agonist with greatest activity at the 5-HT ib/d receptor 
subtypes, has been seen to have generalised vasoconstrictor properties. 
Cerebral vasoconstriction is thought to be an important part of the mechanism 
by which sumatriptan relieves acute migraine pain and initial reports suggested 
that this drug was a selective vasoconstrictor in the cranial circulation. This 
thesis has conclusively disproved this line of thought. Sumatriptan induced 
rises in systemic and pulmonary arterial pressure are rarely of clinical concern 
but the known coronary vasoconstrictive properties require cautious 
prescription of this drug to patients who may be at risk of coronary artery 
disease.
Previous invasive haemodynamic assessment of sumatriptan’s actions also 
suggested a greater magnitude of vasoconstriction in the pulmonary compared 
to the systemic circulation. This possibility has been looked at more closely in 
this thesis and, by including the results of previously reported studies with 
present results, there is some evidence to suggest that sumatriptan is a more 
potent vasoconstrictor in the pulmonary circulation. Whether this reflects a 
greater density of 5-HT-\ receptors in the pulmonary circulation remains open
to question. It may be that the systemic arterial circulation is exposed to 
additional hormonal or central nervous system influence which is not present 
within the pulmonary circulation.
168
Sumatriptan has also been previously noted to cause increases in pulmonary 
artery wedge pressure raising the possibility of a negative isotropic effect or of
a venoconstrictive action. This thesis looked at the effect of sumatriptan on left
haemodynamic effects with acute increases in both systemic and pulmonary 
arterial pressures following administration. Naratriptan 1.5mg subcutaneously
169
ventricular end diastolic pressure (LVEDP) and ventricular contractility (rate of 
change of left ventricular pressure, dP/dt). No evidence of negative inotropism 
was observed and it is assumed that the observed rise in LVEDP is 
consequent upon an acute increase in afterload. No confirmatory evidence of a 
venoconstrictive action has been observed.
I
SYSTOLIC TIME INTERVALS
As stated earlier, one of the limitations in cardiovascular pharmacology is the 
need for invasive haemodynamic assessments. The possibility of performing 
non-invasive haemodynamic studies is an attractive option. Measurement of 
systolic time intervals represents an established method of assessing the 
effects of cardioactive drugs. This study measured systolic time intervals from 
haemodynamic traces. This confirmed the acute increase in afterload after 
sumatriptan administration with significant increases in the pre-ejection period,
''■a-left ventricular ejection time and total electro-mechanical systole. Although 
there was no direct correlation between the rise in any of the STI’s and
,
systemic blood pressure, the results suggest that measurement of STI’s may Ibe a suitable non invasive method of assessing the haemodynamic effects of
j;:;
serotonergic agents.
I
NARATRIPTAN
Naratriptan is a newer 5-HT^ agonist which, like sumatriptan, is effective in the
Î 
%treatment of acute migraine. It has been seen to have a similar "%pharmacological profile to sumatriptan and not surprisingly displays similar
169 I
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caused an approximate 11-12% increase in systemic arterial pressure which is 
less than the 20% augmentation seen after sumatriptan 6mg s.c. Interestingly 
this therapeutic dose of naratriptan was not associated with significant 
coronary artery vasoconstriction unlike previous findings with a therapeutic 
dose of 6mg s.c. sumatriptan. Why naratriptan and sumatriptan should have 
differing effects on the coronary circulation is unclear. The difference may 
simply reflect dose differences or arise from subtle as yet unknown differences 
in receptor interaction between the two drugs. Regardless, these observations 
could have therapeutic importance.
ELETRIPTAN
Eletriptan is a “second generation" 5-HTi receptor agonist. It is a potent and 
selective agonist at the 5-HTid receptor subtype with 13 fold selectivity for the 
5-HTid receptor subtype over the 5-HTib subtype. Eletriptan infusion produced 
no significant rise in either systemic or pulmonary arterial pressures unlike 
sumatriptan and naratriptan. Total systemic and pulmonary vascular resistance 
increased following eletriptan administration implying vasoconstriction in the 
respective circulations. Cardiac output, however, fell significantly after 
eletriptan and, as this parameter is used as the denominator in the formulae for 
the calculation of SVR and PVR, it may be that the apparent rise in SVR and 
PVR reflects the change in cardiac output. It is difficult to explain why eletriptan 
should reduce cardiac output as 5-HT receptors are not known to have 
inotropic actions.
The lack of coronary vasoconstriction after eletriptan is consistent with 
evidence suggesting that eletriptan has greater cranioselectivity than
170
171
sumatriptan. In animal models, eletriptan-mediated coronary constriction 
occurs at a dose four times higher than sumatriptan. It is possible that the 
apparent differences in the pharmacological profile of eletriptan compared to 
sumatriptan and naratriptan result from its enhanced selectivity for the 5-HTid 
receptor subtype. If the 5-HT id receptor is selectively distributed within the
1
cranial circulation, eletriptan may potentially have a “safer” cardiovascular 
profile but this awaits confirmation.
%KETANSERIN
Ketanserin is a G-HTg antagonist with additional alpha adrenoceptor
antagonist properties. It has well documented vasodilator properties in the 
pulmonary and systemic circulation. More recently, ketanserin has been shown 
to prevent coronary artery vasoconstriction following percutaneous 
transluminal coronary angioplasty (P.T.C.A.). This thesis assessed the effect of 
intravenous ketanserin on coronary artery dimensions in patients with stable 
angina but identified no coronary vasodilator properties. It is assumed that, in 
patients with stable symptoms, circulating levels of serotonin are low and 
consequently 5-HT2 receptor antagonists may exhibit minimal influence on
resting coronary artery tone. Following PTCA however, local serotonin levels 
rise and cause vasoconstriction. Ketanserin can obviously inhibit this serotonin
■■■efflux and prevent coronary artery vasoconstriction. Whether ketanserin or 
other 5-HT2 antagonists may have therapeutic applications in the treatment of
myocardial infarction or unstable angina remains to be established.
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SUMATRIPTAN AND FOREARM BLOOD FLOW
Subcutaneous sumatriptan was found to have no effect on forearm blood flow 
as assessed by strain gauge plethysmography. This might have been 
expected as naratriptan also had no effect on forearm blood flow when 
administered by the subcutaneous route, intra-arterial administration of 
sumatriptan has however been associated with dose dependent reductions in 
forearm blood flow. Intra-arterial administration has the obvious advantage of 
isolating the forearm circulation from systemic effects, in this study, systemic 
effects may have occurred and in particular, noradrenaline levels fell after 
sumatriptan administration. It is possible that a direct 5-HTi-mediated 
vasoconstriction followed sumatriptan administration but that this was negated 
by the reduction in plasma noradrenaline levels which caused a vasodilator 
response.
SUMMARY
This thesis has shown that 5-HTi and 5-HT2 receptors have important
modulatory roles in the systemic, pulmonary and coronary circulations. 
Sumatriptan, naratriptan and eletriptan, 5-HT'j agonists, are systemic and
pulmonary vasoconstrictors whereas ketanserin, a 5-HT2 antagonist acts as a 
systemic and pulmonary vasodilator. There is some evidence that 5-HTi 
receptors may be more densely distributed in the pulmonary compared to the 
systemic circulation. The potential role of systolic time intervals as a non- 
invasive method of assessing the cardiovascular effects of serotonergic 
compounds has been highlighted.
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FUTURE WORK
Further studies of the effects of serotonergic agents on the coronary circulation
■
would be of interest. Many subjects in this thesis had normal epicardial
■
coronary arteries and it could be presumed they had intact endothelial function.
A number of other factors predisposing to endothelial dysfunction were 
prevalent in the patient population however and the functional capacity of the
This could be assessed in similar quantitative coronary angiographic studies.
use of intravascular ultrasound and flow wires in these protocols would allow 
coronary artery responses to 5-HT^ agonists and 5-HT^ antagonists to be
assessed with heightened accuracy. Intravascular ultrasound and flow wire 
usage would however significantly increase research costs.
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endothelium for each patient was not known. It would be advantageous to
'Sknow if the effects of the various serotonergic agents on the coronary I
circulation are dependent on endothelial function.
:
Normal endothelial function could be confirmed by determining whether Iacetylcholine produces a coronary vasodilator response. Thereafter the
■Ik
various 5-HT agonists and antagonists could be administered and the coronary 
responses established. These responses could then be compared to those of 
patients with documented dysfunctional endothelium (eg. vasoconstrictor 
response to acetylcholine) or in patients with normally functioning endothelium 
who were pre-treated with L-NAME or NMMA (which would inhibit nitric oxide 
synthase). This would particularly help establish the interaction between the 5- 
HTi receptor and EDRF release in vivo.
In addition to performing quantitative coronary angiography, the concomitant
:
' f
■i
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The issue of differing 5-HTi receptor density/function between the systemic 
and pulmonary circulations requires further examination. This could be difficult 
to demonstrate in vivo in the absence of clinically available, highly selective 5- 
HTi receptor antagonists. One possible in vitro study would be to take 
specimens, from "heart beating" donors, of both the systemic and pulmonary 
arterial circulation and construct dose response curves to each of the triptans 
in a conventional organ bath set up with an isometric transducer. The 
maximum contractile response (Emax) and the concentration eliciting 50% of
Emax (ECso) could then be established for each agonist in the respective
circulations to determine rank order of potency (ECso) and efficacy (Emax)- It 
would be important to perform these studies initially in the presence of an 
intact endothelium and then repeating the experiments after denuding the 
endothelium and washing the preparations. This would confirm firstly, whether 
the triptans have greater efficacy and potency on the pulmonary circulation and 
would also clarify the in vitro interaction between 5-HTi receptors and 
endothelial derived relaxing factor in the human systemic and pulmonary 
circulation.
Should selective 5-HTi antagonists become available, their haemodynamic
Iand coronary vasomotor properties could be established using experimental 
protocols similar to those performed for the 5-HT^ agonists. Again the studies
would need to be performed in patients with documented normally functioning 
endothelium and also after inhibition of NO synthase. These 5-HTi antagonists 
could be used to challenge the effects of the triptans studied in this thesis. This 
again would involve similar protocols but would require the patients to be pre­
treated with various doses of the 5- HTi antagonist. If the dose of 5-HTi
174
antagonist required to inhibit the vasoconstrictor response of the triptan 
differed between the pulmonary and systemic circulation, this might add to the 
evidence suggesting differential 5-HTi receptor density and function.
Systolic time intervals were calculated from invasively obtained arterial 
pressure tracings in this thesis. The potential use of STI’s as a non-invasive 
marker of the haemodynamic effects of 5-HT^ agonists has been discussed.
This needs to be evaluated further with the conventional technique of 
measuring STI’s using the electrocardiogram, phonocardiogram and carotid 
arterial pulse waveforms. Repeated measurement of the STI's (using the 
conventional non-invasive technique described in chapter 5) in healthy 
volunteers could establish the reproducibility of this procedure. The effect of 
sumatriptan on the STI's measured non-invasively could then be established 
using a randomised, placebo controlled trial. A power calculation to estimate 
the required number of patients would be required.
It is impossible to comment on whether sumatriptan-induced effects on the 
venous circulation occurred in this study. It is possible to measure total venous 
capacity and venous outflow (emptying rate) using the strain gauge 
plethysmography technique but this was not part of the present study. This is a 
potential area of future research and could be assessed using the protocol 
employed in chapter 9. Sumatriptan would however be administered intra- 
arterially and this would obviate the need for two study days.
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Changes in systolic time intervals-A non invasive marker for the
Appendix 3a. Sumatriptan haemodynamic data.
Placebo was administered at time = Omins
Sumatriptan was administered at time = 20 mins
Heart Rate Timepoint (mins)
Subject -10 0 10 20 30 40 50 60
E0291 65 68 66 64 57 56 67 68
E0293 56 57 56 50 &5 52 52 50
E0294 74 70 69 69 69 62 63 60
E0295 78 72 66 65 66 65
E0296 64 55 65 60 58 64 58 57
E0297 55 57 57 50 57 54 46 46
E0298 71 71 72 73 78 71 70 74
E0299 59 58 54 75 68 63 70 72
E0300 74 78 75 76 70 74 67 72
Cardiac output
Subject -10 0 10 20 30 40 50 60
E0291 5.33 5.18 5.11 4.56 4.67 4.49 4.52 5.02
E0293 5.1 6.5 4.8 5 5.1 5.1 4.4 4.5
E0294 4.7 5 4.9 5 4.7 4.8 4.5
E0295 5.3 4.6 5 4.9 5.1 5.2
E0296 4.5 4.3 4.2 4.5 4.2 4.4 4.3 3.9
E0297 3.6 3.5 3.3 3.1 3 3.2 3.3 3
E0298 7.3 6.8 7 7.7 7.6 6.9 6.8 7.4
E0299 4.8 4.4 5 4.3 4.1 4.2 3.7 4.1
E0300 5 5 4.8 4.6 4.4 4.6 4.2 4.1
Systolic arterial pressure
Subject -10 0 10 20 30 40 50 60
E0291 120 128 126 134 162 152 160 163
E0293 136 138 139 142 166 166 158 150
E0294 142 145 133 166 160 164 156
E0295 94 90 120 126 118 113
E0296 92 100 105 105 110 124 130 130
E0297 110 117 108 112 137 134 126 132
E0298 98 102 106 104 108 120 121 118
E0299 100 120 116 120 140 140 140 156
E0300 154 140 156 152 174 180 156 144
Diastolic arterial pressure
Subject -10 0 10 20 30 40 50 60
E0291 60 68 64 72 82 76 81 79
E0293 60 58 56 60 68 68 68 60
E0294 80 80 74 84 76 82 79
E0295 56 56 68 74 68 63
E0296 54 58 64 64 64 70 70 70
E0297 58 62 60 68 72 68 68 66
E0298 59 56 60 58 60 62 64 66
E0299 58 60 60 66 78 80 80 92
E0300 80 75 82 84 88 92 82 79
Mean arterial pressure
Subject -10 0 10 20 30 40 50 60
E0291 92 92 92 96 116 106 108 112
E0293 85 88 86 88 100 100 100 90
E0294 106 106 100 116 112 116 112
E0295 74 72 92 96 88 84
E0296 71 78 82 80 84 90 112 90
E0297 79 84 80 85 96 94 88 90
E0298 76 76 80 80 84 88 88 86
E0299 78 92 80 88 100 104 104 110
E0300 110 100 110 112 122 126 112 106
S
3
I
3-
S
I
Appendix 3a. Sumatriptan haemodynamic data.
Placebo was administered at time = Omins
Sumatriptan was administered at time = 20 mins
Pulmonary artery systolic pressure
Subject -10 0 10 20 30 40 50 60
E0291 24 25 23 23 26 27 29 30
E0293 24 23 24 22 22 23 23 20
E0294 23 24 21 24 30 33 29 32
E0295 17 15 20 28 26 22
E0296 23 20 22 23 20 23 27 24
E0297 16 20 17 18 22 23 19 17
E0298 28 30 31 31 34 37 35 35
E0299 20 26 20 24 28 24 24 24
E0300 35 39 37 37 44 42 30 31
Pulmonary artery diastolic pressure
Subject -10 0 10 20 30 40 50 60
E0291 10 10 10 9 11 11 12 13
E0293 7 6 6 8 6 10 10 9
E0294 4 8 4 7 7 9 9 11
E0295 4 3 8 11 9 8
E0296 8 6 8 8 8 8 10 8
E0297 6 7 5 6 10 10 8 7
E0298 8 16 15 10 16 18 17 17
E0299 8 14 8 10 12 10 10 8
E0300 14 14 12 11 15 14 10 7
Mean pulmonary artery pressure
Subject -10 0 10 20 30 40 50 60
E0291 15 16 16 16 18 18 20 21
E0293 12 13 12 12 11 16 15 12
E0294 13 14 13 15 18 19 17 19
E0295 10 8 12 18 17 14
E0296 14 12 11 12 12 13 16 14
E0297 9 11 9 10 14 14 13 10
E0298 18 20 18 16 22 23 22 22
E0299 10 16 12 14 16 14 13 12
E0300 22 23 22 21 25 25 16 15
Right atrial pressure
Subject -10 0 10 20 30 40 50 60
E0291 6 7.5 7 7.5 7 9 8 11
E0293 4 3 5 5 3 5 6 4
E0294 7 8 7 7 7 8 7 8
E0295 0.5 0.2 3 6 5 4
E0296 3 3 2 3 3 5 6 5
E0297 3 2 2 2 4 4 3 3
E0298 8 2 2 3 5 4 6 3
E0299 4 8 5 6 6 10 10 6
E0300 8 8 6 8 8 8 9 9
Pulmonary artery wedge pressure
Subject -10 0 10 20 30 40 50 60
E0291 7 8 7.5 8 12 12 12 15
E0293 4 6 6 5 4 7 6 6
E0294 6 5 5 7 10 10 8 8
E0295 4 3 6 12 10 8
E0296 7 7 6 5 5 7 8 8
E0297 5 6 4 4 9 10 7 6
E0298 6 3 7 5 7 7 8 9
E0299 2 10 6 8 10 8 7 8
E0300 14 13 10 11 12 13 9 6
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Appendix 3a. Sumatriptan haemodynamic data.
Placebo was administered at time = Omins
Sumatriptan was administered at time = 20 mins
Left ventricular end diastolic pressure
Subject -10 0 10 20 30 40 50 60
E0291 8 7 8 8 9 11 11 12.5
E0293 8 9 10 9 12 12.5 12 10
E0294 10 5 7 7 19 13 11 11
E0295 5 4 10 14 12 10
E0296 7 4 8 7 7 9 16 15
E0297 6 6 6 4 14 14 11 10
E0298 3 4 4 6 8 9 10 8
E0299 7 9 10 10 9 10 11 12
E0300 14 12 15 11 17 15 11 8
Peak rate of LV pressure rise (dP/dt)
Subject -10 0 10 20 30 40 50 60
E0291 2360 2915 2429 3401 3262 3158 2637
E0292 2640 1740 2100 2400
E0293 4140 2400 3240 2640 2460 2880
E0294 2640 3240 2640 2640 3180 2400 2520 1920
E0295 1260 1560 1200 840 720 1320
E0296 1100 1125 1000 1250 1250 1065 1000 1000
E0297 1500 1550 950 1200 1375 1100 1225 1400
E0298 2640 2940 3000 2820 2940 3480 2460 2460
E0299 2280 2340 2100 2220 2280 1680 1680 1560
E0300 3952 3640 4004 3120 3120 2496 3952 2912
Pulmonary vascular resistance
Subject -10 0 10 20 30 40 50 60
E0291 120 124 133 140 103 107 142 96
E0293 125 86 100 112 110 141 163 106
E0294 102 96 130 176 187 167 195
E0295 91 87 96 98 110 92
E0296 124 93 95 124 133 109 149 123
E0297 89 114 121 129 107 100 145 107
E0298 131 200 126 114 158 186 165 141
E0299 133 109 96 112 117 114 130 78
E0300 128 160 200 174 236 209 133 176
Systemic vascular resistance
Subject -10 0 10 20 30 40 50 60
E0291 1291 1305 1330 1552 1867 1728 1770 1610
E0293 1270 1046 1317 1328 1521 1490 1709 1529
E0294 1622 1506 1699 1732 1807 1841
E0295 1109 1249 1424 1469 1302 1230
E0296 1209 1395 1524 1369 1543 1545 1972 1744
E0297 1689 1874 1891 2142 2453 2250 2060 2320
E0298 745 870 891 800 831 974 965 897
E0299 1233 1527 1360 1525 1834 1790 2032 2029
E0300 1632 1472 1733 1809 2073 2052 1962 1893
I
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Appendix 5a. The effect of sumtriptan on systolic time intervals.
Heart Rate Timepoint (mins)
SUBJECT Baseline Placebo 10 20 30 40
E0296 55 60 57 57 56 59
E0297 54 56 55 44 46 43
E0294 69 72 68 62 63
E0299 54 53 61 59 65 71
E0300 71 73 75 71 68 66
E0293 67 51 59 56 52 48
E0298 77 72 71 71 73 72
E0295 71 72 64 65 66 65
EOOl 57 56 53 57 51 55
E002 62 59 56 56 52 65
E003 74 73 69 68 70
E004 80 87 94 89 83 96
E005 74 70 72 74 72
E006 69 63 60 53 53 62
E007 64 67 65 61 60
E008 58 60 62 59 66
E009 82 81 78 84 73 75
EOlO 85 79 73 74
EOll 81 77 85 79
E012 66 67 70 71
E013 59 55 57 57
E014 63 66 58 56
E015 66 64 56 60
E016 49 43 40 40
E017 107 97 86 82
E018 53 47 43 46
Systolic arterial pressure
Baseline Placebo 10 20 30 40
SUBJECT 96 105 110 124 130 130
E0296 114 110 137 134 126 132
E0297 142 139 166 160 164
E0294 110 118 140 140 140 156
E0299 147 154 174 180 156 144
E0300 137 141 166 166 158 150
E0293 100 105 108 120 121 118E0298 94 90 120 126 118 113
E0295 124 134 124 128 128 122
EOOl 120 118 132 120 120 120
E002 150 188 164 170 160
E003 134 134 136 162 150 128
E004 120 144 120 110 120
E005 118 120 148 130 132 144
E006 154 220 210 200 200
E007 156 196 188 190 190
E008 102 110 120 124 120 128E009 133 132 150 145
EOlO 146 144 190 176
EOll 158 143 160 168
E012 129 133 164 150
E013 116 114 120 118
E014 120 12 0 150 128
E015 150 161 194 181
E016 120 121 140 130
E017 119 123 144 134
E018
Appendix 5a. The effect of sumtriptan on systolic time intervals.
Diastolic arterial pressure
SUBJECT Baseline Placebo 10 20 30 40E0296 56 64 64 70 70 70E0297 60 64 72 68 68 66E0294 80 77 84 76 82
E0299 59 63 78 80 80 92
E0300 78 83 88 92 82 79E0293 59 58 68 68 68 60E0298 58 59 60 62 64 66E0295 56 56 68 74 68 64
EOOl 80 82 78 80 80 78
E002 70 70 80 80 70 76
E003 80 90 80 80 80
E004 82 82 100 96 100 96E005 80 90 84 78 80
E006 80 80 90 78 78 80
E007 88 108 100 100 100
E008 60 80 80 80 80
E009 70 80 80 80 78 78
EOlO 83 82 90 85
EOll 82 83 108 94
E012 88 81 92 96
E013 75 79 86 80
E014 75 73 76 76
E015 72 75 80 76
E016 94 82 103 77
E017 80 80 80 80
E018 62 61 64 64
Mean arterial pressure
SUBJECT Baseline Placebo 10 20 30 40
E0296 75 81 84 90 112 90
E0297 82 83 96 94 88 90
E0294 106 103 116 112 116
E0299 85 84 100 104 104 110E0300 105 111 122 126 112 106
E0293 87 87 100 100 90 90
E0298 76 80 84 88 88 86
E0295 74 72 92 96 88 84
EOOl 100 102 98 98 102 100E002 90 80 100 100 90 90
E003 110 128 118 120 116
E004 110 104 120 122 120 110
E005 100 116 100 92 100E006 90 100 108 100 100 110E007 116 14 8 146 136 140
E008 96 120 120 118 120
E009 88 96 100 100 94 96
EOlO 103 105 110 110
EOll 108 109 144 128
E012 111 103 116 120
E013 95 99 118 108
E014 90 90 96 90
E015 90 91 110 100
E016 128 123 161 126
E017 93 93 100 100
E018 80 83 94 90
Appendix 5a. The effect of sumtriptan on systolic time intervals.
Electromechanical systole (EMS)
SUBJECT Baseline Placebo 10 20 30 40
E0296 580 601 582 608 616 626
E0297 558 559 572 588 628 580
E0294 603 608 618 614 620
E0299 535 537 548 546 548 536
E0300 577 583 596 588 566 566
E0293 558 575 590 592 582 576
E0298 613 612 621 629 653 629
E0295 626 652 666 658 654 652
EOOl 557 576 559 576 626 616
E002 592 595 608 591 583 618
E003 580 626 661 632 611
E004 543 583 592 571 580 586
E005 596 624 645 602 627
E006 618 587 617 632 622 625
E007 555 615 610 579 588
E008 644 626 622 627 628
E009 483 461 488 509 496 551
EOlO 613 604 651 660
EOll 641 626 633 651
E012 597 586 634 612
E013 595 599 628 652
E014 552 556 596 578
E015 621 607 629 620
E016 587 593 673 658
E017 649 650 683 656
E018 584 604 593
Left ventricular ejection time(LVET)
SUBJECT Baseline Placebo 10 20 30 40
E0296 431 441 423 449 457 464
E0297 440 425 429 434 430 429
E0294 428 436 453 451 441
E0299 441 445 450 436 432 418
E0300 410 410 410 404 396 396
E0293 447 457 433 464 441 443
E0298 438 429 439 435 450 436
E0295 424 425 444 458 444 444
EOOl 440 455 453 458 448 454
E002 445 438 450 447 446
E003 461 486 504 490 464
E004 382 418 410 398 411 388
E005 413 411 432 409 404
E006 433 424 421 434 456 441
E007 429 461 456 446 448
E008 480 478 473 476 460
E009 316 318 326 335 327 320
EOlO 411 421 440 420
EOll 440 439 459 460
E012 435 440 457 458
E013 422 429 442 432
E014 407 414 416 404
E015 421 429 439 432
E016 414 418 462 451
E017 446 429 460 443
E018 436 434 436
Appendix 5a. The effect of sumtriptan on systolic time intervals.
Pre-ejection period (PEP)
SUBJECT Baseline Placebo 10 20 30 40
E0296 149 160 159 159 159 162
E0297 118 134 143 154 198 151
E0294 175 172 165 163 179
E0299 94 92 98 110 116 118
E0300 167 173 186 184 170 170E0293 111 118 157 128 141 133
E0298 175 183 182 194 203 193
E0295 202 227 222 200 210 208
EOOl 117 121 106 118 178 162
E002 147 157 158 591 136 172
E003 119 140 157 142 147
E004 161 165 182 173 169 198
E005 183 213 213 193 223
E006 185 163 196 198 166 184
E007 126 154 154 133 140
E008 164 148 149 151 168
E009 167 143 162 174 169 231
EOlO 202 183 211 240
EOll 201 187 174 191
E012 162 146 177 154
E013 173 170 186 220
E014 145 142 180 174
E015 200 178 190 188
E016 173 175 211 207
E017 203 221 223 213
E018 148 170 157
179 193
PEP:LVET Ratio
SUBJECT Baseline Placebo 10 20 30 40
E0296 0 .34 6 0 .363 0 .3 7 6 0 .3 5 4 0 . 348 0 .34 9
E0297 0 .268 0 .315 0 .333 0 .355 0 . 460 0 .352E0294 0 .40 9 0 .3 9 4 0 .364 0 .361 0 .40 6
E0299 0 .213 0 .207 0 .2 1 8 0 .252 0 .26 9 0 .282
E0300 0 .407 0 .422 0 .4 5 4 0 .455 0 .4 2 9 0 .42 9
E0293 0 .248 0 .258 0 .3 6 3 0 .2 7 6 0 . 320 0 .30 0
E029B 0 .40 0 0 .427 0 .415 0 .446 0 .45 1 0 .443
E0295 0 .47 6 0 . 534 0 . 500 0 .437 0 .473 0 .468EOOl 0 .26 6 0 .266 0 .2 3 4 0 .2 5 8 0 .3 9 7 0 .3 5 7
E002 0 .3 3 0 0 .3 5 8 0 .3 5 1 # D IV /0 ! 0 .3 0 4 0 .3 8 6
E003 0 .258 0 .2 8 8 0 .3 1 2 0 .290 0 .3 1 7E004 0 .4 2 1 0 .3 9 5 0 .444 0 .4 3 5 0 .411 0 . 510
E005 0 .443 0 . 518 0 .493 0 .472 0 . 552E006 0 .427 0 .384 0 .466 0 .4 5 6 0 .3 6 4 0 .417
E007 0 .294 0 .3 3 4 0 .3 3 8 0 .298 0 .3 1 3E008 0 . 342 0 .310 0 .3 1 5 0 .317 0 .3 6 5E009 0 .5 2 8 0 .450 0 .4 9 7 0 .5 1 9 0 .5 1 7 0 . 722EOlO 0 .4 9 1 0 .43 5 0 .4 8 0 0 .5 7 1
EOll 0 .4 5 7 0 . 426 0 .379 0 .4 1 5E012 0 .372 0 .332 0 .3 8 7 0 .336
E013 0 .410 0 .3 9 6 0 .421 0 . 509
E014 0 . 356 0 . 343 0 .433 0 .431
E015 0 .4 7 5 0 .4 1 5 0 .433 0 . 435
E016 0 .418 0 .419 0 .4 5 7 0 .459
E017 0 .455 0 . 515 0 .4 8 5 0 .481
ED18 0 .3 3 9 0 .3 9 2 0 .360
Appendix 6a. Naratriptan Haemodynamic data
Placebo was administered at time = -1 Omins.
Naratriptan was administered at time- Omins
Heart Rate Timepoint (mins)
Subjec -20 -10 0 10 20 30 40
1414 64 64 65 67 67 68 71
1415 75 74 76 80 76 76 76
1416 75 72 70 70 72 68 73
1417 64 62 62 61 65 70 68
1418 77 83 74 79 79 68 83
1419 74 70 66 68 68 63 66
1420 64 62 62 64 70 68 70
1421 65 62 63 66 75 70 63
1425 54 50 50 49 53 48 48
Cardiac Output
Subjec -20 -10 0 10 20 30 40
1414 4.8 4.6 4.6 4.7 5 4.6 4.8
1415 6.6 6.5 7.8 7.9 8.5 7.3 7.5
1416 4.7 4.8 4.7 4.5 4.2 4.3 4.2
1417 6.3 5.9 6 5.9 6.2 6.5 6.6
1418 5.4 5.6 5.4 5.2 5.1 5.1 5.1
1419 6.1 5.9 6.2 6.1 5.7 5.6 5.6
1420 7.3 7.3 7.5 7.7 7.6 7.2 6.7
1421 5.3 5 5 5.7 6.2 5.1 5
1425 4.6 4.5 4.7 4.5 4.4 4.6 4
Systolic arterial pressure
Subjec -20 -10 0 10 20 30 40
1414 169 195 187 216 216 208 200
1415 128 126 149 160 153 154 153
1416 130 128 122 132 133 132 132
1417 120 115 120 125 130 130 136
1418 104 106 98 116 120 114 118
1419 130 124 102 122 132 140 126
1420 150 165 170 178 180 180 180
1421 180 180 178 196 204 190 184
1425 94 94 89 104 103 106 106
Diastolic arterial pressure
Subjec -20 -10 0 10 20 30 40
1414 89 100 98 104 110 104 100
1415 80 82 86 92 88 88 88
1416 67 66 64 70 70 68 74
1417 60 60 60 65 70 70 70
1418 66 64 60 70 72 70 64
1419 60 62 60 64 68 68 66
1420 80 80 80 82 90 80 90
1421 70 72 76 82 88 80 74
1425 54 54 48 52 55 56 57
Mean arterial pressure
Subjec -20 -10 0 10 20 30 40
1414 120 136 136 156 160 148 148
1415 104 104 116 120 116 120 116
1416 90 92 91 96 97 96 99
1417 80 90 80 100 100 100 100
1418 90 84 84 90 94 90 90
1419 80 85 80 90 96 100 92
1420 110 115 115 130 130 120 120
1421 108 108 112 128 140 120 120
1425 70 70 64 72 74 76 74
Appendix 6a. Naratriptan Haemodynamic data
Placebo was administered at time = -1 Omins.
Naratriptan was administered at time= Omins
Pulmonary artery systolic pressure
Subjec -20 -10 0 10 20 30 40
1414 32 35 36 41 42 40 41
1415 23 23 23 28 27 27 28
1416 10 10 9 17 19 19 16
1417 25 26 28 28 29 29 31
1418 20 20 22 22 22 20 21
1419 18 17 16 26 25 22 23
1420 29 30 26 31 28 28 28
1421 27 30 30 38 40 35 32
1425 25 26 23 29 27 26 27
Pulmonary artery diastolic pressure
Subjec -20 -10 0 10 20 30 40
1414 10 14 14 18 16 17 15
1415 10 7 12 15 15 14 15
1416 0 0 1 4 6 6 3
1417 8 9 11 10 13 11 12
1418 8 4 7 10 8 8 8
1419 9 6 4 8 8 5 6
1420 11 9 7 12 9 10 8
1421 12 9 12 15 14 9 13
1425 10 11 9 8 14 12 11
Mean pulmonary arterial pressure
Subjec -20 -10 0 10 20 30 40
1414 20 24 25 28 26 28 26
1415 17 14 17 21 19 18 19
1416 5 6 5 9 10 10 8
1417 12 14 15 16 18 18 20
1418 12 10 10 14 13 12 12
1419 12 10 11 16 16 14 14
1420 15 16 13 19 17 16 16
1421 17 16 17 24 25 20 18
1425 16 17 15 18 20 17 18
Right atrial pressure
Subjec -20 -10 0 10 20 30 40
1414 6 8 8 10 8 8 6
1415 9 7 8 9 9 9 9
1416 0 0 0 1 1 2 0
1417 9 8 8 8 8 8 9
1418 3 4 5 4 5 4 5
1419 6 6 8 6 6 6 6
1420 9 10 9 9 10 10 9
1421 6 5 6 8 8 7 6
1425 7 9 7 9 9 10 10
Pulmonary artery wedge pressure
Subjec -20 -10 0 10 20 30 40
1414 12 15 14 15 20 15 12
1415 10 6 10 11 10 11 10
1416 3 2 2 6 4 5 4
1417 10 8 8 8 11 11 12
1418 3 4 4 6 6 6 6
1419 3 5 3 8 8 5 4
1420 6 8 8 9 12 8 6
1421 7 5 6 10 12 7 5
1425 12 13 12 15 15 14 14
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Appendix 6a. Naratriptan Haemodynamic data
Placebo was administered at time = -1 Omins.
Naratriptan was administered at time= Omins
Pulmonary vascular resistance
Subjec -20 -10 0 10 20 30 40
1414 133 157 191 170 96 226 233
1415 85 98 72 101 85 77 96
1416 34 67 51 53 114 102 86
1417 25 81 86 108 90 86 97
1418 133 86 89 123 110 94 94
1419 118 68 103 105 112 129 143
1420 99 88 53 104 53 89 119
1421 151 176 176 196 168 204 208
1425 70 71 51 53 91 52 80
Systemic vascular resistance
Subjec -20 -10 0 10 20 30 40
1414 1900 2226 2226 2519 2432 2434 2366
1415 1152 1194 1108 1124 1007 1216 1141
1416 1531 1533 1548 1688 1828 1748 1885
1417 902 1112 886 1247 1187 1132 1103
1418 1288 1143 1170 1323 1396 1349 1333
1419 970 1071 929 1102 1263 1342 1229
1420 1107 1151 1131 1257 1263 1222 1325
1421 1540 1648 1712 1684 1703 1772 1824
1425 1096 1084 970 1120 1182 1148 1280
Appendix 6b. Naratriptan coronary artery data
PROXIMAL ARTERIES
ARTERY SUBJECT BASELIN PLACEB MIN 10 MIN 20 MIN 30
Cx 1414 2.09 1.92 1.73 2.26 1.85
LAD 1414 3.15 3.07 2.95 3.23 2.78
IM S 1415 5.36 5.6 5.27 5 5.27
Cx 1415 3.38 3.21 3.29 3.06 3
LAD 1415 4 4.24 4.66 3.55 4
IM S 1416 3.8 3.8 3.8 4.1 4
Cx 1416 3.1 2.7 2.8 2.7 2.5
LAD 1416 3.6 3.5 3.6 3.4 3.2
RCA 1417 2.97 2.93 2.92 3.36 3.07
LMS 1418 3.5 3.54 3.79 3.8 3.32
Cx 1418 2.33 2.47 2.8 2.68 2.58
LAD 1418 3.28 3.35 3.24 3.24 3.3
LMS 1419 4.6 4.77 4.6 4.5 4.77
Cx 1419 3.16 3.33 3.45 2.91 3.31
LAD 1419 3.55 3.66 3.82 3.55 3.55
RCA 1420 3.17 3.27 3.17 3.25
LMS 1421 5.63 5.7 5.66 5.64 5.64
Cx 1421 3.16 3.11 3.09 3 3.07
LAD 1421 4.02 4.18 4.15 3.85 3.89
LMS 1425 5.33 5.33 5.33 5.31 5.41
Cx 1425 3.67 3.67 3.75 3.68 3.73
LAD 1425 5 5 5.17 4.94 5.07
LMS 1423 5.94 5.33 5.32 5.33 5.24
Cx 1423 3.66 3.68 3.48 3.66 3.66
LAD 1423 4.27 3.66 3.48 3.38 3.68
MID ARTE RIES
Cx 1414 1.89 1.32 1.79 1.51 1.35
GM 1414 1.73 1.78 1.69 1.87 1.6
LAD 1414 1.93 2.06 1.98 2.09 1.95
Cx 1415 2.4 2.86 2.57 2.88 2.56
LAD 1415 3.48 3.92 3.39 3.22 3.21
LAD 1416 2.2 2.2 2 1.9 2
GM 1416 2.2 2 1.9 1.7 1.9
RCA 1417 2.71 2.71 2.71 3.06 2.74
PDA 1417 2.4 2.55 2.53 2.6 2.4
Cx 1419 1.45 1.49 1.54 1.55 1.46
GM 1419 2.05 2 2.18 2.26 1.94
RCA 1420 3.23 3.17 2.87 2.63
Cx 1421 2.92 3.07 2.97 2.86 3.06
LAD 1421 1.9 2.13 2.23 1.75 2
GM 1421 1.9 2 2.05 1.75 2
Cx 1425 2.67 2.33 2.33 2.31 2.3
LAD 1425 3.62 3.3 3.3 3.3 3.51
GM 1425 3 2.87 2.41 2.38 2.42
Cx 1423 2.33 2.01 1.9 2 2.14
LAD 1423 1.94 1.93 1.9 2 2.1
GM 1423 1.77 1.7 1.73 1.69 1.74
Appendix 6b. Naratriptan coronary artery data
DISTAL ARTERIES
ARTERY SUBJECT BASELIN PLACEB MIN 10 MIN 20 MIN 30
Cx 1414 1.49 1.18 1.22 1.11
LAD 1414 1.96 1.48 1.81 1.27 1.39
Cx 1415 1.5 1.33 1.34 1.57 1.25
LAD 1415 1.58 1.69 1.71 2.02 1.62
OM 1415 1.69 1.71 2.02 1.62
LAD 1416 2.1 1.6 1.8 1.6 1.5
RCA 1417 1.8 1.73 1.7 1.49 1.46
Cx 1419 1.36 1.33 1.31 1.29 1.4
LAD 1419 1.21 1.2 1.28 1.17 1.29
PDA 1420 2.2 2.13 1.88 1.95
LAD 1421 1.26 1.27 1.11 1.18 1.2
Cx 1425 1.94 1.67 1.94 1.74 1.82
LAD 1425 1.37 1.41 1.41 1.4 1.35
Cx 1423 1.4 1.2 1.41 1.33 1.42
LAD 1423 1.39 1.35 1.34 1.33 1.36
LAD Left anterior descending
RCA Right coronary artery
Cx Circumflex
PDA Posterior descending artery
LMS Left main stem
OM Obtuse marginal
Appendix 7a. Eletripfan haemodynamic data.
Piacebo infusion was administered between times 0 -1 0  mins
Eietriptan infusion was administered between times 15-25 mins.
Heart Rate
Subject 0 5 10 15 20 25 30 35 40 45 50 55 GO
001 75 80 76 74 75 75 75 80 80 79 76 70
002 75 66 66 71 71 72 72 60 58 58 56 58 58
003 75 75 75 75 78 75 75 70 72 75 70 75
004 62 57 67 63 64 68 66 61 60 65 61 70 68
005 60 60 58 58 60 60 60 60 60 60 60 60 68
006 62 72 67 65 70 72 65 65 70 66 70 64 66
007 74 60 64 60 62 60 74 60 72 70 75 60 60
008 60 50 50 50 50 50 50 50 50 54 50 56 60
009 72 75 70 80 70 75 60 70 75 72 60 75 75
010 84 90 94 94 80 80 80 64 80 75 75 75 75
Systolic arterial pressure
Subject 0 5 10 15 20 25 30 35 40 45 SO 55 60
001 120 120 120 120 120 130 134 124 126 124 130 120
002 150 123 120 122 130 141 138 138 122 132 130 126 128
003 114 120 124 126 124 136 128 130 134 128 126
004 178 172 164 156 186 172 170 174 178 168 166 152 170
005 122 102 116 116 120 120 122 130 130 128 134 132 136
006 108 100 116 104 118 120 122 134 148 154 145 134 142
007 110 114 120 124 128 130 126 126 126 122 140 140 134
008 100 95 100 94 96 93 100 103 102 104 104 104 110
009 140 110 118 118 118 120 120 126 116 122 120 120 140
010 170 166 148 156 166 170 190 170 168 162 164 160 182
Diastolic arterial pressure
Subject 0 5 10 15 20 25 30 35 40 45 50 55 60
001 70 72 72 70 74 74 78 76 74 74 76 70
002 60 60 60 58 58 66 60 60 56 60 58 58 58
003 58 74 74 78 78 82 78 80 80 78 80
004 84 82 78 77 84 82 80 81 80 80 81 78 80
005 64 57 62 60 62 66 64 64 68 64 70 68 70
006 64 60 64 60 66 68 70 80 82 82 82 75 80
007 60 68 68 68 70 66 68 68 66 64 74 76 70
008 52 53 54 56 56 50 53 57 60 58 58 60 57
009 90 80 80 80 80 80 78 82 78 80 76 74 84
010 84 86 80 90 88 90 92 90 84 86 86 90 94
Pulmonary artery systolic pressure
Subject 0 5 10 15 20 25 30 35 40 45 50 55 GO
001 19 20 21 20 23 22 22 22 20 22 22 22
002 28 18 17 15 16 20 21 22 18 19 22 20 20
003 24 28 26 30 30 36 30 31 31 30 28
004
005 19 21 19 18 17 18 20 22 23 22 24 22 22
006 23 24 23 25 26 26 27 28 27 27 26 27 27
007 24 24 23 21 22 23 19 22 23 20 22 20 24
008 14 14 13 12 14 16 17 18 16 16 16 16 15
009 18 16 16 16 18 17 17 18 18 18 18 20 18
010 24 28 26 24 24 28 26 28 23 22 24 25 26
Pulmonarj artery diastolic pressure
Subject 0 5 10 15 20 25 30 35 40 45 50 55 GO
001 6 7 7 7 12 12 10 10 8 8 8 8
002 12 6 6 5 6 8 7 6 7 7 10 8 8
003 8 10 10 12 10 36 30 31 31 30 28
004
005 9 7 8 9 10 10 11 11 12 10 11 10 10
006 8 10 10 11 13 11 12 13 14 13 17 15 13
007 10 12 12 12 12 12 10 11 11 10 12 9 11
008 4 5 4 6 6 4 6 5 6 4 5 6 3
009 8 8 8 8 8 9 8 8 8 8 8 8 7
010 8 8 4 4 8 8 8 8 4 6 8 7 12
Pulmonary artery wedge pressure
Subject 0 5 10 15 20 25 30 35 40 45 50 55 60
001 3 10 7 7 8 a 7 8 7 8 7 8
002 8 6 4 4 6 7 6 8 6 6 7 6 7
003 7 10 10 10 11 11 id 9 10 9 8
004
005 11 9 10 10 10 11 11 12 11 12 10 10 10
006 10 11 12 13 11 12 13 15 14 13 15 13 13
007 14 16 12 12 13 13 11 12 11 9 13 12 12
008 7 6 4 7 5 7 6 7 6 5 5 6 5
009 6 5 5 5 7 7 7 7 7 7 7 8 6
010 7 4 3 3 3 5 8 7 5 3 5 5 6
Right atrial pressure
Subject 0 5 10 15 20 25 30 35 40 45 50 55 GO
001 2 2 2 3 3 3 4 4 4 5 4 4
002 3 2.5 1.5 1 2 3 3 3.5 3 2,5 3 3 3
003 6 4 4 5 6 7 6 6 6 6 5
004
005 9 5 6 6 6 6 7 8 7 6 7 8 7
006 6 8 8 9 9 9 9 10 9 9 11 10 10
007 7 8 8 8 8 8 7 6 6 7 7 6 8
008 4 3 4 2 2 4 2 4 2 2 3 4 2
009 4 7 7 7 7 7 7 6 7 6 5 5
010 4 9 7 7 7 9 6 7 6 8 8 8 6
Appendix 7a. Eletriptan haemodynamlc data.
Placebo Infusion was administered between times 0 -1 0  mins
Eletriptan infusion was administered between times 15-25 mins.
Systemic vascular resistance Proximal coronary artery segments
Subject 0 15 30 45 60 Subject 0 15 30 45 60
001 1145 1209 1177 1443 1317 001 2.7 2.7 2.9 3.2 3
002 987 842 1114 1344 1310 002 2.57 2.69 2.6 2.59 2.76
003 967 1308 1299 1434 1322 003 2.88 2.84 2.96 2.6 2.76
004 004 1.76 2.01 2.27 2.1 2.27
005 1681 1451 1760 1915 1843 005 2.78 2.68 0.95 1.21 2.57
006 1006 1026 1038 1440 1393 006 2.95 3.22 3.16 2.75 3
007 1112 1531 1553 1555 1756 007 3.14 3.06 2.76 3.21 3.26
008 1298 1486 1504 1656 1650 008 3.2 3.7 3.4 3.3 3.2
009 1291 959 1029 1031 1048 009 3.4 3.5 3.8 3.3 3.4
010 1499 1520 1844 1850 1971 010 4.2 4.1 3.9 4.2 3.6
Distal coronary artery segments
Subject 0 15 30 45 60 Subject 0 15 30 45 60
001 114 67 76.8 141 71.6 001 1.9 1.6 2.3 1.8 2.1
002 67.7 48.4 64 78.6 63.1 002 2.08 2.03 1.97 2.17 1.76
003 65.4 121 147 141 120 003 1.44 1.88 2.41 1.84 2.01
004 004 1.49 1.74 2.6 1.9 1.95
005 64 76 89 91 130 005 2.6 2.7 2.68 2.13 2.35
006 77 67 50 87 89 006 1.8 1.9 1.91 1,81 1.81
007 31 91 73 112 80 007 2.78 2.29 2.11 2.21 2.16
008 19.1 20.4 83.6 86 86.3 008 2.7 2.5 2.5 2.8 2.4
009 63.3 61.4 62 49.7 60.2 009 2.9 2.7 3 3 3.4
010 129.2 132.8 109,4 119.9 167 010 4.3 4.1 4.1 4.2 4.3
Middle coronary artery segments
Subject 0 15 30 45 60 Subject 0 15 30 45 60
001 6.29 5.82 6.25 5.1 6.59 001 2.1 2.2 2.2 2-2 2.2
002 8.27 8.27 6.25 5.09 5.07 002 1.54 1.85 1.78 1.76 1.53
003 6.12 5.93 5.97 5.69 5.99 003 2,02 Ï.73 1.9 1.9 2.05
004 004 1.34 1.81 1.95 1.69 1.9
005 3.76 4.19 3.59 3.51 3,69 005 2.94 2.84 2.16 2.13 2.11
006 6.2 6 6.4 6.5 5.4 006 1.44 1.24 1.53 1.45 1.34
007 5.25 4.39 4.38 4.27 4.01 007 2.69 2.79 2.23 2.69 2.69
008 4.19 3.93 3.83 3.72 3.71 008 2.5 2.7 2.5 2.5 2.4
009 6.32 6.51 6.45 6.44 6.64 009 2.9 2.6 2.8 2.4 2.7
010 6.19 5.42 5.12 4.67 4.79 010 2.7 2.5 2.9 2.6 2.7
S
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Appendix 8a. Ketanserin haemodynamlc data.
Systolic arterial pressure Diastolic arterial pressure
Subject Baseline Placebo Ket 5mln Ket ISmin Baseline Placebo Ket 5mln Ket 15min
EL 140 140 108 110 66 56 64 56
JF 115 131 100 108 70 62 65 60
RC 154 171 147 162 97 97 92 89
WL 145 139 120 142 59 60 62 51
DM 114 129 125 122 73 61 66 73
GC 121 123 120 124 71 73 74 67
KW 168 173 149 160 84 88 85 80
AC 143 147 112 124 68 61 69 57
RMcW 128 138 117 124 71 61 65 61
WR 138 141 125 122 77 67 74 70
Mean arterial pressure Pulmonary artery systolic pressure
Subject Baseline Placebo Ket 5mln Ket 15mln Baseline Placebo Ket 5mln Ket 15min
EL 92 96 78 82
JF 88 96 78 85 24 24 28 20.5
RC 113 122 108 119 27 14 24 16
WL 92 89 78 96 20.5 20 20 19
DM 90 96 97 94 23 20 22 20
GC 97 90 90 95 25 25 23 28
KW 120 121 109 120 20 18 18 19
AC 100 101 81 91 20 17 20 15
RMcW 88 95 83 86 19 19 19 18
WR 102 105 94 92 26 25 27 25
Pulmonary artery diastolic pressure Mean pulmonary artery pressure
Subject Baseline Placebo Ket 5mln Ket 15mln Baseline Placebo Ket 5mln Ket 15min
EL
JF 10 7 12 9 16 18 IS 12
RC 8.5 8 12 13.5 20 18 11 11
WL 4 5 8 6 13 14 12 12
DM 8 8 8 8 16 14 13 13
GC 10 12 12 11 16 16 15 17
KW 7 6 7 5 13 11 12 12
AC 4 6 6 9 13 13 8 10
RMcW 3 2 2 4 8 10 8 8
WR 8 6 7 7 14 15 15 12
Pulmonary artery wedge pressure Cardiac output
Subiect Baseline Placebo Ket 5ml n Ket 15min Baseline Placebo Ket 5mln Ket 15mln
EL
JF 7 4 7 .5 5 5 .4 6 . 03 5 . 62 5 .4 8
RC 8 7 7 13 6 .7 6 6 . 82 6 . 76 7 .3 6
WL 9 8 11 10 6 . 8 4 . 18 6 .5 2 4 . 55
DM 10 7 .5 8 7 6 .2 5 . 7 5 .9 6 .1
GC 4 4 8 S 5 .4 5 .0 5 5 . 05 4 . 87
KW 6 6 6 5 5 . 9 5 . 94 5 . 82 6 .  08
AC 3 3 7 6 4 .2 9 4 . 15 4 . 69 4 .3 9
RMcW 6 4 6 2 4 . 09 4 . 06 4 .3 4 . 34
WR 6 . 2 5 6 . 75 6 . 5 6 . 7
.1
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Appendix 8a. Ketanserin haemodynamic data.
1 1 I !Systemic vascular resistance Pulmonary vascular resistance
Subject Baseline Placebo Ket 5min Ket 15min Baseline Placebo Ket 5min Ket 15min
EL
JF 1 039 1211 1170 1201 128 119 139 161
RC 1183 1136 1310 1310 36 47 129 76
WL 908 1538 1094 1627 37 47 57 53
DM 1274 1154 1174 1305 41 84 84 118
GC 1 2 99 1528 1289 1365 174 193 127 164
KW 1 4 57 1526 1572 1562 82 81 67 105
AC 1364 1768 1760 18 89 85 137 116 128
RMcW 1488 1567 1623 1754 37 78 79 111
WR 1058 1122 1101 11 56
Heart Rate
Baseline Placebo Ket 5min Ket 15min
Subiect 54 53 58 59
EL 75 75 78 72
JF 91 97 98 98
RC 49 49 51 51
WL 60 52 54 54
DM 67 70 72 71
GC 94 87 87 90
KW 68 65 66 66
AC 48 54 52 49
RMcW 82 78 91 79
WR
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Appendix 8b. Ketanserin coronary artery data.
Proximal coronary artery segments
Baseline Placebo Ket 5min Ket 15m in
5 . 5 5 . 1 5 . 4 4 . 9
4 . 6 3 . 8 4 3 . 7
4 . 1 4 . 3 4 . 1 4 . 3
3 . 9 4 . 1 4 . 3 3 . 5
3 . 4 3 . 6 3 . 7 3 . 5
3 . 5 3 . 8 3 . 7 3 . 8
5 . 3 5 . 6 5 5 . 5
5 . 1 5 4 . 8 4 . 8
3 . 7 3 . 7 3 . 2 3 . 1
4 . 1 4 . 1 3 . 8 3 . 5
3 . 3 3 . 3 3 . 4 3 . 3
3 . 4 3 . 3 3 . 5 3 . 2
Middle coronary artery segments
Baseline Placebo Ket 5min Ket 15min
3 2 . 7 2 . 7 2 . 7
2 . 2 1 . 9 2 2
2 . 8 2 . 9 3 . 1 3 . 2
2 . 6 2 . 6 2 . 2 2 . 1
2 . 1 2 2 . 2 2 . 3
2 2 . 3 2 . 2 3 . 3
2 . 5 1 . 9 2 . 5 2 . 4
3 . 2 2 . 8 2 . 7 2 . 8
Distal coronary artery segments
Baseline Placebo Ket 5min Ket 15min
1 . 8 1 . 6 1 . 4 1 . 5
1 . 5 1 . 6 1 . 6 1 . 4
1 . 6 1 . 5 1 . 7 1 . 8
1 . 5 1 . 5 1 . 2 1 . 3
1 . 1 0 . 9 1 1
1 . 2 0 . 9 1 0 . 7
Appendix 9a. Sumatriptan forearm blood flow data.
Plasma noradrenaline (nmol/l) Placebo cay
Subject Baseline 7 mins 14 mins 21 mins 28 mins 35 mins
TB 0.91 0.9 0 .94 1.03 0.91 0.97
NC 0.72 0.78 0.76 0.72 0.64 0.68
DC 0.6 0.49 0 0.55 0.52 0.45
MJ 0.47 0.46 0.37 0.43 0.5 0.73
PM 0.72 0.62 0.66 0.72 0.74 0.75
JM 1.04 1 0.92 0.85 0.95 0.98
SM 0.52 0.68 0.63 0.62 0.65 0.63
DR 0.47 0.47 0.41 0.49 0.47 0.46
SW 0.8 0.95 0.89 0.86 0.87 0.84
SH
Plasma noradrenaline (nmol/l Sumatriptan day
Subject Baseline 7 mins 14 mins 21 mins 28 mins 35 mins
TB 0.82 0.63 0.51 0.43 0.4 0.48
NC 0.56 0.65 0.67 0.41 0.58 0.65
DC 0.9 1.04 0.75 0.51 0.55 0.64
MJ 0.34 0 .29 0.27 0.19 0.24 0.23
PM 0.69 0.65 0.41 0.51 0.41 0.36
JM 0.51 0.46 0.4 0.38 0.33 0.32
SM 0.69 0.4 0.43 0.37 0.36 0.44
DR 0.48 0.36 0.33 0.26 0.33 0.31
SW 0.74 0.77 0.64 0.58 0.6 0.81
SH
Systolic BP (mmHg Placebo d ay
Subject Baseline 7 mins 14 mins 21 mins 28 mins 35 mins
NC 117 120 127 119 119 118
DR 115 122 129 129 121 128
SM 121 126 124 116 121 118
SH 116 118 121 116 118 121
DC 124 124 124 117 125 118
SW 120 116 116 117 117 111
MJ 121 124 129 127 125 123
PM 114 109 108 115 114 113
TB 107 106 110 107 111 107
JM 128 127 127 127 127 118
Systolic BP (mmHg Sumatripi an day
Subject Baseline 7 mins 14 mins 21 mins 28 mins 35 mins
NC 120 132 130 127 125 124
DR 120 130 112 129 128 120
SM 127 130 123 131 131 131
SH 114 130 124 121 123 121
DC 127 129 128 128 120 128
SW 122 138 137 137 135 136
MJ 133 131 130 137 136 136
PM 118 127 132 129 119 124
TB 121 120 119 127 111 119
JM 119 132 131 131 130 129
Appendix 9a. Sumatriptan forearm blood flow data.
Diastolic BP (mmHg ) Placebo cay
Subject Baseline 7 mins 14 mins 21 mins 28 mins 35 mins
NC 62 62 61 64 59 68
DR 63 64 63 67 67 61
SM 45 48 46 48 51 39
SH 82 81 76 74 79 81
DC 54 57 56 57 58 54
SW 54 49 50 50 56 52
MJ 64 61 61 63 67 63
PM 64 65 57 64 67 62
TB 57 64 69 65 66 61
JM 70 73 60 64 68 68
Diastolic BP (mmHg ) Sumatript an day
Subject Baseline 7 mins 14 mins 21 mins 28 mins 35 mins
NC 71 84 79 73 71 69
DR 64 67 64 71 70 69
SM 42 40 44 50 41 57
SH 79 85 83 83 87 85
DC 54 65 66 58 58 67
SW 59 63 72 64 60 71
MJ 64 65 68 71 66 66
PM 66 75 75 71 72 79
TB 54 57 52 48 59 53
JM 54 72 69 64 68 67
Heart Rate (bpm) Placebo d ay
Subject Baseline 7 mins 14 mins 21 mins 28 mins 35 mins
NC 71 67 72 67 68 67
DR 52 50 51 54 50 44
SM 57 59 58 60 60 60
SH 74 73 75 72 76 75
DC 60 58 56 64 64 65
SW 53 47 49 52 49 49
MJ 64 60 62 58 57 53
PM 61 56 57 65 55 56
TB 80 76 77 76 80 77
JM 68 66 64 61 57 61
Heart Rate (bpm) Sumatripi an day
Subject Baseline 7 mins 14 mins 21 mins 28 mins 35 mins
NC 64 63 64 57 60 67
DR 53 54 47 55 58 55
SM 58 56 61 56 55 62
SH 78 88 87 82 78 76
DC 63 58 57 57 60 66
SW 63 56 63 60 53 55
MJ 63 57 62 64 62 59
PM 73 67 74 74 70 70
TB 77 77 76 75 69 71
JM 65 70 63 58 62 61
Appendix 9a. Sumatriptan forearm blood flow data.
Right forearm blood flow (ml/1 OOml/min Placebo day
Subject Baseline 7 mins 14 mins 21 mins 28 mins 35 mins
TB 2.02 2.52 2.13 2.3 2.31 1.73
NC 6.9 7.46 7.48 7.3 7.29 6.86
DC 2.41 2 .37 2.11 2.41 2.62 2.7
MJ 2.69 2.81 2.58 2.55 2.55 2.65
PM 3.45 3.23 3.25 3.48 3.87 3.33
JM 2.85 2.98 2.73 1.87 2.15 1.74
SM 4.29 4.89 4.5 4.02 4 .17 4.11
DR 4.69 4 .24 4.16 3.99 3.98 3.67
SW 2.21 2.65 2 .9 2.38 2.38 2.45
SH 3.72 3.74 2.71 3.06 2.81 4.17
Right forearm blooc flow (ml/1 OOml/min Sumatripi an day
Subject Baseline 7 mins 14 mins 21 mins 28 mins 35 mins
TB 2.36 3.88 4.2 3.75 3.51 3.38
NC 3.71 6.66 5.75 5.05 4 .74 4 .85
DC 2 .44 2.88 2.89 3.23 3.36 3.11
MJ 3.92 4.38 4.15 3.94 3.66 3.99
PM 4.13 3.72 5.63 5.06 4.8 4 .29
JM 1.56 2.01 1.43 1.48 1.57 1.39
SM 4 .27 4 .89 4.5 4.02 4 .17 4.11
DR 3.18 3.11 2.78 3.02 3.53 3.09
SW 4.5 3.37 3.71 3.72 3.65 3.45
SH 3.14 5.22 5.33 5.46 5.59 5.28
Left forearm blood low Placebo day
Subject Baseline 7 mins 14 mins 21 mins 28 mins 35 mins
TB 2.86 3.52 3.02 3.38 3 .66 3.74
NC 11.21 12.43 11.73 11.27 11.5 9.96
DC 4.31 4.21 4 .53 4.45 4.4 4.6
MJ 3.64 4 .06 4 .07 3.99 4.43 4.24
PM 3.41 3.17 3.23 3.49 3 .74 3.26
JM 2 .76 2.7 3.91 2.07 2 .27 2.13
SM 4 .84 6.12 5 .44 4.88 5.1 5.12
DR 5.33 5.12 4.58 4.74 4 .27 4.37
SW 2 .63 2 .84 2.75 3.13 2 .72 2.93
SH 3.41 3.33 2 .74 2.97 3.23 4.34
Left forearm blood low Sumatripi an day
Subject Baseline 7 mins 14 mins 21 mins 28 mins 35 mins
TB 3.64 5.2 5.17 4.89 4.3 4.37
NC 5.53 7.06 6.29 6.01 5.57 5.84
DC 3.22 2.79 2 .86 2.76 2 .87 2.92
MJ 3.59 3.71 3.4 3.24 2 .77 3.01
PM 4.19 3.09 5.05 4.76 3.96 3.46
JM 2.41 2.58 1.85 2.1 1.83 1.8
SM 4.84 6.12 5.44 4.88 5.1 5.12
DR 4.95 3.81 3.14 3.2 3.61 3.25
SW 5.02 3.77 4 .55 4.61 4.3 4.44
SH 4.3 9.03 9 9.62 9.67 9.89
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